EXHIBIT 10.2

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE REDACTED PORTIONS OF THIS EXHIBIT, AND SUCH CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

CELL LINE COLLABORATION AND LICENSE AGREEMENT

      This Cell Line Collaboration and License Agreement (the “Agreement”) is made and entered into as of July 1, 2002 (the “Effective Date”), by and between Athersys, Inc. , a Delaware corporation having its principal offices at 3201 Carnegie Avenue, Cleveland, Ohio 44115 (“Athersys”), and Bristol-Myers Squibb Company , a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”). Athersys and BMS may be referred to herein individually as a “Party” and collectively as the “Parties.”

Recitals

      A.  Athersys has developed and owns technology and intellectual property rights relating to methods for activating gene or protein expression in cells, referred to by Athersys as the Random Activation of Gene Expression or RAGE technology, which includes the RAGE-VT technology useful for creating cell lines that express particular desired proteins.

      B.  BMS desires to engage Athersys to create certain such cell lines, using the RAGE-VT technology, each of which expresses a specific cell surface or cellular protein of interest to BMS, and to obtain license rights to use such cell lines for internal research, development and commercialization of pharmaceutical products.

      C.  Athersys is willing to create and provide BMS with the desired cell lines pursuant to the terms of this Agreement.

      D.  Concurrently with entering into this Agreement, Athersys and BMS are amending that certain Research Collaboration and License Agreement between the Parties dated December 8, 2000 (the “Original Agreement”), regarding a pilot program relating to Athersys creating certain cell lines for BMS expressing particular desired proteins using the RAGE-VT technology. For the avoidance of doubt, the Parties’ respective rights and obligations with respect to such cell lines shall continue to be governed by the Original Agreement (as may be amended from time to time) and not this Agreement.

      Now, Therefore , in consideration of the foregoing and the covenants and promises contained in this Agreement, the Parties agree as follows:

1.

Definitions

     As used herein, the following capitalized terms shall have the following meanings (with terms defined in the singular having the same meanings when used in the plural):

      1.1 “Accepted Cell Line” shall have the meaning assigned to such term in Section 2.3(a).

      1.2 “Affiliate” shall mean, with respect to a Party, any corporation or other entity that, directly or indirectly, controls, is controlled by or is under the common control with such Party. For the purpose of this definition, “control” shall mean (a) the direct or indirect ownership of fifty percent (50%) or more of the outstanding shares or other voting rights of the subject entity to elect directors, or (b) if such amount of ownership of a foreign entity is not permitted by law, ownership of the maximum amount of such entity as permitted by law, or (c) the actual ability to control and direct the management of the subject entity.

      1.3 “Athersys Know-How” shall mean the Information that is Controlled by Athersys during the term of this Agreement and relates directly to Collaboration Cell Lines or their method of manufacture or use in the Field or for Counterscreening, as applicable, but excluding Athersys Patents.

      1.4 “Athersys Patents” shall mean all Patents that are Controlled by Athersys during the term of the Agreement and contain a Valid Claim covering a Collaboration Cell Line or its method of manufacture or use in the Field or for Counterscreening, as applicable.

      1.5 “Athersys Technology” shall mean the Athersys Know-How and Athersys Patents collectively.

      1.6 “Candidate Compound” shall mean:

           (a) any compound that has activity, with respect to the target protein expressed by the applicable Accepted Cell Line, which activity is initially discovered or detected by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line, where such activity is potentially useful for therapeutic or prophylactic use, or

           (b) any compound that is an analog, homolog, isomer or other chemical derivative of a compound that meets the criteria in subsection (a) above (the “Parent Compound”), provided that such compound (i) was made by or on behalf of BMS or its Affiliate or sublicensee based on information relating to the Parent Compound, and (ii) has activity that is potentially useful for therapeutic or prophylactic use and is similar or related to the activity of such Parent Compound (with the understanding that such activity may be superior to the activity of the Parent Compound, in any appropriate criteria).

      1.7 “Collaboration Cell Line” shall have the meaning assigned to such term in Section 2.1(b).

      1.8 “Confidential Information” shall mean (a) any proprietary or confidential information or material of a Party in tangible form disclosed hereunder that is (i) marked as “Confidential” at the time it is delivered to the receiving Party, or (ii) designated as confidential or proprietary in a written memorandum provided to the receiving Party by the disclosing Party within thirty (30) days of such disclosure, or (b) any proprietary or confidential information of a Party disclosed orally hereunder that is identified as confidential or proprietary when disclosed and designated as confidential or proprietary in a written memorandum provided to the receiving Party by the disclosing Party within thirty (30) days of such oral disclosure by the disclosing Party. Further, it is agreed that if Athersys discloses to BMS that it is working on a particular protein or gene target, such information shall be treated by BMS as the Confidential Information

of Athersys. Still further, it is agreed that Athersys shall treat the fact that BMS has nominated a specific target under Section 2.1 and the fact that Athersys has provided BMS with a corresponding Collaboration Cell Line under Section 2.2 as Confidential Information of BMS.

      1.9 “Controlled” shall mean, with respect to any material, Information or intellectual property right, that a Party owns or has a license to such material, Information or intellectual property right and has the ability to grant to the other Party the licenses or sublicenses thereto as provided for herein without violating the terms of any agreement with any Third Party.

      1.10 “Counterscreening” shall mean testing a BMS compound, which has known activity against one target, for activity against another target that is expressed in an Accepted Cell Line, for the purpose of determining the relative selectivity and potency of the BMS compound for the first target.

      1.11 “Counterscreening Cell Line” shall mean an Accepted Cell Line that was selected by BMS to be used in Counterscreening as provided in Section 2.5.

      1.12 “Counterscreening License” shall have the meaning assigned to it in Section 3.3.

      1.13 “Field” shall mean use of the Accepted Cell Lines by BMS solely for BMS’s internal discovery, research, development and/or commercialization of Products. For the avoidance of doubt, subject to Section 3.5(b), the Field shall include BMS’s use of the Accepted Cell Lines in connection with any bona fide collaboration between BMS and an academic and/or corporate collaborator, provided that any compounds initially discovered or detected pursuant to such collaboration by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line shall be deemed to be Candidate Compounds. The Field expressly excludes the use of Accepted Cell Lines by BMS for Counterscreening.

      1.14 “HTS” shall mean high throughput screening using BMS’ test deck of compounds in primary screening of the Accepted Cell Line. HTS shall be deemed “completed” when BMS has screened the test deck, confirmed positive responses, and completed standard data analysis.

      1.15 “Improvement” shall mean any improvement, modification or enhancement to the Athersys Know-How or the inventions claimed in the Athersys Patents (and/or the practice thereof), and any Information and intellectual property rights relating thereto, that the possessing Party has the right to disclose to the other Party without violating contractual obligations to a Third Party. For the avoidance of doubt, the following shall be owned by BMS and shall not comprise Improvements: (i) Information comprising the results of any assays or other screening or testing generated by BMS through use of the Accepted Cells Lines under the terms of this Agreement, and any Information developed based on evaluating or using such results (which shall exclude, for clarity, any such Information that relates to the manufacture of such Accepted Cell Lines via the RAGE-VT method or use of same); (ii) any methodology, process or tool, whether previously existing or created during the Term (without use of an Accepted Cell Line), that is proprietary to BMS and that BMS uses to generate the Information referred to in clause (i); and (iii) any invention based on, or improvement, modification, or enhancement of, the

proprietary know-how of BMS that is created in connection with the subject matter of this Agreement and the use or practice of which does not involve the use of any Athersys Technology.

      1.16 “Information” shall mean information, results and/or data of any type whatsoever, in any tangible or intangible form, including without limitation databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions.

      1.17 “License” shall have the meaning assigned to it in Section 3.2.

      1.18 “Net Sales” shall mean the amount invoiced or otherwise billed by BMS or its Affiliate or licensee for sales or other commercial disposition of a Product to a Third Party purchaser, less the following to the extent included in such billing or otherwise actually allowed or incurred with respect to such sales: (i) discounts, including cash, trade and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a product, charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments (or their respective agencies, purchasers and reimbursers) or to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups; (ii) credits or allowances actually granted upon rejections or returns of Products, including for recalls or damaged goods; (iii) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Products, to the extent billed; (iv) customs duties, tariffs, surcharges and other governmental charges incurred in connection with the exportation or importation of a Product; (v) bad debts relating to sales of Products that are actually written off by BMS in accordance with generally accepted accounting principles, consistently applied, during the applicable royalty calculation period, and (vi) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on sale of Products, including without limitation value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based on net income of the seller; provided that all of the foregoing deductions are calculated in accordance with generally accepted accounting principles consistently applied throughout the party’s organization.

Notwithstanding the foregoing, if any Product is sold under a bundled or capitated arrangement with other BMS products, then, solely for the purpose of calculating Net Sales for royalty purposes hereunder, any discount on such Product sold under such an arrangement shall be no greater, on a percentage basis based on the gross selling price prior to discount, than the largest percentage discount applied on the other pharmaceutical products sold within such bundled arrangement for the applicable accounting period. In case of any dispute as to the applicable discount numbers under the preceding sentence, the determination of same shall be calculated and certified by BMS’ independent public accountants, whose decision shall be binding.

A sale of a Product is deemed to occur upon the earliest of invoicing or transfer of title in the Product to the Third Party purchaser. In the event that BMS, after reasonable efforts, cannot calculate accurately the Net Sales of a sublicensee in a particular country, the Parties will meet and negotiate in good faith an appropriate means for calculating “Net Sales” in such a situation.

For sake of clarity and avoidance of doubt, sales by BMS, its Affiliates or sublicensees of a Product to a Third Party distributor of such Product in a given country shall be considered sales to a Third Party customer, but sales and/or transfers of a Product between or among BMS, its Affiliates or sublicensees shall not be considered sales to a Third Party customer, so long as such recipient subsequently resells the Product. Any Products used (but not sold for consideration) for promotional or advertising purposes or used for clinical or other research purposes shall not be considered in determining Net Sales hereunder.

In the event a Product is sold as an end-user product consisting of a combination of active functional elements or as a combined product and/or service, Net Sales, for purposes of determining royalty payments on such Product, shall be calculated by multiplying the Net Sales of the end-user product and/or service by the fraction A over A+B, in which A is the gross selling price of the Product portion of the end-user product and/or service when such Product is sold separately during the applicable accounting period in which the sales of the end-user product were made, and B is the gross selling price of the other active elements and/or service, as the case may be, of the end-user product and/or service sold separately during the accounting period in question. All gross selling prices of the elements of such end-user product and/or service shall be calculated as the average gross selling price of the said elements during the applicable accounting period for which the Net Sales are being calculated. In the event that, in any country or countries, no separate sale of either such above-designated Product or such above designated elements of the end-user product and/or service are made during the accounting period in which the sale was made or if gross retail selling price for an active functional element, component or service, as the case may be, cannot be determined for an accounting period, Net Sales allocable to the Product in each such country shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining same that takes into account, on a country by country basis, variations in potency, the relative contribution of each active agent, component or service, as the case may be, in the combination, and relative value to the end user of each active agent, component or service, as the case may be.

Notwithstanding the foregoing, it is agreed that drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients” or “active functional elements,” the presence of which in a Product would be deemed to create a combination product subject to the terms of the preceding paragraph.

      1.19 “Patents” shall mean all issued United States and foreign patents (including all reissues, extensions, renewals, substitutions, re-examinations, supplementary protection certificates and the like, and patents of addition) and pending United States and foreign patent applications (including, without limitation, all provisional and nonprovisional applications and all continuations, continuations-in-part and divisions thereof).

      1.20 “Product” shall mean any product containing a Candidate Compound, including any formulation, dosage form, packaged form or delivery means thereof.

      1.21 “RAGE Technology” shall mean any and all intellectual property, whether or not patentable, that is owned or licensed by Athersys and relates to Athersys’ techniques for

activating gene expression, which are referred to by Athersys collectively as Random Activation of Gene Expression or RAGE technology.

      1.22 “Term” shall have the meaning assigned to it in Section 11.1.

      1.23 “Third Party” means any entity other than Athersys, BMS or an Affiliate of either of them.

      1.24 “Valid Claim” shall mean either (i) a claim of issued and unexpired letters patent which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a claim of a pending patent application that has not been pending for more than seven (7) years and that has not been abandoned or finally rejected without the possibility of appeal or refiling.

2.

Collaboration Program

      2.1 Review of Proposed Cell Lines by Athersys.

           (a) Subject to the limits set forth in Section 2.2, Athersys shall create new Accepted Cell Lines based on RAGE-VT cell lines that BMS proposes, as set forth in Exhibit A, and Athersys has accepted as provided below. BMS shall use reasonable, good faith efforts to assure that the aggregate level of technical difficulties and legal risks associated with the cell lines that BMS nominates is balanced and provides Athersys a reasonable opportunity to perform hereunder. Athersys shall have the right to review and approve, as provided in Exhibit A, the target protein to be expressed in each RAGE-VT cell line that BMS proposes be made under this Agreement. Athersys shall complete such review within forty-five (45) days after the date Athersys receives information from BMS regarding a proposed target to be expressed in a RAGE-VT cell line, or upon any other schedule to which the Parties may mutually agree in writing. Athersys shall use reasonable, good faith efforts to assure that the aggregate level of technical difficulties and legal risks associated with the cell lines that Athersys accepts is balanced and provides a reasonable opportunity for the generation of Accepted Cell Lines hereunder.

           (b) While Athersys is completing such review, the Parties shall promptly negotiate specific Acceptance Criteria for such cell line based upon the Acceptance Criteria as generically set forth in Exhibit A. Upon agreement by the Parties on the specific Acceptance Criteria for a particular proposed RAGE-VT cell line, such Acceptance Criteria shall be included in Exhibit A, and, subject to review and subsequent approval of the target protein by Athersys under this Section 2.1, Athersys shall promptly thereafter commence work under Section 2.2 to create a RAGE-VT cell line based thereon, and any such cell line shall be a “Collaboration Cell Line.”

           (c) If Athersys rejects any of the proposed RAGE-VT cell lines in accordance with the parameters set forth in Exhibit A, Athersys shall promptly notify BMS, and BMS shall have the right to amend Exhibit A in order to designate a replacement RAGE-VT cell line (for each one of the RAGE-VT cell lines originally proposed and rejected by Athersys) within sixty

 

(60) days after receiving notice of the rejection; provided, however, that Athersys shall again have the right to review and approve any such proposed replacement cell line, as above.

           (d) BMS shall propose RAGE-VT cell lines hereunder from time to time in quantities reasonably believed (taking into account, among other things, Athersys’ right under this Section 2.1, to reject cell lines that BMS proposes) to be sufficient for Athersys to generate, and for BMS to accept (subject to satisfaction of the acceptance criteria agreed upon by the Parties), a minimum of fifteen (15) Collaboration Cell Lines over a three (3) year period (subject to Section 2.9), beginning on the Effective Date, with five (5) in year one, five (5) in year two and five (5) in year three; provided, however, that in the event Athersys rejects a RAGE-VT cell line nominated by BMS, BMS shall always have a full sixty (60) day period within which to nominate a replacement cell line, regardless of the deadline for meeting any applicable minimum under this Section 2.1.

      2.2 Supply of Collaboration Cell Lines; Status Reports. Athersys shall use reasonable efforts to deliver to BMS each Collaboration Cell Line that Athersys approves under Section 2.1 within six (6) months after such approval. Athersys shall provide BMS with summary reports, which shall be written, of the status and progress of Athersys’s efforts to provide Collaboration Cell Lines every eight (8) weeks. Such reports shall be sent to the attention of the BMS Project Coordinator. Athersys shall not be obligated to supply to BMS more than a total of eight (8) Collaboration Cell Lines per year over the Term.

      2.3 Review of Collaboration Cell Lines by BMS.

           (a) BMS shall have the right, for a period of forty-five (45) days after receiving a particular Collaboration Cell Line, to review such Collaboration Cell Line for the purpose of evaluating whether or not the production of protein meets the specific Acceptance Criteria for the particular Collaboration Cell Line as agreed by the Parties (pursuant to Section 2.1) and set forth in Exhibit A. Unless BMS provides written notice to Athersys that such Collaboration Cell Line does not meet such specific Acceptance Criteria within such period, such Collaboration Cell Line shall be accepted by BMS and shall be an “Accepted Cell Line” for all purposes hereunder. Even if any Collaboration Cell Line fails to produce the amount of protein meeting the specific Acceptance Criteria set forth in Exhibit A, BMS shall nonetheless have the right, but not the obligation, to accept such Collaboration Cell Line as an Accepted Cell Line, by written notice to Athersys within such forty-five (45) day period. If BMS does not accept a Collaboration Cell Line, BMS and Athersys shall discuss the reason(s) such Collaboration Cell Line was not accepted, and if BMS and Athersys agree that modifying the approach to creating a Collaboration Cell Line is feasible and desirable, Athersys shall make such modification and present such modified Collaboration Cell Line to BMS for evaluation and acceptance (if applicable) as provided herein.

           (b) Athersys shall provide the BMS Project Coordinator with at least two (2) weeks’ advance notice of Athersys’ intent to deliver a Collaboration Cell Line to BMS for review under Section 2.3(a), so that BMS may attempt to allocate internal resources appropriately. In the event Athersys fails to give such notice with respect to any given Collaboration Cell Line, the BMS review period therefor shall be extended to sixty (60) days.

      2.4 Infringement by Accepted Cell Lines. If at any time during the term of the License or Counterscreening License applicable to a particular Accepted Cell Line, such Accepted Cell Line becomes, or in Athersys’ opinion is likely to become, the subject of a Third Party patent infringement claim based on BMS’ practice of such License or Counterscreening License, then Athersys shall use commercially reasonable efforts, at its sole expense, either (i) to procure for BMS the right to continue using such Accepted Cell Line, or (ii) to replace or modify such Accepted Cell Line so that it becomes noninfringing while still having substantially the same functionality and efficacy as prior to such replacement or modification. In the event Athersys is not successful in its efforts under clause (i) and/or (ii) of the preceding sentence within three (3) months after any such claim arises, Athersys shall, at BMS’s request, meet to discuss in good faith other possible solutions to the claim.

      2.5 Selection of Counterscreening Cell Lines. As to a particular cell line that BMS requests to be made under Section 2.1, BMS may specify in writing, at the time the request for such cell line is made, that such cell line will be a Counterscreening Cell Line when accepted under Section 2.3, and such cell line then would be used solely for Counterscreening pursuant to the Counterscreening License. BMS may so specify no more than fifty percent (50%) of the Collaboration Cell Lines requested in a particular year be used for Counterscreening.

      2.6 Project Coordinators. Each Party shall designate an individual (a “Project Coordinator”) to coordinate, on such Party’s behalf, the day-to-day interaction of and communication between the Parties under this Agreement. Each Project Coordinator shall possess the education, training and experience necessary to make him or her reasonably technically qualified to serve as a Project Coordinator. Each Party shall be free to replace its Project Coordinator with new a appointee who has authority to act on behalf of such Party, upon notice to the other Party.

      2.7 BMS Diligence. BMS agrees that, for each Accepted Cell Line (but excluding all Counterscreening Cell Lines), BMS shall initiate and use reasonably diligent efforts to complete an HTS program for such Accepted Cell Line as soon as practicable after the date such cell line is designated or deemed an Accepted Cell Line. Notwithstanding the preceding sentence, an Accepted Cell Line shall be deemed to have completed HTS twelve (12) months after acceptance unless the Cell Line fails to perform as prescribed in Exhibit A. BMS shall provide Athersys with reasonable reports regarding its progress in conducting such HTS screening.

      2.8 BMS Termination of Cell Lines.

           (a) Prior to Cell Line Acceptance. With respect to Collaboration Cell Lines for which acceptance has not yet occurred, upon thirty (30) days notice to Athersys, BMS may terminate Athersys’ development of one Collaboration Cell Line per year during the period prior to which the Collaboration Cell Line is eligible to be deemed an Accepted Cell Line pursuant to Section 2.3(a). If a Collaboration Cell Line is so terminated, then BMS shall be obligated to pay Athersys fifty percent (50%) of the payment due for achievement of the milestone subsequent to the last previously achieved milestone, under Section 4.1(a) or 4.1(c), as the case may be, for such Collaboration Cell Line.

           (b) Following HTS Completion. With respect to any Accepted Cell Line (other than Counterscreening Cell Lines) for which HTS completion has occurred and BMS has paid the corresponding milestone payment under Section 4.1(a), upon thirty (30) days notice to Athersys, BMS may, for reasonable business, scientific and/or technical reasons (which shall be disclosed to Athersys, on a confidential basis), terminate its License with respect to such Accepted Cell Line, which termination shall be effective after payment of the next license fee due under Section 4.1(b). On the due date of such payment the license to such Accepted Cell Line granted under Section 3.2 shall automatically terminate, and after payment of such license fee BMS shall have no further payment obligations to Athersys with respect to such Accepted Cell Line subject to the following covenant. With respect to any such Accepted Cell Line for which BMS has terminated its license rights pursuant to this Section 2.8(b), BMS covenants that BMS and its Affiliates and licensees shall not use, develop or commercialize any materials, results, data or information (including, without limitation, any compound or composition, or any derivative, homolog or isomer thereof) that was originally created or originally identified through BMS’ prior use of such Accepted Cell Line; provided, however, that the foregoing covenant shall not preclude BMS and its Affiliates from continuing to conduct discovery, research, development and commercialization activities with respect to the target protein expressed by such Accepted Cell Line so long as BMS and its Affiliates abide by such covenant in so doing.

      2.9 BMS Termination of Collaboration Program. BMS shall have the right to terminate the collaboration program contemplated by this Section 2 at the end of the second year of the collaboration program, by giving Athersys written notice of such termination at least ninety (90) days prior to the second anniversary of the commencement of the collaboration program. BMS acknowledges that Athersys will incur certain wind-down and FTE re-allocation costs and expenses in the event of any such early termination and, therefore, agrees to pay Athersys the sum of $125,000 to help offset such costs. Such payment shall be made within thirty (30) days after delivery of BMS’ termination notice pursuant to this Section 2.9.

3.

Licenses.

      3.1 Evaluation License. Subject to the terms of this Agreement, as to each Collaboration Cell Line provided to BMS by Athersys hereunder, Athersys grants to BMS a royalty-free, non-exclusive , worldwide license, without the right to sublicense, under the Athersys Technology solely to conduct internal research evaluation of such Collaboration Cell Line as provided in Section 2.3 of this Agreement during the forty-five (45) day period after BMS first receives such Collaboration Cell Line.

      3.2 Research and Development License. Subject to the terms of this Agreement, and effective upon BMS’s acceptance of a particular Accepted Cell Line (other than a Counterscreening Cell Line), Athersys grants to BMS a royalty-bearing, non-exclusive, worldwide license, without the right to sublicense, under the Athersys Technology solely to use such Accepted Cell Line in the Field (the “License”).

      3.3 Counterscreening License. Subject to the terms of this Agreement, and effective only upon BMS’s acceptance of a particular Accepted Cell Line that BMS elected under Section

2.5 to be a Counterscreening Cell Line, Athersys hereby grants to BMS a non-exclusive, worldwide license (the “Counterscreening License”), without the right to sublicense, under the Athersys Technology solely to use each such Counterscreening Cell Line for Counterscreening. For clarity, a particular Accepted Cell Line may not be used by BMS (or its Affiliate) for use both in the Field and for Counterscreening except as specified in 4.1 (e).

      3.4 Duration of Athersys Licenses.

           (a) Field License Duration. The License granted in Section 3.2, as to a particular Accepted Cell Line, shall be perpetual, subject to payment of all applicable fees, unless terminated by BMS as provided in Section 2.8(b).

           (b) Counterscreening License Duration. Subject to payment of all applicable fees, the Counterscreening License granted in Section 3.3 shall be perpetual, as to a particular Counterscreening Cell Line.

      3.5 Negative Covenants.

           (a) No Other Use by BMS. BMS covenants and agrees that it shall not use the Collaboration Cell Lines for any purpose other than as set forth in Section 3.1 and shall not use the Accepted Cell Lines or any materials derived therefrom for any purpose other than as set forth in Sections 3.2 and 3.3, as applicable. BMS further covenants and agrees that it shall not use or practice the Athersys Technology for any purpose except as expressly permitted in the licenses granted to BMS under Sections 3.1, 3.2 and 3.3, as applicable.

           (b) No Transfer to Third Parties. BMS covenants and agrees that BMS shall not transfer Collaboration Cell Lines or Accepted Cell Lines or any Information pertaining thereto or any materials derived therefrom, to any Third Party for any purpose, except that BMS may transfer such Information and materials to collaborators to the extent necessary for BMS to exercise its right to use the Accepted Cell Lines in connection with bona fide collaborations with academic and/or commercial partners in the Field, but may not transfer the Accepted Cell Lines to such entities except with Athersys’ prior written consent. For clarity, BMS covenants and agrees that BMS shall not transfer Collaboration Cell Lines or Accepted Cell Lines, or any Information pertaining thereto or any materials derived therefrom, to any Third Party for Counterscreening.

      3.6 Athersys Reserved Rights. BMS understands and agrees that Athersys owns and reserves to itself all rights, title and interest in the Athersys Technology, and to the Collaboration Cell Lines and the Accepted Cell Lines, subject only to the licenses granted in Sections 3.1, 3.2 and 3.3, respectively.

      3.7 Records And Reports.

           (a) Records. BMS shall maintain complete and accurate records that fully and properly reflect all work done and all results achieved, including raw data, in the evaluation of Collaboration Cell Lines, the use of Accepted Cell Lines and the discovery, research and development of Candidate Compounds (“Records”). The Records shall be kept with sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and shall be

kept separate and distinct from other work conducted by BMS, all in a manner consistent with BMS’ other internal research and development record keeping.

           (b) Copies and Inspection of Records. Athersys shall have the right, during normal business hours and upon reasonable notice, to inspect the Records for purposes consistent with this Agreement. Athersys shall maintain all Information learned from such inspection of the Records in confidence in accordance with Article 7. All inspections, copying and visits hereunder shall be conducted in a manner and frequency so as not to disrupt BMS’s business and in a manner so as not to cause any disclosure of any other BMS Confidential Information.

           (c) Semi-Annual Reports. Within thirty (30) days following the end of each six (6) month period during the term of the License with respect to each Accepted Cell Line, BMS shall provide to Athersys a written progress report that shall describe the results and developments of the use of such Accepted Cell Line, and the discovery, research and development of Candidate Compounds therewith. With such reports, BMS shall disclose to Athersys in summary form ( i.e., in a manner that does not require BMS to disclose sensitive or competitively-enabling data or information) the development, making, conception or reduction to practice of all Candidate Compounds that are discovered, made, investigated, conceived or reduced to practice by use of such Accepted Cell Line or assays based thereon. In addition, BMS shall fully disclose to Athersys in each such report any Improvements that BMS may have developed during the period covered by such report.

4.

Payments.

      4.1 License Fees.

           (a) Screening License Fees. For each Collaboration Cell Line requested by BMS that is to be used in the Field ( i.e., excluding the Counterscreening Cell Lines), BMS shall pay Athersys non-refundable license fees upon achievement of the milestone events as provided in the following schedule:

BMS and Athersys shall jointly determine the occurrence of any of the foregoing milestone events with respect to a particular Collaboration Cell Line, and the applicable payments for each event shall be due and payable within thirty (30) days of the Parties’ having made such a determination.

           (b) Additional Annual License Fees. For each Accepted Cell Line that is to be used in the Field ( i.e., excluding the Counterscreening Cell Lines) with respect to which the License has not terminated due to BMS previously exercising its right to terminate its License under Section 2.8(b), BMS shall also pay Athersys non-refundable license fees upon achievement of the milestone events as provided in the following schedule:

For clarity, if BMS exercises its right to terminate the License as provided in Section 2.8(b) as to a particular Accepted Cell Line, BMS shall make the next payment due as provided above after serving notice of such termination.

           (c) Counterscreening License Fees. For each Counterscreening Cell Line requested to be made by BMS, BMS shall pay Athersys non-refundable license fees upon achievement of the milestone events as provided in the following schedule:

BMS and Athersys shall jointly determine the occurrence of any of the foregoing milestone events with respect to a particular Counterscreening Cell Line, and the applicable payments for each event shall be due and payable within thirty (30) days of the Parties’ having made such a determination.

           (d) Additional Counterscreening License Fees. For each Accepted Cell Line specified as a Counterscreening Cell Line pursuant to Section 2.5 that is accepted by BMS pursuant to Section 2.3, BMS shall pay Athersys a non-refundable license fee of either: (i) an aggregate of [*] dollars ($[*]) license fee, which shall be payable in six (6) installments of [*] dollars ($[*]) each, to be paid at the end of each six (6) month period after the date of acceptance by BMS of the applicable Accepted Cell Line; or (ii) [*] dollars ($[*]) for the use, in perpetuity, of the Counterscreening License, such fee to be payable on the six (6) month anniversary of the date of acceptance by BMS of the applicable Accepted Cell Line.

           (e) Counterscreening License Fee for Accepted Cell Line. For any particular Accepted Cell Line used in the Field for which BMS has completed payment of all milestone payments under Sections 4.1(a) and (b) ( i.e. , a total of $[*] for such Accepted Cell Line), BMS may elect in writing to Athersys to obtain the perpetual right to use such Accepted Cell Line in Counterscreening (under the terms of a Counterscreening License under Section 3.3) by a one-time payment of $[*] to be made within thirty (30) days of such notice.

      4.2 Milestone Payments. For each Accepted Cell Line used in the Field, BMS shall pay Athersys the milestone payments set forth in Exhibit B within thirty (30) days after each milestone event has been achieved for each Candidate Compound identified for clinical development by BMS or its Affiliate or sublicensee for the particular Accepted Cell Line.

      4.3 Royalty Payments. BMS shall pay Athersys a royalty equal to [*] percent ([*]%) of Net Sales of all Products worldwide. Each payment of royalties under this Agreement shall be accompanied by a statement of the amount of the total amounts received and calculated as Net Sales during such period, and all other information necessary to determine the appropriate amount of such payments.

      4.4 Royalty Term. For each Product, on a country-by-country basis, BMS shall pay to Athersys royalties under Section 4.3 commencing on the first commercial sale in the applicable country and continuing until the later of (a) the last to expire Patent in such country owned or controlled by BMS or its affiliate or licensee containing a Valid Claim covering such Product or the Candidate Compound therein, or covering the manufacture, use or formulation of such Product or compound, or (b) ten (10) years from the date of such first commercial sale in such country.

      4.5 Blocked Currency. In each country where the local currency is blocked and cannot be removed from the country, at the election of Athersys, royalties accrued in that country shall be paid to Athersys in such country in local currency by deposit in a local bank designated by Athersys.

      4.6 Non-Monetary Consideration. In the event BMS (or its Affiliates or sublicensees) receives any non-monetary consideration in connection with the sale or other commercial disposition of Products, Athersys’s royalty shall be based on the fair monetary value of such other consideration. In such case, BMS shall disclose to Athersys, on a confidential basis, the terms of such arrangement, and the Parties shall agree in good faith on such monetary value, which shall then be included in Net Sales for the period in which it was received by BMS (or its Affiliates or sublicensees).

5.

Records and Audit.

      5.1 Records and Audit. During the term of this Agreement and for a period of three (3) years thereafter, BMS shall keep complete and accurate records pertaining to the sale or other disposition of all Products, in sufficient detail to permit Athersys to confirm the accuracy of all payments due hereunder. Athersys shall have the right to cause an independent, certified public accountant to audit such records to confirm BMS’s Net Sales and royalty payments and payments under Section 4.2; provided, however, that such auditor shall not disclose BMS’s Confidential Information to Athersys, except to the extent such disclosure is necessary to verify the portion of the amount of royalties and payments due under this Agreement. Such audits may be exercised once a year, within three (3) years after the period to which such records relate, upon notice to BMS and during normal business hours. Athersys shall bear the full cost of such audit unless such audit discloses a variance of more than five percent (5%) from the amount of royalties and payments under Section 4.2 previously paid for such year. In such case, BMS shall bear the full cost of such audit. The terms of this Section 5.1 shall survive any termination or expiration of this Agreement for a period of three (3) years.

6.

Intellectual Property.

      6.1 Ownership .

           (a) Athersys. Athersys shall remain the sole owner of the Athersys Technology, the RAGE Technology, the Collaboration Cell Lines and the Accepted Cell Lines, including any improvements thereto made by Athersys. Athersys shall have the sole responsibility, at its discretion, for patent prosecution and choice of patent counsel in relation to Athersys Patents, and shall pay all expenses associated therewith. BMS hereby assigns and agrees to assign to Athersys its entire interest in any Improvements, which shall be deemed to be part of the Athersys Technology.

           (b) BMS. BMS shall be the sole owner of any inventions and information resulting from BMS’ use of the Accepted Cell Lines, including any Products, but excluding all Improvements. BMS shall have the sole responsibility, at its discretion, for patent prosecution and choice of patent counsel in relation to such BMS-owned inventions and the Products and shall pay all expenses associated therewith.

      6.2 Enforcement of Patent Rights . Each Party shall have the sole right, but not the obligation, to institute, prosecute or control any action or proceeding with respect to infringement by a Third Party of one or more issued Patents owned by such Party.

7.

Confidentiality; Publicity.

      7.1 Confidential Information. The Parties agree that, for the Term of this Agreement and for five (5) years thereafter, the receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose, except for the purposes expressly permitted by this Agreement, any Confidential Information furnished to it by the disclosing Party. The foregoing obligation shall not apply to any information received by a Party to the extent that it can be established by such receiving Party by competent evidence that such information:

           (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure;

           (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;

           (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement;

           (d) was independently developed by the receiving Party as demonstrated by competent written evidence prepared contemporaneously with such independent development; or

           (e) was subsequently lawfully disclosed to the receiving Party by a person other than a Party hereto.

      7.2 Authorized Disclosure . Notwithstanding the foregoing, a Party may disclose the Confidential Information of the other Party to the extent such disclosure is necessary to be disclosed in the following instances:

           (a) Regulatory filings made by BMS;

           (b) Prosecuting or defending litigation or responding to valid subpoenas;

           (c) Complying with applicable governmental regulations;

           (d) Conducting clinical trials of BMS, its Affiliates and sublicensees;

           (e) Disclosure, in connection with the performance of this Agreement, to Affiliates, employees, consultants, or agents, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section 7;

           (f) Disclosure that is required by applicable law or governmental regulation; and

           (g) Disclosure of the existence and terms of this Agreement and of general summaries of the progress made by the Parties under this Agreement (but excluding the identification of any target nominated by BMS under Section 2.1 and of any Collaboration Cell Line or Accepted Cell Line developed by Athersys hereunder) to existing or potential investment bankers, investors and/or merger or acquisition parties, provided that the disclosing Party obtains from such recipient prior to disclosure an agreement to be bound by obligations of confidentiality and non-use at least similar in scope to those set forth in this Section 7.

      7.3 Disclosure. If a Party is required to make any disclosure of another Party’s Confidential Information that is authorized under subsections (a), (b), (c), (d) or (f) of Section 7.2, it will give reasonable advance notice to the latter Party of such disclosure and will afford the latter Party a reasonable opportunity, and will cooperate reasonably with such Party, to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise) and to limit the extent of the disclosure as much as possible. Except as otherwise required by law, and subject to Section 7.5, neither Party shall issue a press release or make any other disclosure of the terms of this Agreement or any aspect of the research conducted pursuant to this Agreement without the prior approval of such press release or disclosure by the other Party hereto. Each Party shall submit any such press release or disclosure to the other Party, and the receiving Party shall have ten (10) business days to review and approve any such press release or disclosure, which approval shall not be unreasonably withheld. If the receiving Party does not respond within such ten (10) day period, the press release or disclosure shall be deemed approved. In addition, if a public disclosure is required by law, including without limitation in a filing with the Securities and Exchange Commission, the disclosing Party shall provide copies of the disclosure reasonably in advance of such filing or other disclosure for the nondisclosing Party’s prior review and comment.

      7.4 Confidential Terms. Except as expressly provided herein, each Party agrees not to disclose any terms of this Agreement or any aspect of the research conducted pursuant to this Agreement to any Third Party without the consent of the other Party.

      7.5 Initial Press Release. The Parties shall issue a mutually approved, initial press release promptly after the Effective Date. The Parties agree that this press release shall be in the form of the press release attached to this Agreement as Exhibit C.

8.

Representations and Warranties.

      8.1 Athersys. Athersys represents and warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the State of Delaware; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Athersys; (iii) the performance of Athersys’s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv) Athersys will not, during the Term of this Agreement, enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement; (v) Athersys has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; (vi) Athersys is the owner of, or has licensed rights to, all of the Athersys Patents in existence on the Effective Date, and has the right to grant the licenses or sublicenses, as the case may be, therefor granted under this Agreement; and (vii) as of the Effective Date, Athersys is not aware of any asserted or unasserted claim or demand which is being, or which Athersys believes can be, rightfully enforced by a Third Party against any of the Athersys Patents that would materially limit, hinder, delay or otherwise adversely affect BMS’s enjoyment of its rights and satisfaction of its obligations under this Agreement.

      8.2 BMS. BMS represents and warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the State of Delaware; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of BMS; (iii) the performance of BMS’s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv) BMS has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v) BMS will not, during the Term of this Agreement, enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement.

      8.3 Disclaimer of Warranties. THE ATHERSYS KNOW-HOW, ATHERSYS PATENTS AND COLLABORATION CELL LINES ARE PROVIDED AND LICENSED TO BMS “AS IS”, AND ATHERSYS AND ITS RESPECTIVE AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS OR ATHERSYS TECHNOLOGY, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE PATENT RIGHTS LICENSED HEREUNDER, OR

NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

      8.4 Unknown Biological Properties. BMS understands and agrees that the Collaboration Cell Lines may have unpredictable and unknown biological and/or chemical properties, that they are to be used with caution, and that they are not to be used for testing in or treatment of humans. BMS shall use the Collaboration Cell Lines in compliance with all applicable laws and regulations, including, but not limited to, any laws or regulations relating to the research, testing, production, storage, transportation, export, packaging, labeling or other authorized use of the Collaboration Cell Lines.

9.

Dispute Resolution.

      9.1 Mediation. If a dispute arises out of or relates to this Agreement, or the breach thereof, and if said dispute cannot be settled through negotiation, the Parties agree first to try in good faith to settle the dispute by good faith discussions by the Vice President of External Science and Technology of BMS and the CEO or senior executive officer of Athersys (or each such person’s designee), and failing resolution thereby by mediation under the Commercial Mediation Rules of the American Arbitration Association, before resorting to arbitration, litigation, or some other dispute resolution procedure.

      9.2 Arbitration. Subject to Section 9.1, Athersys and BMS agree that any dispute or controversy arising out of, in relation to, or in connection with this Agreement, or the validity, enforceability, construction, performance or breach thereof, shall be settled by binding arbitration in New York, New York, under the then-current Rules of Commercial Arbitration of the American Arbitration Association by one (1) arbitrator appointed in accordance with such Rules. The arbitrator shall determine what discovery will be permitted, based on the principle of limiting the cost and time that the Parties must expend on discovery; provided, however, that the arbitrator shall permit such discovery as he or she deems necessary to achieve an equitable resolution of the dispute. The decision and/or award rendered by the arbitrator shall be written, final and non-appealable, absent manifest error, and may be entered in any court of competent jurisdiction. The Parties agree that, any provision of applicable law notwithstanding, they will not request, and the arbitrator shall have no authority to award punitive or exemplary damages against any Party. The costs of any arbitration, including administrative fees and fees of the arbitrator, shall be shared equally by the Parties, unless the arbitrator determines otherwise.

10.

Indemnification.

      10.1 By BMS. Subject to Section 10.3, BMS shall indemnify, defend and hold harmless Athersys and its directors, officers and employees (each an “Athersys Indemnitee”) from and against any and all liabilities, damages, losses, costs or expenses (including attorneys’ and professional fees and other expenses of litigation and/or arbitration) (each a “Liability”) resulting from a claim, suit or proceeding made or brought by a Third Party against an Athersys Indemnitee arising from or occurring as a result of (i) any breach of the representations and warranties set forth in Section 8.2, or (ii) the performance (or failure to perform) by BMS of its obligations hereunder.

      10.2 By Athersys. Subject to Section 10.3, Athersys shall indemnify, defend and hold harmless BMS and its directors, officers and employees (each a “BMS Indemnitee”) from and against any and all Liabilities resulting from a claim, suit or proceeding made or brought by a Third Party against a BMS Indemnitee arising from or occurring as a result of (i) any breach of the representations and warranties set forth in Section 8.1, or (ii) the performance (or failure to perform) by Athersys of its obligations hereunder.

      10.3 Limitation on Indemnity Obligations.

           (a) Negligence, etc. No Athersys Indemnitee or BMS Indemnitee (each, an “Indemnitee”) shall be entitled to the indemnification under Section 10.1 or 10.2, as the case may be, to the comparative extent the Liability for which indemnification is sought was caused by a grossly negligent, reckless or intentional act or omission by the Party with which such Indemnitee is affiliated or any of such Party’s Affiliates or sublicensees or any of their respective directors, officers, employees or authorized agents.

           (b) Target Proteins and Collaboration Cell Lines. Athersys acknowledges and agrees that it will conduct a reasonable intellectual property investigation of each target protein that is the basis of a particular Collaboration Cell Line, and of matters relating to the creation of the Collaboration Cell Line, that BMS selects and Athersys agrees to produce pursuant to Section 2.1, which shall be in addition to any such investigation that BMS may have conducted. BMS also acknowledges and agrees that it will conduct a reasonable intellectual property investigation of each target protein that BMS proposes for selection by Athersys as the basis for producing a Collaboration Cell Line pursuant to Section 2.1, which shall be in addition to any such investigation that Athersys may conduct, and shall disclose to Athersys the results of such investigation. BMS shall not be obligated to provide indemnification under Section 10.1 against any Liabilities resulting from a claim, suit or proceeding to the extent it is alleged, proven or agreed in such claim, suit or proceeding that any such target protein (or the creation of the corresponding Collaboration Cell Line) infringes upon or otherwise violates the intellectual property rights of any Third Party, except to the comparative extent such infringement or violation results from a grossly negligent, reckless or intentional act or omission by BMS or any of BMS’ Affiliates or any of their respective directors, officers, employees or authorized agents.

      10.4 Procedure. In the event that an Indemnitee intends to claim indemnification under this Article 10, it shall promptly notify the indemnifying Party in writing of such alleged Liability. The indemnifying Party shall have the sole right to control the defense and settlement thereof. The indemnifying Party shall have the right to settle or compromise any Liabilities for which it is providing indemnification under this Article 10, provided that the consent of the Indemnitee (which shall not be unreasonably withheld or delayed) shall be required in the event any such settlement or compromise would adversely affect the interests of such Indemnitee. The Indemnitees shall cooperate with the indemnifying Party and its legal representatives in the investigation of any action, claim or liability covered by this Article 10. The Indemnitees shall not, except at their own cost, voluntarily make any payment or incur any expense with respect to any claim or suit without the prior written consent of the indemnifying Party, which the indemnifying Party shall not be required to give.

11.

Term and Termination.

      11.1 Term of Agreement. The term of this Agreement (the “Term”) shall commence on the Effective Date and continue until expiration upon the end of all royalty and payment obligations of BMS under Article 4, or until such earlier date as the Parties agree in writing to terminate the Agreement or the Agreement terminates as provided below.

      11.2 Termination for Cause. Either Party may terminate this Agreement in the event the other Party has materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued without cure for sixty (60) days after written notice thereof was provided to the breaching Party by the non-breaching Party. Any termination shall become effective at the end of such sixty (60) day period unless the breaching Party has cured any such breach or default prior to the expiration of the sixty (60) day period. Notwithstanding the above, in the case of a failure to timely pay any amounts due hereunder, the period for cure of any subsequent default following notice thereof shall be thirty (30) days and, unless payment is made within such period the termination shall become effective at the end of such period.

      11.3 Effect of Termination.

           (a) Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching Party may be entitled to injunctive relief as a remedy for any such breach.

           (b) Return of Confidential Information. Upon any termination of this Agreement, each of Athersys and BMS shall promptly return to the other Party all Confidential Information of the other; provided that counsel of each Party may retain one (1) copy of such Confidential Information solely for archival purposes.

           (c) Survival. Sections 3.5 and 11.3, and Articles 4, 5, 6, 7, 9, 10 and 12 of this Agreement shall survive termination of this Agreement for any reason.

12.

Miscellaneous.

      12.1 Governing Law. This Agreement and any dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to its conflict of laws rules and regulations.

      12.2 Independent Contractors. The relationship of the parties hereto is that of independent contractors. The parties hereto are not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby.

      12.3 Assignment. Neither Party may assign its rights or obligations under this Agreement absent the prior written consent of the other Party, not to be unreasonably withheld; provided, however, that either Party may assign this Agreement without such consent to any of its Affiliates or to any successor in interest by merger, acquisition or sale of all or substantially all of its assets in a manner such that the assignee will be liable and responsible for the performance and observance of all its duties and obligations hereunder. This Agreement shall be binding upon the successors and permitted assigns of the Parties. Any attempted delegation or assignment not in accordance with this Section 12.3 shall be void and of no force or effect. In the case of BMS, if any such successor in interest had, before its merger with, or acquisition or purchase of, BMS, an agreement with Athersys providing such entity with a license to the RAGE Technology, then within ninety (90) day after the effective date of such merger, acquisition or purchase Athersys may terminate this agreement, upon written notice to such successor in interest.

      12.4 Notices. All notices, requests and other communications hereunder shall be in writing and shall be personally delivered or sent by telecopy or other electronic facsimile transmission or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other parties hereto:

      12.5 Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting Party if the failure is occasioned by war or terrorism, strike, fire, Act of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the nonperforming Party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance.

      12.6 Advice of Counsel. BMS and Athersys have each consulted counsel of their choice regarding this Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly.

      12.7 Compliance with Laws. Each Party will comply with all applicable laws and regulations in connection with its performance under this Agreement. Each Party shall furnish to the other Party any information requested or required by that Party during the term of this Agreement or any extensions hereof to enable that Party to comply with the requirements of any U.S. or foreign federal, state and/or government agency.

      12.8 Severability. In the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. In such event, the parties shall in good faith attempt to negotiate a substitute clause for any provision declared invalid or unenforceable, which substitute clause shall most nearly approximate the intent of the Parties in agreeing to such invalid provision, without itself being invalid.

      12.9 Waiver. It is agreed that no waiver by either Party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default.

      12.10 Complete Agreement. This Agreement, together with its Exhibits, constitutes the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and that all prior agreements, including the term sheet, respecting the subject matter hereof, either written or oral, expressed or implied, are merged and canceled, and are null and void and of no effect as of the Effective Date. No amendment or change hereof or addition hereto shall be effective or binding on either of the parties hereto unless reduced to writing and duly executed on behalf of both Parties. For clarity, the cells lines created under the Original Agreement, and any amendments thereto, are not considered within the subject matter of this Agreement.

      12.11 Use of Name. Unless otherwise permitted by this Agreement or required by applicable laws or regulations, neither Party shall use the name or trademarks of the other Party without the prior written consent of such other Party.

      12.12 Headings. The captions to the several Sections and Articles hereof are not a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation.

      12.13 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original and which together shall constitute one instrument.

* * *

      In Witness Whereof , BMS and Athersys have executed this Agreement by their respective duly authorized representatives.

Exhibit A

RAGE-VT CELL LINES

A. Creation of Collaboration Cell Lines

Within ninety (90) days after the Effective Date, BMS shall provide Athersys with an initial list of specific proteins for which BMS requests that Athersys will create RAGE libraries, for Athersys’ review under Section 2.1(a). If Athersys accepts such proposed proteins as provided therein, Athersys shall seek to create RAGE libraries, and screen and isolate Collaboration Cell Lines expressing such proteins after the Parties agree upon Acceptance Criteria for each particular Collaboration Cell Line. Such list may be supplemented from time to time by mutual agreement of the Parties or by designation of additional specific proteins by BMS and acceptance of such proteins by Athersys, as provided in Section 2.1 and in accordance with the procedure provided below.

From time to time, BMS may nominate specific proteins for consideration by Athersys under Section 2.1 for use in constructing a Collaboration Cell Line using its RAGE technology and other Athersys Know-How. Any such Collaboration Cell Line shall conform to the general specifications set forth in Section B below and to any other specific requirements agreed to by the Parties.

Athersys shall have the right, before accepting such request of a particular protein by BMS hereunder, to review and approve the technical and intellectual property feasibility of constructing the requested Collaboration Cell Line. If requested by Athersys, BMS shall promptly provide to Athersys the relevant technical requirements of BMS for the requested Collaboration Cell Line. Athersys shall make its determination of technical feasibility, intellectual property analysis and/or conflict with preexisting exclusive research obligations to Third Parties or preexisting internal research programs for which research has commenced prior to receiving notice (a “Pre-existing Program”), within forty-five (45) days of the request by BMS. If Athersys believes that the project is not constrained by any of these considerations or fails to provide any such notice within such forty-five (45) day period, then the nominated protein (and corresponding Collaboration Cell Line) shall be deemed to be added to this Exhibit A. If Athersys believes the project is constrained by any of such considerations and provides such notice within such forty-five (45) day period, such protein and cell line shall not be added to Exhibit A; provided that Athersys shall provide to BMS all pertinent information Controlled by Athersys regarding the basis for its rejection of such request. In that event, BMS shall be entitled to nominate another protein (with the foregoing process being repeated), until a protein nominated by BMS hereunder is accepted by Athersys. For purposes of calculating the maximum number of cell lines permitted under this Agreement, any substitute request made by BMS shall be deemed to have been made as of the date of the original request.

In addition, in the event Athersys commences a Pre-existing Program with respect to a target (either internally or with a Third Party), and BMS subsequently proposes such target under Section 2.1, Athersys shall promptly inform BMS of such program and request that BMS propose a substitute target. In such event, Athersys shall, upon BMS’ request, provide, on a confidential basis, a reasonable demonstration of such commencement and prosecution of any

As used in this Exhibit B, the phrase “Initiation of first Phase III clinical study” shall be deemed to include, if a party conducts a Phase II/III study on a Candidate Compound, the point during such Phase II/III clinical trial when the party conducting the trial has the regulatory approval to proceed with such trial as a pivotal trial.

BMS shall promptly notify Athersys of the first occurrence of any milestone with respect to each Candidate Compound. Milestone payments shall be made only once with respect to any given Candidate Compound, regardless of the number of indications sought (or approvals obtained) with respect to such Candidate Compound, whether alone or in combination with other compounds or products, and regardless of any new dosage strengths, preparations or forms of administration for such Candidate Compound.

If BMS develops as a back-up Candidate Compound that inhibits or otherwise modulates the activity of a particular molecular target of a Candidate Compound on which BMS is already making milestone payments, then BMS may conduct clinical development on such back-up or follow-on Candidate Compounds and shall not be obligated to make any milestone payments with respect to any such back-up or follow-on Candidate Compound, except as otherwise provided below. In the event that a particular Candidate Compound is dropped from active clinical development work or marketing for safety or efficacy reasons and is specifically replaced with a different Candidate Compound targeting the same molecular target as such dropped Candidate Compound, such new Candidate Compound shall be deemed a “Replacement Compound.” BMS shall not be obligated to make milestone payments that were earlier made with respect to a dropped Candidate Compound and replaced by a Replacement Compound, but, subject to the preceding paragraph, BMS shall pay all milestone payments for milestone events achieved by such Replacement Compound that had not been achieved by such dropped Candidate Compound.

Exhibit C

FORM PRESS RELEASE

Exhibit C

ATHERSYS EXPANDS PARTNERSHIP WITH BRISTOL-MYERS SQUIBB

CLEVELAND, August 5, 2002 - Athersys Inc. today announced that it has successfully completed the initial phase of its alliance with Bristol-Myers Squibb Company (NYSE: BMY) and has expanded the collaboration to include the delivery of additional validated drug targets during the next 3 years, with guaranteed yearly minimums. The agreement covers the use of the targets for drug discovery in multiple therapeutic areas.

The companies originally entered into a research and development collaboration in January 2001. Under the terms of that agreement, Athersys applied its RAGE-VT™ technology to provide Bristol-Myers Squibb with an initial set of validated drug targets for use in pharmaceutical screening and development. The collaboration anticipated a potential expansion upon successful conclusion of the initial phase, at the option of both companies.

Bristol-Myers Squibb plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated drug target cell lines produced and optimized for high-throughput screening by Athersys. In exchange, Athersys will receive license fees for each target cell line, as well as milestone payments on the development of therapeutic candidates, and royalty payments on sales of products that are developed by Bristol-Myers Squibb against the designated drug targets.

“Athersys is committed to partnering with leading pharmaceutical companies like Bristol-Myers Squibb to provide access to cell lines expressing validated biological targets for applications in high-throughput drug screening and lead compound optimization. Our relationship with Bristol- Myers Squibb has been highly successful and the expansion of this collaboration marks an important landmark for Athersys,” said Gil Van Bokkelen, Ph.D., chairman, president and chief executive officer of Athersys. “This collaboration is in keeping with our overall business strategy to improve our partners’ access to drug targets, while using the revenues from these collaborations to build our in-house pipeline of novel therapeutics.”

Athersys is a functional genomics and biopharmaceutical company engaged in the development, application and commercialization of novel gene expression tools and therapeutic products. The company’s research and development programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expression™) and SMC™ (Synthetic Microchromosome™) vector system. RAGE is a novel gene expression system that provides the unique ability to produce protein from virtually every gene in the human genome, without requiring the cloning of individual genes or use of cDNA libraries. RAGE greatly accelerates the identification and validation of novel drug targets by enabling the direct correlation of a disease process or characteristic with expression of a specific protein. As a result, RAGE has powerful applications in functional genomics; the generation of validated drug targets; discovery of novel antibody drug targets; structural proteomics and rational drug design; and the production of protein therapeutics. Athersys is developing novel therapeutic products based on its proprietary technologies, through partnerships and internal research and development programs. This press release and further information on Athersys, Inc. can be found on the World Wide Web at: www.athersys.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early stage of products under development; uncertainties related to patent protection; uncertainties relating to clinical trials; dependence on third parties, including strategic partners, collaborators and key personnel; and risks relating to the development and commercialization, if any, of Athersys’ proposed products (such as effectiveness of our products, marketing, manufacturing, safety, regulatory, patent or product liability, supply, competition and other risks).

Contacts:

William Lehmann
Executive Vice President
Corporate Development and Finance
Athersys Inc.
(216) 431-9900
bjlehmann@athersys.com

EXHIBIT 10.3

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE REDACTED PORTIONS OF THIS EXHIBIT, AND SUCH CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

EXTENDED COLLABORATION AND LICENSE AGREEMENT

      This Extended Collaboration and License Agreement (the “Agreement”) is made and entered into as of January 1, 2006 (the “Effective Date”), by and between Athersys, Inc. , a Delaware corporation having its principal offices at 3201 Carnegie Avenue, Cleveland, Ohio 44115 (“Athersys”), and Bristol-Myers Squibb Company , a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”). Athersys and BMS may be referred to herein individually as a “Party” and collectively as the “Parties.”

Recitals

      A.  Athersys has developed and owns technology and intellectual property rights relating to methods for activating gene or protein expression in cells, referred to by Athersys as the Random Activation of Gene Expression or RAGE technology, which includes the RAGE-VT technology useful for creating cell lines that express particular desired proteins.

      B.  BMS desires to engage Athersys to create certain such cell lines, using the RAGE-VT technology, each of which expresses a specific cell surface or cellular protein of interest to BMS, and to obtain license rights to use such cell lines for internal research, development and commercialization of pharmaceutical products.

      C.  Athersys is willing to create and provide BMS with the desired cell lines pursuant to the terms of this Agreement.

      D.  The Parties entered into a Research Collaboration and License Agreement, dated December 8, 2000 (the “Original Agreement”) and subsequently entered into a Cell Line Collaboration and License Agreement dated July 1, 2002 (the “Prior Agreement”), each related to the creation of cell lines by Athersys for use by BMS.

      E.  Concurrently with entering into this Agreement, Athersys and BMS are amending the Prior Agreement to acknowledge that BMS has fulfilled its obligation to propose and accept a minimum number of cell lines as set forth in the Prior Agreement.

      F.  For avoidance of doubt, all cell lines nominated by BMS after July 1, 2002 and prior to the Effective Date of this Agreement shall be governed by the Prior Agreement and all cell lines nominated by BMS prior to July 1, 2002 shall be governed by the Original Agreement and not this Agreement. All cell lines nominated by BMS after the Effective Date of this Agreement shall be governed by this Agreement.

      Now, Therefore , in consideration of the foregoing and the covenants and promises contained in this Agreement, the Parties agree as follows:

1.

Definitions

     As used herein, the following capitalized terms shall have the following meanings (with terms defined in the singular having the same meanings when used in the plural):

      1.1 “Accepted Cell Line” shall have the meaning assigned to such term in Section 2.3(a).

      1.2 “Affiliate” shall mean, with respect to a Party, any corporation or other entity that, directly or indirectly, controls, is controlled by or is under the common control with such Party. For the purpose of this definition, “control” shall mean (a) the direct or indirect ownership of fifty percent (50%) or more of the outstanding shares or other voting rights of the subject entity to elect directors, or (b) if such amount of ownership of a foreign entity is not permitted by law, ownership of the maximum amount of such entity as permitted by law, or (c) the actual ability to control and direct the management of the subject entity.

      1.3 “Athersys Know-How” shall mean the Information that is Controlled by Athersys during the term of this Agreement and relates directly to Collaboration Cell Lines or their method of manufacture or use in the Field or for Counterscreening, as applicable, but excluding Athersys Patents.

      1.4 “Athersys Patents” shall mean all Patents that are Controlled by Athersys during the term of the Agreement and contain a Valid Claim covering a Collaboration Cell Line or its method of manufacture or use in the Field or for Counterscreening, as applicable.

      1.5 “Athersys Technology” shall mean the Athersys Know-How and Athersys Patents collectively.

      1.6 “Candidate Compound” shall mean:

           (a) any compound that has activity, with respect to the target protein expressed by the applicable Accepted Cell Line, which activity is initially discovered or detected by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line, where such activity is potentially useful for therapeutic or prophylactic use, or

           (b) any compound that is an analog, homolog, isomer or other chemical derivative of a compound that meets the criteria in subsection (a) above (the “Parent Compound”), provided that such compound (i) was made by or on behalf of BMS or its Affiliate or sublicensee based on information relating to the Parent Compound, and (ii) has activity that is potentially useful for therapeutic or prophylactic use and is similar or related to the activity of such Parent Compound (with the understanding that such activity may be superior to the activity of the Parent Compound, in any appropriate criteria).

      1.7 “Collaboration Cell Line” shall have the meaning assigned to such term in Section 2.1(b).

      1.8 “Confidential Information” shall mean (a) any proprietary or confidential information or material of a Party in tangible form disclosed hereunder that is (i) marked as

“Confidential” at the time it is delivered to the receiving Party, or (ii) designated as confidential or proprietary in a written memorandum provided to the receiving Party by the disclosing Party within thirty (30) days of such disclosure, or (b) any proprietary or confidential information of a Party disclosed orally hereunder that is identified as confidential or proprietary when disclosed and designated as confidential or proprietary in a written memorandum provided to the receiving Party by the disclosing Party within thirty (30) days of such oral disclosure by the disclosing Party. Further, it is agreed that if Athersys discloses to BMS that it is working on a particular protein or gene target, such information shall be treated by BMS as the Confidential Information of Athersys. Still further, it is agreed that Athersys shall treat the fact that BMS has nominated a specific target under Section 2.1 and the fact that Athersys has provided BMS with a corresponding Collaboration Cell Line under Section 2.2 as Confidential Information of BMS.

      1.9 “Controlled” shall mean, with respect to any material, Information or intellectual property right, that a Party owns or has a license to such material, Information or intellectual property right and has the ability to grant to the other Party the licenses or sublicenses thereto as provided for herein without violating the terms of any agreement with any Third Party.

      1.10 “Counterscreening” shall mean testing a BMS compound, which has known activity against one target, for activity against another target that is expressed in an Accepted Cell Line, for the purpose of determining the relative selectivity and potency of the BMS compound for the first target.

      1.11 “Counterscreening Cell Line” shall mean an Accepted Cell Line that was selected by BMS to be used in Counterscreening as provided in Section 2.5.

      1.12 “Counterscreening License” shall have the meaning assigned to it in Section 3.3.

      1.13 “Field” shall mean use of the Accepted Cell Lines by BMS solely for BMS’s internal discovery, research, development and/or commercialization of Products. For the avoidance of doubt, subject to Section 3.5(b), the Field shall include BMS’s use of the Accepted Cell Lines in connection with any bona fide collaboration between BMS and an academic and/or corporate collaborator, provided that any compounds initially discovered or detected pursuant to such collaboration by using an Accepted Cell Line or materials or assays derived from an Accepted Cell Line shall be deemed to be Candidate Compounds. The Field expressly excludes the use of Accepted Cell Lines by BMS for Counterscreening.

      1.14 “HTS” shall mean high throughput screening using BMS’ test deck of compounds in primary screening of the Accepted Cell Line. HTS shall be deemed “completed” when BMS has screened the test deck, confirmed positive responses, and completed standard data analysis.

      1.15 “Improvement” shall mean any improvement, modification or enhancement to the Athersys Know-How or the inventions claimed in the Athersys Patents (and/or the practice thereof), and any Information and intellectual property rights relating thereto, that the possessing Party has the right to disclose to the other Party without violating contractual obligations to a Third Party. For the avoidance of doubt, the following shall be owned by BMS and shall not

comprise Improvements: (i) Information comprising the results of any assays or other screening or testing generated by BMS through use of the Accepted Cells Lines under the terms of this Agreement, and any Information developed based on evaluating or using such results (which shall exclude, for clarity, any such Information that relates to the manufacture of such Accepted Cell Lines via the RAGE-VT method or use of same); (ii) any methodology, process or tool, whether previously existing or created during the Term (without use of an Accepted Cell Line), that is proprietary to BMS and that BMS uses to generate the Information referred to in clause (i); and (iii) any invention based on, or improvement, modification, or enhancement of, the proprietary know-how of BMS that is created in connection with the subject matter of this Agreement and the use or practice of which does not involve the use of any Athersys Technology.

      1.16 “Information” shall mean information, results and/or data of any type whatsoever, in any tangible or intangible form, including without limitation databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions.

      1.17 “License” shall have the meaning assigned to it in Section 3.2.

      1.18 “Net Sales” shall mean the amount invoiced or otherwise billed by BMS or its Affiliate or licensee for sales or other commercial disposition of a Product to a Third Party purchaser, less the following to the extent included in such billing or otherwise actually allowed or incurred with respect to such sales: (i) discounts, including cash, trade and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a product, charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments (or their respective agencies, purchasers and reimbursers) or to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups; (ii) credits or allowances actually granted upon rejections or returns of Products, including for recalls or damaged goods; (iii) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Products, to the extent billed; (iv) customs duties, tariffs, surcharges and other governmental charges incurred in connection with the exportation or importation of a Product; (v) bad debts relating to sales of Products that are actually written off by BMS in accordance with generally accepted accounting principles, consistently applied, during the applicable royalty calculation period, and (vi) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on sale of Products, including without limitation value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based on net income of the seller; provided that all of the foregoing deductions are calculated in accordance with generally accepted accounting principles consistently applied throughout the party’s organization.

Notwithstanding the foregoing, if any Product is sold under a bundled or capitated arrangement with other BMS products, then, solely for the purpose of calculating Net Sales for royalty purposes hereunder, any discount on such Product sold under such an arrangement shall be no greater, on a percentage basis based on the gross selling price prior to discount, than the largest percentage discount applied on the other pharmaceutical products sold within such bundled

arrangement for the applicable accounting period. In case of any dispute as to the applicable discount numbers under the preceding sentence, the determination of same shall be calculated and certified by BMS’ independent public accountants, whose decision shall be binding.

A sale of a Product is deemed to occur upon the earliest of invoicing or transfer of title in the Product to the Third Party purchaser. In the event that BMS, after reasonable efforts, cannot calculate accurately the Net Sales of a sublicensee in a particular country, the Parties will meet and negotiate in good faith an appropriate means for calculating “Net Sales” in such a situation.

For sake of clarity and avoidance of doubt, sales by BMS, its Affiliates or sublicensees of a Product to a Third Party distributor of such Product in a given country shall be considered sales to a Third Party customer, but sales and/or transfers of a Product between or among BMS, its Affiliates or sublicensees shall not be considered sales to a Third Party customer, so long as such recipient subsequently resells the Product. Any Products used (but not sold for consideration) for promotional or advertising purposes or used for clinical or other research purposes shall not be considered in determining Net Sales hereunder.

In the event a Product is sold as an end-user product consisting of a combination of active functional elements or as a combined product and/or service, Net Sales, for purposes of determining royalty payments on such Product, shall be calculated by multiplying the Net Sales of the end-user product and/or service by the fraction A over A+B, in which A is the gross selling price of the Product portion of the end-user product and/or service when such Product is sold separately during the applicable accounting period in which the sales of the end-user product were made, and B is the gross selling price of the other active elements and/or service, as the case may be, of the end-user product and/or service sold separately during the accounting period in question. All gross selling prices of the elements of such end-user product and/or service shall be calculated as the average gross selling price of the said elements during the applicable accounting period for which the Net Sales are being calculated. In the event that, in any country or countries, no separate sale of either such above-designated Product or such above designated elements of the end-user product and/or service are made during the accounting period in which the sale was made or if gross retail selling price for an active functional element, component or service, as the case may be, cannot be determined for an accounting period, Net Sales allocable to the Product in each such country shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining same that takes into account, on a country by country basis, variations in potency, the relative contribution of each active agent, component or service, as the case may be, in the combination, and relative value to the end user of each active agent, component or service, as the case may be.

Notwithstanding the foregoing, it is agreed that drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients” or “active functional elements,” the presence of which in a Product would be deemed to create a combination product subject to the terms of the preceding paragraph.

      1.19 “Patents” shall mean all issued United States and foreign patents (including all reissues, extensions, renewals, substitutions, re-examinations, supplementary protection

certificates and the like, and patents of addition) and pending United States and foreign patent applications (including, without limitation, all provisional and nonprovisional applications and all continuations, continuations-in-part and divisions thereof).

      1.20 “Product” shall mean any product containing a Candidate Compound, including any formulation, dosage form, packaged form or delivery means thereof.

      1.21 “RAGE Technology” shall mean any and all intellectual property, whether or not patentable, that is owned or licensed by Athersys and relates to Athersys’ techniques for activating gene expression, which are referred to by Athersys collectively as Random Activation of Gene Expression or RAGE technology.

      1.22 “Term” shall have the meaning assigned to it in Section 11.1.

      1.23 “Third Party” means any entity other than Athersys, BMS or an Affiliate of either of them.

      1.24 “Valid Claim” shall mean either (i) a claim of issued and unexpired letters patent which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a claim of a pending patent application that has not been pending for more than seven (7) years and that has not been abandoned or finally rejected without the possibility of appeal or refiling.

2.

Collaboration Program

      2.1 Review of Proposed Cell Lines by Athersys.

           (a) Subject to the limits set forth in Section 2.2, Athersys shall create new Accepted Cell Lines based on RAGE-VT cell lines that BMS proposes, as set forth in Exhibit A , and Athersys has accepted as provided below. BMS shall use reasonable, good faith efforts to assure that the aggregate level of technical difficulties and legal risks associated with the cell lines that BMS nominates is balanced and provides Athersys a reasonable opportunity to perform hereunder. Athersys shall have the right to review and approve, as provided in Exhibit A , the target protein to be expressed in each RAGE-VT cell line that BMS proposes be made under this Agreement. Athersys shall complete such review within forty-five (45) days after the date Athersys receives information from BMS regarding a proposed target to be expressed in a RAGE-VT cell line, or upon any other schedule to which the Parties may mutually agree in writing. Athersys shall use reasonable, good faith efforts to assure that the aggregate level of technical difficulties and legal risks associated with the cell lines that Athersys accepts is balanced and provides a reasonable opportunity for the generation of Accepted Cell Lines hereunder.

           (b) While Athersys is completing such review, the Parties shall promptly negotiate specific Acceptance Criteria for such cell line based upon the Acceptance Criteria as generically set forth in Exhibit A . Upon agreement by the Parties on the specific Acceptance Criteria for a particular proposed RAGE-VT cell line, such Acceptance Criteria shall be included

7

8

9

10

11

12

Event		Payment
Six (6) Month Anniversary of Completion of HTS for Accepted Cell Line		$[*]
•     Payable at the end of the six (6) month period beginning on the date BMS completes HTS for such Accepted Cell Line
Twelve (12) Month Anniversary of Completion of HTS for Accepted Cell Line		$[*]
•     Payable at the end of the twelve (12) month period beginning on the date BMS completes HTS for such Accepted Cell Line
Eighteen (18) Month Anniversary of Completion of HTS for Accepted Cell Line		$[*]
•     Payable at the end of the eighteen (18) month period beginning on the date BMS completes HTS for such Accepted Cell Line
Twenty-Four (24) Month Anniversary of Completion of HTS for Accepted Cell Line		$[*]
•     Payable at the end of the twenty-four (24) month period beginning on the date BMS completes HTS for such Accepted Cell Line

1		Confidential treatment has been requested for the redacted portions of this exhibit, and such confidential portions have been omitted and filed separately with the Securities and Exchange Commission.

13

Event		Payment
Agreed upon Acceptance Criteria		$[*]
•     Athersys accepts BMS’ request for the development of a Collaboration Cell Line, and the Parties mutually agree upon Acceptance Criteria therefor
Clonal Cell Line Isolated		$[*]
•     Verified through RT- PCR proof of appropriate vector integration
Cell Line Acceptance (designation of Counterscreening Cell Line)		$[*]
•     Achievement, pursuant to Section 2.3(a), of all specific Acceptance Criteria previously mutually agreed upon by the Parties for the proposed Counterscreening Cell Line

1		Confidential treatment has been requested for the redacted portions of this exhibit, and such confidential portions have been omitted and filed separately with the Securities and Exchange Commission.

14

1		Confidential treatment has been requested for the redacted portions of this exhibit, and such confidential portions have been omitted and filed separately with the Securities and Exchange Commission.

15

16

---

 

18

19

---

 

21

22

23

24

25

26

				Testing to determine if
Category		Criteria		Criteria are Met by:
1. Vector integration upstream of target gene in HEK 293 or HT 1080 cells or other cell lines specified by the Parties		RT-PCR demonstrating RIG vector (RAGE specific vector) spliced to target sequence mRNA		Athersys
2. Target gene mRNA over-expression (RAGE vs. parental)		Quantitative PCR (qPCR) demonstrating >10 fold mRNA increase		Athersys
3. Target protein over-expression (RAGE vs. parental) and functionality (Primary Assay format)		•      Functional assay: such as FLIPR with dose response, agonist/antagonist, cAMP determination
		or
		•      Protein over-expression: a ten-fold increase of Target protein in RAGE clone versus parental, as determined by Western blot or FACS analysis		Athersys
4. RAGE clone robustness		•      Freeze/thaw
		•      Expression stability (e.g. qPCR) over four weeks		Athersys
5. RAGE cell line performance in HTS		Performance in Primary Assay under simulated HTS conditions and general Cell Line characteristics.		BMS

 

1		Confidential treatment has been requested for the redacted portions of this exhibit, and such confidential portions have been omitted and filed separately with the Securities and Exchange Commission.

2

 

EXHIBIT 10.35

CONFIDENTIAL

Execution Copy

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE REDACTED PORTIONS OF THIS EXHIBIT, AND SUCH CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

STRATEGIC ALLIANCE AGREEMENT

By and Between

ATHERSYS, INC.

and

ANGIOTECH PHARMACEUTICALS, INC.

Effective as of May 5, 2006

TABLE OF CONTENTS

		Page
ARTICLE I. DEFINITIONS			2
ARTICLE II. CERTAIN TRANSACTION COMPONENTS			11
2.1 Concurrent Execution.			11
2.2 Right of First Negotiation for Non-Licensed Cardiovascular Indications.			11
2.3 Additional Investment.			13
2.4 Phase I Milestone Fee.			13
2.5 Exclusivity.			14
2.6 Retained Rights.			14
2.7 Costs Borne by Each Party.			15
2.8 Certain Restrictions on Athersys’ Activities Outside of Cardiovascular Indications.			15
ARTICLE III. JOINT STEERING COMMITTEE			15
3.1 Joint Steering Committee.			15
3.2 Subcommittees.			15
3.3 Chairperson.			15
3.4 JSC Meetings.			15
3.5 Responsibilities of the Joint Steering Committee.			16
3.6 Voting; Decision-Making.			19
3.7 JSC Disputes.			19
ARTICLE IV. PRE-CLINICAL DEVELOPMENT			20
4.1 Existing Pre–Clinical Development Programs.			20
4.2 Costs for Existing Pre-Clinical Development Programs.			21
4.3 New Pre-Clinical Development Programs.			21
ARTICLE V. CLINICAL DEVELOPMENT			21
5.1 Proposed Clinical Plans; Clinical Development Plans.			21
5.2 Athersys Responsibilities.			21
5.3 Angiotech Responsibilities.			22
5.4 Subcontracting.			22

 - i -

TABLE OF CONTENTS
(continued)

		Page
ARTICLE VI. OPT-OUT RIGHTS			23
6.1 Opt-Out Rights.			23
6.2 Development Updates.			25
6.3 Failure to Exercise Sole Development Option.			25
6.4 Diligence Requirement.			25
ARTICLE VII. COSTS, PAYMENTS AND FINANCIAL RECORD KEEPING			26
7.1 Clinical Development Costs.			26
7.2 Development Costs Quarterly Reconciliation.			26
7.3 Milestone Payments.			27
7.4 Profit Sharing.			27
7.5 Royalties on Sole Development Products.			27
7.6 Calculation and Payment of Royalties.			29
7.7 Sharing of Sole Development Income.			30
7.8 Financial Record Keeping.			31
7.9 Audits.			31
7.10 Late Payments.			31
ARTICLE VIII. COMMERCIALIZATION			32
8.1 Commercialization of Cell Therapy Products.			32
ARTICLE IX. MANUFACTURE AND SUPPLY OF CLINICAL DEVELOPMENT CANDIDATES AND CELL THERAPY PRODUCTS			32
9.1 Athersys’ Manufacturing Obligation.			32
9.2 Manufacturing Costs.			33
9.3 Manufacturing Compliance.			33
9.4 Product Conformity.			33
9.5 Ordering; Forecasting; Acceptance and Rejection.			33
9.6 Inspection.			34
9.7 Supply Disruption.			34
9.8 Back-Up Supplier.			34

 - ii -

TABLE OF CONTENTS
(continued)

		Page
ARTICLE X. REGULATORY MATTERS			35
10.1 Ownership of Regulatory Documentation and Reference Rights; Regulatory Strategy.			35
10.2 Regulatory Communications.			35
10.3 Other Regulatory Responsibilities.			36
10.4 Cell Therapy Product Complaints and Recalls.			36
10.5 Compliance With All Applicable Laws and Regulations; Cooperation.			36
ARTICLE XI. INTELLECTUAL PROPERTY			37
11.1 Existing Intellectual Property Rights Retained.			37
11.2 Ownership Of New Intellectual Property.			37
ARTICLE XII. CLINICAL PROGRAM RECORD KEEPING			37
12.1 Scientific, Patent and Regulatory Records.			37
12.2 Review of Records.			37
12.3 Policies For Records.			38
ARTICLE XIII. CONFIDENTIAL INFORMATION			38
13.1 Confidential Information.			38
13.2 Confidentiality Obligations.			38
13.3 Permitted Disclosures.			39
13.4 Publication.			41
ARTICLE XIV. REPRESENTATIONS AND WARRANTIES			41
14.1 Authority.			41
14.2 No Conflicts.			41
14.3 Additional Representations and Warranties of Athersys.			42
14.4 Additional Covenants of Athersys.			44
14.5 Additional Covenants of Angiotech.			46
14.6 Disclaimer Of Warranties.			47
ARTICLE XV. INDEMNIFICATION AND INSURANCE			47
15.1 Indemnification By Athersys.			47
15.2 Indemnification By Angiotech.			48
15.3 Insurance.			49

 - iii -

TABLE OF CONTENTS
(continued)

		Page
ARTICLE XVI. TERM AND TERMINATION			49
16.1 Term.			49
16.2 Termination.			49
16.3 Effects of Termination.			52
16.4 Survival Of Obligations.			53
ARTICLE XVII. DISPUTE RESOLUTION			53
17.1 Dispute Resolution Process.			53
17.2 Injunctive Relief.			54
ARTICLE XVIII. MISCELLANEOUS PROVISIONS			55
18.1 Governing Law.			55
18.2 Assignment.			55
18.3 Compliance With Laws.			55
18.4 Further Assurances.			55
18.5 Severability.			55
18.6 Waivers And Amendments; Preservation Of Remedies.			56
18.7 Headings.			56
18.8 Counterparts.			56
18.9 Successors.			56
18.10 Notices.			56
18.11 No Consequential Damages.			57
18.12 Independent Contractor.			57
18.13 Complete Agreement.			57

SCHEDULES
Schedule 1.13
Schedule 1.14
Schedule 1.33
Schedule 1.45
Schedule 2.2
Schedule 4.1
Schedule 7.3
Schedule 7.4
Schedule 14.3(b)
Schedule 14.3(g)

 - iv -

TABLE OF CONTENTS
(continued)

		Page
Schedule 14.3(l)
EXHIBITS
Exhibit A – Note Purchase Agreement
Exhibit B – License Agreement
Exhibit C – Sublicense Agreement

STRATEGIC ALLIANCE AGREEMENT

     This Strategic Alliance Agreement (this “ Strategic Alliance Agreement ”) is made and entered into as of May 5, 2006 (the “ Effective Date ”), by and between Athersys, Inc., a corporation organized under the laws of Delaware and having a place of business at 3201 Carnegie Avenue, Cleveland, Ohio 44115 (“ Athersys ”), and Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia and having a place of business at 1618 Station Street, Vancouver, British Columbia, Canada V6A 1B6 (“ Angiotech ”). In this Strategic Alliance Agreement, Athersys and Angiotech may each be referred to as a “ Party ” and collectively as the “ Parties .”

RECITALS

     A. Angiotech is engaged in, among other things, design, research, development, manufacture and commercialization of medical devices and therapeutic, biopharmaceutical and biosurgery products and biomaterials.

     B. Athersys is engaged in, among other things, the research and development of therapeutic biologics to treat disease.

     C. Angiotech and Athersys desire to enter into a strategic alliance relating to the research, development, manufacture, market and commercialization of clinical development candidates and cell therapy products for the treatment and/or prophylaxis of certain cardiovascular diseases, disorders and conditions.

     D. Concurrently with the execution of this Strategic Alliance Agreement, Angiotech and Athersys are entering into that certain Note Purchase Agreement attached hereto as Exhibit A , pursuant to which Angiotech will loan $5,000,000.00 to Athersys pursuant to a convertible promissory note (the “ Note ”) on the terms and conditions set forth therein (such Note Purchase Agreement and the exhibits and schedules thereto, the “ Purchase Agreement ”).

     E. Concurrently with the execution of this Strategic Alliance Agreement, Angiotech and Athersys are entering into that certain License Agreement attached hereto as Exhibit B (such License Agreement and the exhibits and schedules thereto, the “ License Agreement ”) concerning Athersys’ license to Angiotech of technology and intellectual property related to certain stem cells and stem cell therapies.

     F. Concurrently with the execution of this Strategic Alliance Agreement, Angiotech and Athersys are entering into that certain Sublicense Agreement attached hereto as Exhibit C (such Sublicense Agreement and the exhibits and schedules thereto, the “ Sublicense Agreement” ) concerning Athersys’ sublicense to Angiotech of technology and intellectual property related to certain stem cells and stem cell therapies licensed from the University of Minnesota.

     G. This Strategic Alliance Agreement, the License Agreement and the Sublicense Agreement hereinafter shall be referred to collectively as the “ Transaction Agreements ”, and unless expressly specified otherwise in the License Agreement, the Sublicense Agreement or this

Strategic Alliance Agreement, the terms and conditions of this Strategic Alliance Agreement shall apply to all Transaction Agreements.

AGREEMENT

     NOW, THEREFORE, in consideration of the covenants and obligations expressed herein, and intending to be legally bound, the Parties agree as follows:

ARTICLE I.
DEFINITIONS

     1.1 “ Affiliate ” means, with respect to any Party, any corporation or other business entity which directly or indirectly through one or more intermediaries controls, is controlled by, or is under common control with such Party, but only for so long as the relationship exists. A corporation or other entity shall be regarded as in control of another corporation or entity (a) if it (or any of its subsidiaries or parents) beneficially owns, holds or directly or indirectly controls more than fifty percent (50%) of the voting capital stock (or such lesser maximum percentage permitted by applicable law considered a control percentage) or other ownership interest of such other corporation or entity, or (b) if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such other corporation or entity, or (c) if it possesses, directly or indirectly, the power to elect or appoint more than fifty percent (50%) of the members of the governing body of such other corporation or entity.

     1.2 “ Angiotech ” has the meaning ascribed to it in the preamble.

     1.3 “ Angiotech Indemnitees ” has the meaning ascribed to it in Section 15.1 .

     1.4 “ Athersys ” has the meaning ascribed to it in the preamble.

     1.5 “ Athersys Indemnitees ” has the meaning ascribed to it in Section 15.2 .

     1.6 “ Athersys Stem Cells ” has the meaning ascribed to it in the License Agreement.

     1.7 “ Athersys Stem Cell Technology ” has the meaning ascribed to it in the License Agreement.

     1.8 “ Cardiovascular Indications ” means myocardial infarction (whether chronic (e.g., ischemia) or acute) and peripheral vascular disease (excluding neurovascular) in humans.

     1.9 “ Cells ” means the following cells identified, developed, and/or intended for use for treatment and/or prophylaxis of a disease or condition in humans: (a) MAPCs; (b) progeny or components of any MAPCs; (c) derivatives of any of the foregoing (a) or (b); (d) genetically-modified MAPCs; and (e) Athersys Stem Cells; and including, without limitation, cells or tissues that are derived from any of the foregoing, as any of the foregoing cells might be at the time of treatment (i) in their native, undifferentiated

state, (ii) in a partially or fully pre-differentiated state, (iii) primed for differentiation (for example, through the introduction of a protein, peptide, gene, polynucleotide, small molecule or other active pharmaceutical ingredient), or (iv) in a modified form.

     1.10 “ Cell Therapy ” means the treatment and/or prophylaxis of a disease or condition, by regional, local, systemic or other delivery, localization and/or administration of Cells. The term “ Cell Therapy ” specifically excludes using (a) any of the Cells as reagents; (b) any of the Cells for diagnostic applications or assays; and (c) any of the Cells for drug and drug target validation screening. The term “ Cell Therapy ” specifically includes (x) delivery, localization and/or administration of a protein, peptide, gene, polynucleotide, small molecule or other active pharmaceutical ingredient (or any combination of the foregoing) at or near the time of delivery, localization and/or administration of Cells; (y) delivery, localization and/or administration of one or more fractions and/or subsets of Cells; and (z) delivery, localization and/or administration of one or more other cell types at or near the time of delivery, localization or administration of Cells.

     1.11 “ Cell Therapy Product ” means a therapeutic and/or prophylactic product for humans that (a) includes a Cell developed under this Agreement that is intended for use or used as Cell Therapy for at least one Cardiovascular Indication, and (b) has obtained Regulatory Approval in a given country or jurisdiction in the Territory.

     1.12 “ Clinical Development Candidate ” means (a) a Cell(s) that meets certain criteria and has certain characteristics that are necessary and desirable for the submission of an IND for use of such Cell(s) in Cell Therapy for at least one Cardiovascular Indication (and, therefore, make such Cell(s) suitable for a Clinical Development Program), as determined by the JSC; or (b) a Cell(s) that is or has been the subject of an IND for use of such Cell(s) in Cell Therapy for at least one Cardiovascular Indication. The term “Clinical Development Candidate” shall expressly exclude Cell Therapy Products.

     1.13 “ Clinical Development Costs ” means the costs incurred by the Parties in connection with their respective activities under a Clinical Development Plan, as such costs are more fully described on Schedule 1.13 .

     1.14 “ Clinical Development Plan ” means, for each Clinical Development Candidate, a detailed plan that sets forth the responsibilities of, and the activities to be conducted by, each of the Parties in advancing each such Clinical Development Candidate to Regulatory Approval for a Cardiovascular Indication (including a detailed budget corresponding to each such plan). Each such Clinical Development Plan shall include, without limitation, the following activities (or their equivalents), to the extent applicable:

          (a) conducting pre-clinical research, pre-clinical development and other pre-clinical studies that are intended to support clinical development of a Clinical Development Candidate for a Cardiovascular Indication;

          (b) preparation and filing of an IND for a Clinical Development Candidate for a Cardiovascular Indication;

          (c) conducting clinical trials of such Clinical Development Candidate for a Cardiovascular Indication, including clinical trials that are intended to support Regulatory Approvals for such Clinical Development Candidate for such Cardiovascular Indication; and

          (d) preparation and filing of documentation, applications (including, for example, an NDA/BLA) and related activities to enable the Parties to seek Regulatory Approval for such Clinical Development Candidate for such Cardiovascular Indication.

Each Clinical Development Plan approved by the Parties shall be attached hereto as Schedule 1.14 .

     1.15 “ Clinical Development Program ” means the clinical development activities conducted by (or to be conducted by) each Party pursuant to a Clinical Development Plan.

     1.16 “ Commercialization Costs ” means the costs incurred by Angiotech in connection with the promotion, marketing, advertising, sale and/or distribution of Cell Therapy Products, as such costs are more fully described on Schedule 1.13 .

     1.17 “ Commercially Reasonable Efforts ” shall mean efforts and deployment of resources, consistent with the exercise of reasonable and prudent scientific and business judgment, normally used by a research-based pharmaceutical company for a product owned by it or to which it has rights, which is of similar market potential at a similar stage in its development or product life, taking into account issues of safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the product, the regulatory and reimbursement structure involved, the cost of scaling up a manufacturing process (including facility costs), the profitability of the applicable products, and other relevant factors.

     1.18 “ Confidential Information ” has the meaning ascribed to it in Section 13.1 .

     1.19 “ Disclosing Party ” has the meaning ascribed to it in Section 13.1 .

     1.20 “ Effective Date ” has the meaning ascribed to it in the preamble.

     1.21 “ FDA ” means the United States Food and Drug Administration and any successor governmental agency having substantially the same function.

     1.22 “ FDA Approval ” means the receipt by a Party of all approvals by the FDA necessary or required for the commercialization in the United States of a Cell Therapy Product.

     1.23 “ First Commercial Sale ” shall mean, for each Cell Therapy Product in each country in the Territory on a country-by-country basis, the first sale by Angiotech, or a sublicensee of Angiotech, of a Cell Therapy Product to an independent Third Party after the required Regulatory Approval to sell such Cell Therapy Product in that country has been granted by the relevant regulatory authority. If Regulatory Approval is not required in order to sell a Cell Therapy Product in a particular jurisdiction, then First Commercial Sale shall mean the first transfer of title by Angiotech, or a sublicensee of Angiotech, of a Cell Therapy Product to an independent Third Party for consideration in any arm’s-length transaction in such jurisdiction. Cell Therapy Product sale shall be deemed to occur on the earlier of (a) the date the Cell Therapy Product is shipped to the purchaser, or (b) the date of the invoice to the purchaser of the Cell Therapy Product.

     1.24 “ IND ” means (a) an Investigational New Drug Application, as defined in the United States Federal Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder, that is required to be filed with the FDA before beginning clinical testing in the United States of a Clinical Development Candidate in human subjects, or any successor application or procedure; and (b) all supplements and amendments thereto, including any supplemental Investigational New Drug Application; and (c) any related foreign counterparts of (a) and (b) that may be filed with respect to the foregoing.

     1.25 “ Intellectual Property ” means all of the following (including any substantial equivalent or counterpart) in any jurisdiction throughout the Territory: (a) Patents and Patent Rights; (b) trademarks, service marks, trade dress, trade names, corporate names, logos and Internet domain names; (c) copyrights, software, source code and copyrightable works; (d) applications and registrations for any of the foregoing; and (e) Know-How.

     1.26 “ JSC ” has the meaning ascribed to it in Section 3.1 .

     1.27 “ JSC Dispute ” has the meaning ascribed to it in Section 3.7(a) .

     1.28 “ Know-How ” means inventions, discoveries, data, information, trade secrets, processes, methods, techniques, materials, technology, results or other know-how, whether or not patentable.

     1.29 “ License Agreement ” has the meaning ascribed to it in the Recitals.

     1.30 “ Local Therapeutic Company ” means a corporation or other business entity engaged in the business of exploiting products for human or veterinary uses wherein all or a substantial portion of the activities of such corporation or other business entity are competitive with those of Angiotech.

     1.31 “ Manufacturing Costs ” means, with respect to each Clinical Development Candidate and Cell Therapy Product, the costs incurred by Athersys in connection with the manufacture and supply of the Clinical Development Candidate or Cell Therapy Product (respectively) to Angiotech or any Third Party on Angiotech’s behalf, as such costs are more fully described on Schedule 1.13 .

     1.32 “ Major Market ” means the following markets: United States, Australia, Canada, United Kingdom, Germany, France, Italy, Spain and Japan.

     1.33 “ MAPC ” means any multipotent adult progenitor cell, including without limitation those described in the Patent Rights listed on Schedule 1.33 or described in any Patent Rights that claim priority to any such Patent Rights listed on Schedule 1.33 .

     1.34 “ NDA/BLA ” means (a) a New Drug Application and/or a Biologics License Application as defined in the United States Federal Food, Drug and Cosmetic Act or the United States Public Health Service Act, each as amended, and the rules and regulations promulgated thereunder, that is required to be filed with the FDA before commercialization of a product in the United States, and any successor application or procedure; (b) all supplements and amendments thereto; and (c) any related foreign counterparts of (a) and (b) that may be filed with respect to the foregoing.

     1.35 “ Net Sales ” means the gross amount invoiced for sale or other commercial disposition of a Cell Therapy Product (or any Cells sold for use in the Therapeutic Field) by Athersys or Angiotech or any of their Affiliates or their respective direct or indirect licensees, sublicensees or subcontractors, to a Third Party (including, without limitation, sales to distributors), in bona fide, arm’s-length transactions, after deduction of the following items (to the extent actually incurred and to the extent not already deducted in the amount invoiced):

          (a) all trade, quantity and cash discounts, wholesaler-charge backs or rebates (including, but not limited to, rebates to governmental agencies, managed care organizations, health management organizations, pharmacy benefit managers and group purchasing organizations) actually allowed;

          (b) all credits or allowances actually granted for rejection or return of a previously sold Cell Therapy Product (or Cells sold for use in the Therapeutic Field);

          (c) excise, sales and other consumption taxes and customs duties;

          (d) retroactive price reductions including, but not limited to, those imposed by governmental agencies; and

          (e) any charge for freight or insurance if separately stated on the same invoice as for the sale of the Cell Therapy Product (or Cells sold for use in the Therapeutic Field) and directly related to the sale or distribution of the Cell Therapy Product (or Cells sold for use in the Therapeutic Field);

all in accordance with standard allocation procedures, allowance methodologies and accounting methods consistently applied, which procedures and methodologies shall be in accordance with generally accepted accounting principles (“ GAAP ”). A “ sale ” of a Cell Therapy Product (or Cells sold for use in the Therapeutic Field) is deemed to occur upon the invoicing, or if no invoice is issued, upon the earlier of shipment or transfer of title in the Cell Therapy Product (or the Cells) to the Third Party. Sales between or among a Party, on the one hand, and its Affiliates, licensees or sublicensees, on the other

hand, shall not be used to calculate “Net Sales” unless the purchasing Affiliate, licensee or sublicensee is an end-user. “ Net Sales ” for purposes of this Strategic Alliance Agreement includes all such sales by assignees or other successors to either Party’s rights under this Strategic Alliance Agreement. If a Cell Therapy Product (or the Cells) is sold as part of a larger bundle or kit that incorporates or includes other products in addition to the Cell Therapy Product (or the Cells), Net Sales will be computed using an average net selling price of the Cell Therapy Product (or the Cells) sold separately or, if such average net selling price is unavailable, it will include only that part of such sale reasonably allocated by the JSC to the value of the Cell Therapy Product (or the Cells) as compared to the value of the larger bundle or kit sold without the Cell Therapy Product (or the Cells).

     1.36 “ Non-Licensed Cardiovascular Indications ” means any disease, disorder, condition, or the prevention, palliation, treatment, or correction of the same, which involves or relates to the heart and/or blood vessels, other than the Cardiovascular Indications and neurovascular disease (including stroke). Non-Licensed Cardiovascular Indications explicitly includes, but is not limited to, congestive heart failure.

     1.37 “ Party ” and/or “ Parties ” has the meaning ascribed to it in the preamble.

     1.38 “ Patent ” means any and all issued and granted patents, or other registration of ownership of an invention, granted by any governmental authority in the Territory, including, but not limited to, patents of implementation, improvement or addition; utility patents; design patents; and inventors’ certificates, as well as those patents that may issue or be granted from any divisions, reissues, continuations (in whole or in part), reexaminations, renewals, substitutions and extensions of any of the foregoing.

     1.39 “ Patent Prosecution ” means the (a) preparation, filing and/or prosecution of applications (of all types) for Patent(s); (b) maintenance of any Patent Rights; and (c) management of any interference or opposition proceeding relating to the foregoing.

     1.40 “ Patent Rights ” means rights in (a) issued Patents and pending provisional and non-provisional applications for Patents, including, without limitation, any continuations, continuations-in-part or divisions directed to inventions disclosed therein; (b) any re-examinations, reissues, renewals, substitutions or extensions of any Patents; and (c) foreign counterparts or equivalents of any of the foregoing.

     1.41 “ Phase I Study ” means a clinical study in human subjects that is intended to initially evaluate the tolerance, safety and/or pharmacological effects of (or to otherwise satisfy the requirements of 21 C.F.R. § 312.21(a) or its foreign equivalent with respect to) a Clinical Development Candidate for a particular Cardiovascular Indication.

     1.42 “ Phase II Study ” means a clinical study in human patients that is intended to initially evaluate the effectiveness of (or to otherwise satisfy the requirements of 21 C.F.R. § 312.21(b) or its foreign equivalent with respect to) a Clinical Development Candidate for a particular Cardiovascular Indication.

     1.43 “ Phase III Study ” means a pivotal clinical study in human patients with a defined dose or set of doses of a Clinical Development Candidate that is designed to ascertain the safety and efficacy of (or to otherwise satisfy the requirements of 21 C.F.R. § 312.21(c) or its foreign equivalent with respect to) such Clinical Development Candidate for a particular Cardiovascular Indication, which Phase III Study is conducted for the purpose of enabling the preparation and submission of applications for Regulatory Approval to the competent regulatory authorities in a country of the Territory.

     1.44 “ Phase IV Study ” means any clinical study in human patients that is commenced after receipt of Regulatory Approval of a Cell Therapy Product in any country of the Territory, which study is conducted within the parameters of the Regulatory Approval, and shall include studies required or requested by the Regulatory Authority as a condition of, or in connection with, obtaining Regulatory Approval with respect to such Cell Therapy Product for a particular Cardiovascular Indication. Phase IV Studies also shall include studies conducted to gather additional information regarding such Cell Therapy Product, including, without limitation, potential risks, medical or pharmacoeconomic benefits, optimal use, dose, route and schedule of administration, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials.

     1.45 “ Pre-Clinical Development Plan ” means a detailed plan that sets forth the responsibilities of, and activities to be conducted by, Athersys (and Angiotech pursuant to Section 4.3 ) in advancing one or more Cells and/or Cell Therapies into one or more potential Clinical Development Candidates for a particular Cardiovascular Indication (including a detailed budget corresponding to each such plan). Each such Pre-Clinical Development Plan shall include, without limitation, the following activities (or their equivalents), to the extent applicable:

          (a) conducting research and development activities related to Cells and Cell Therapy, as a step in the ultimate objective of identifying and characterizing Clinical Development Candidates; and

          (b) conducting pre-clinical research, pre-clinical development and other pre-clinical studies that are intended to facilitate and support progression of one or more Cells and/or Cell Therapies to selection as Clinical Development Candidates, and ultimately to Regulatory Approval of such Clinical Development Candidate(s) as a Cell Therapy Product(s);

An initial draft Pre-Clinical Development Plan(s) has been prepared by Athersys and presented to Angiotech prior to the Effective Date. Within ninety (90) days after the Effective Date, the JSC shall finalize such draft Pre-Clinical Development Plan(s), and such final Pre-Clinical Development Plan shall be attached hereto as Schedule 1.45 .

     1.46 “ Pre–Clinical Development Program ” means the pre-clinical development activities conducted by (or to be conducted by) each Party pursuant to a Pre-Clinical Development Plan.

     1.47 “ Profit(s) ” has the meaning ascribed to it on Schedule 7.4 .

     1.48 “ Purchase Agreement ” has the meaning ascribed to it in the Recitals.

     1.49 “ Receiving Party ” has the meaning ascribed to it in Section 13.1 .

     1.50 “ Regulatory Approval ” means any and all approvals (including any applicable governmental price and reimbursement approvals), licenses, registrations or authorizations of any federal, national, multinational, state, provincial or local regulatory agency, department, bureau, commission, council or other governmental entity necessary for the commercial manufacture, use, storage, import, export, transport, distribution, promotion, marketing, offer for sale and sale of a therapeutic and/or prophylactic product in a country of the Territory.

     1.51 “ Royalty Term ” shall mean, for a particular Sole Development Product in a particular country in the Territory, the period of time from First Commercial Sale of such Sole Development Product to the date on which market exclusivity in such country ends, which shall mean the later date to occur of the following: (a) the expiration of all Patent Rights covering such Sole Development Product in such country; or (b) the expiration of market exclusivity related to such Sole Development Product in such country.

     1.52 “ Sole Development Income ” shall mean any payments that the Developing Party receives from a licensee or sublicensee of the rights owned by or granted to the Developing Party hereunder, in consideration for the license or sublicense of such rights as applicable to a Sole Development Product, including, without limitation, license fees, milestone payments, license maintenance fees, and other payments received for such a license or sublicense, but specifically excluding royalty-type payments based on Net Sales, bona fide payments for research and development, marketing, sales and/or other services, bona fide reimbursement for costs and expenses incurred by the Developing Party (such as patent prosecution costs), payments to the extent of fair market value for the issuance of equity or debt (or for debt financing such as loans), and payments resulting from any bona fide arms length agreement relating to the supply to such licensee or sublicensee of the applicable Sole Development Products (and/or ingredients or components thereof).

     1.53 “ Sole Development Product ” has the meaning ascribed to it in Section 6.1.

     1.54 “ Strategic Alliance Agreement ” has the meaning ascribed to it in the preamble.

     1.55 “ Sublicense Agreement ” has the meaning ascribed to it in the Recitals.

     1.56 “ Successful Completion ” means, with respect to a clinical study of a Clinical Development Candidate in human patients, (a) completion of such clinical study; (b) the meeting of all primary and secondary clinical endpoints of such clinical study or the advancement of the Clinical Development Candidate to the next phase of clinical trials (or to commercialization, where the subject clinical study is a Phase III Study), even though the Clinical Development Candidate does not meet all secondary endpoints; and

(c) delivery to the JSC of the corresponding written, completed study report prepared according to the study protocol.

     1.57 “ Term ” has the meaning ascribed to it in Section 16.1 .

     1.58 “ Territory ” means the world.

     1.59 “ Therapeutic Field ” means, as the context requires, a field comprising any one or more of the Cardiovascular Indications.

     1.60 “ Third-Party ” means a person or entity other than Angiotech or Athersys.

     1.61 “ Third Party Payments ” shall mean all amounts payable to a Third Party for rights or licenses to Intellectual Property in connection with the manufacture, use, sale, offer for sale or importation of Clinical Development Candidates and/or Cell Therapy Products, including without limitation license fees, milestone payments, license maintenance fees, royalties and other payments made for such a right or license.

     1.62 “ Transaction Agreements ” has the meaning ascribed to it in the Recitals.

     1.63 Additional Definitions.

ARTICLE II.
CERTAIN TRANSACTION COMPONENTS

     2.1 Concurrent Execution . Each Party shall execute all of the Transaction Agreements and the Purchase Agreement, and shall deliver each of them to the other Party, and each of the Transaction Agreements and the Purchase Agreement shall be effective as of the Effective Date. Neither Party shall have any obligations under any of the Transaction Agreements or the Purchase Agreement unless and until all of the Transaction Agreements and the Purchase Agreement have been so executed and delivered.

     2.2 Right of First Negotiation for Non-Licensed Cardiovascular Indications .

          (a) Throughout the Term, Angiotech shall have the first right to negotiate to obtain an exclusive license to Cell Therapy for all or any part of the Non-Licensed Cardiovascular Indications. Athersys shall promptly notify Angiotech in writing if: (a) Athersys intends to initiate a research and/or development and/or commercialization program for Cell Therapy involving any of the Non-Licensed Cardiovascular Indications; (b) Athersys intends to take any action to initiate any process to license (whether exclusively or non-exclusively) to a Third Party (or otherwise grant to a Third Party) any rights to develop or commercialize Cell Therapy for any of the Non-Licensed Cardiovascular Indications; or (c) Athersys receives an unsolicited offer from a Third Party that desires to acquire any rights to develop or commercialize Cell Therapy for any of the Non-Licensed Cardiovascular Indications (where each of the events set forth in (a-c) above shall obligate Athersys to provide such written notice, hereinafter termed an “ Offer Notice ”). The Offer Notice shall specify the indications within the Non-Licensed Cardiovascular Indications to which the notice applies, and in the case of (c), shall summarize the terms of the Third Party’s offer. Upon Angiotech’s receipt of the Offer Notice, Angiotech shall have fifteen (15) days (the “ Offer Period ”) to notify Athersys that Angiotech desires to negotiate with Athersys to obtain a license for Cell Therapy for

the applicable Non-Licensed Cardiovascular Indications (such notice by Angiotech is hereinafter referred to as the “ Negotiation Notice ”). If Angiotech delivers such Negotiation Notice to Athersys, Athersys shall negotiate in good faith exclusively with Angiotech, for a period of not less than ninety (90) days from the date of Athersys’ receipt of the Negotiation Notice (the “ Negotiation Period ”), mutually acceptable, commercially reasonable terms and conditions of an exclusive license to Angiotech for the applicable Non-Licensed Cardiovascular Indications. Accordingly, Angiotech shall have the right of first and exclusive negotiation to obtain an exclusive license to Cell Therapy for all or any part of the Non-Licensed Cardiovascular Indications identified in the Negotiation Notice. If Angiotech fails to deliver the Negotiation Notice prior to expiration of the Offer Period, or if Athersys and Angiotech are unable to consummate a mutually acceptable transaction prior to expiration of the Negotiation Period, Athersys shall be free to license Cell Therapy for the applicable Non-Licensed Cardiovascular Indications to a Third Party. If Athersys is unable to complete a transaction granting rights to Cell Therapy for the applicable Non-Licensed Cardiovascular Indications to a Third Party within ninety days (90) days after (y) the expiration of the applicable Offer Period if Angiotech has not delivered a Negotiation Notice, or (z) the expiration of the applicable Negotiation Period if Angiotech has delivered a Negotiation Notice, then Athersys’ notification requirement shall “reset” with respect to Cell Therapy for the applicable Non-Licensed Cardiovascular Indications. For the avoidance of doubt, this right of first negotiation shall apply to Cell Therapy for all indications within the Non-Licensed Cardiovascular Indications.

          (b) In addition to Section 2.2(a) above, throughout the Term with respect to Cell Therapy involving congestive heart failure, Angiotech shall have the right of first refusal to obtain a license to Cell Therapy for congestive heart failure as described in this Section 2.2(b) . Upon the receipt by Athersys from a Third Party of any offer for any rights relating to Cell Therapy for congestive heart failure that Athersys desires to accept (a “ CHF Offer ”), Athersys shall provide written notice of such CHF Offer to Angiotech (the “ CHF Offer Notice ”). The CHF Offer Notice shall include a detailed summary of the material terms and conditions of the CHF Offer (the “ Terms and Conditions ”). If the Terms and Conditions are substantially more favorable to such Third Party than the terms and conditions offered by Angiotech pursuant to Section 2.2(a) , Angiotech shall have thirty (30) days from receipt of the CHF Offer Notice to accept or reject the CHF Offer according to the Terms and Conditions. If Athersys and Angiotech do not conclude such transaction within a ninety (90)-day period of exclusive, good faith negotiations that begins on receipt of Angiotech’s notice of “acceptance,” or if Angiotech does not provide such written notice before expiration of its 30-day acceptance period (or if Angiotech rejects the CHF Offer in writing before the end of such 30-day period), Athersys shall then have ninety (90) days to negotiate definitive, binding agreements with such Third Party on terms and conditions not substantially more favorable to such Third Party than the Terms and Conditions. If (i) Athersys is unable to complete such a transaction within such ninety (90) day period with such Third Party, then the notification requirement shall “reset” with respect to Cell Therapy for congestive heart failure, or (ii) the terms and conditions negotiated with such Third Party and acceptable to both Athersys and such Third Party concerning such transaction are substantially more favorable to such Third Party than the Terms and Conditions, then the terms and conditions of the transaction as

negotiated shall be considered to be a new CHF Offer that is subject to the right of first refusal on behalf of Angiotech described in this Section 2.2(b) .

     2.3 Additional Investment .

          (a) Angiotech shall make an additional $5,000,000.00 investment in Athersys pursuant to the terms described in Section 2.3(b) within ten (10) business days after Athersys fulfills the first of the following conditions to occur (provided that if Athersys fulfills any such condition prior to January 1, 2007, then such condition shall be deemed to have been fulfilled on January 1, 2007):

          (i) Athersys has commenced at least one additional pre-clinical animal study between the Effective Date and January 1, 2007 (in accordance with the applicable Pre-Clinical Development Plan) and either (A) such study has been completed prior to January 1, 2007 in accordance with the applicable pre-clinical animal study protocol; or (B) such study is ongoing as of January 1, 2007 and is being conducted in accordance with the applicable pre-clinical animal study protocol, or

          (ii) at any time after January 1, 2007 Athersys completes at least one additional pre-clinical study (in accordance with the applicable Pre-Clinical Development Plan) in accordance with the applicable pre-clinical animal study protocol.

          (b) With respect to the investment described in (a) above:

          (i) if the Note has not been converted into capital stock of Athersys prior to the date of such investment, then Angiotech and Athersys shall enter into a note purchase agreement, in substantially the form of the Purchase Agreement, pursuant to which Angiotech shall loan $5,000,000.00 in cash to Athersys pursuant to a convertible promissory note having the same terms and conditions as the Note; and

          (ii) if the Note has been converted into capital stock of Athersys prior to the date of such investment, then Angiotech and Athersys shall enter into a securities purchase agreement, in substantially the form of the Purchase Agreement (except for necessary adaptations for a securities purchase instead of a note purchase), pursuant to which Angiotech shall purchase with cash the number of whole shares of capital stock of Athersys that can be purchased with $5,000,000.00 in cash, at one hundred ten percent (110%) of the per share price at which stock is sold in the Bona Fide Financial Investment (as defined in the Note), on the terms and conditions set forth therein. The class and series of capital stock shall be the same as that sold in the Bona Fide Financial Investment.

     2.4 Phase I Milestone Fee .

          (a) As soon as reasonably practicable after the passage of thirty (30) days (or such other period of time during which the FDA may then be permitted to impose a

clinical hold) following the first IND submission to the FDA in connection with the first Clinical Development Candidate hereunder without the FDA imposing a clinical hold, thereby enabling the Parties to lawfully initiate a Phase I Study of such Clinical Development Candidate, subject to Section 2.4(b) below, the Parties shall enter into a one-time only securities purchase agreement, in substantially the form of the Purchase Agreement (except for necessary adaptations for a securities purchase instead of a note purchase), pursuant to which Angiotech shall purchase with cash the number of whole shares of capital stock of Athersys that can be purchased with $ 5,000,000 in cash, at the per share price determined in accordance with Schedule 2.2 , on the terms and conditions set forth therein (the “ Phase I Milestone Fee ”). For the avoidance of doubt, Angiotech shall not be required to enter into any further securities purchase agreement(s) in connection with any subsequent IND submission .

          (b) Angiotech, in its sole discretion, may elect to decline payment of the Phase I Milestone Fee by providing written notice of such election within the applicable 30-day period set forth in Section 2.4(a) . Within thirty (30) days after receipt of such written notice from Angiotech, Athersys shall provide written notice to Angiotech choosing one of the following items as a replacement for the Phase I Milestone Fee:

          (i) requiring Angiotech to, within ten (10) business days following the Successful Completion of the first Phase III Study for a Clinical Development Candidate in the U.S. (or foreign equivalent trial) in any Cardiovascular Indication, pay to Athersys a one-time milestone payment in cash equal to $ 10,000,000 (the “ Replacement Fee ”) upon the Successful Completion of the first Phase III Study for a Clinical Development Candidate in the U.S. (or foreign equivalent trial) in any of the Cardiovascular Indications; or

          (ii) modifying the split of Profits from the commercialization of a Cell Therapy Product described in Schedule 7.4 to be [*]% to Athersys and [*]% to Angiotech.

     2.5 Exclusivity . Except as expressly provided pursuant to a Clinical Development Plan or in any Transaction Agreement, during the Term Athersys shall not engage (itself or with a Third Party) in any clinical development or commercialization activities directed to the Cardiovascular Indications using any stem cells.

     2.6 Retained Rights . Except as expressly set forth herein or as otherwise mutually agreed by the Parties in writing, no Intellectual Property rights or licenses are granted by Angiotech to Athersys under this Strategic Alliance Agreement. Angiotech retains all rights to Angiotech Intellectual Property. Except as expressly set forth herein or as otherwise mutually agreed by the Parties in writing, no Intellectual Property rights or licenses are granted by Athersys to Angiotech under this Strategic Alliance Agreement.

Athersys retains all rights to Athersys Intellectual Property to the extent such Intellectual Property rights are not expressly granted to Angiotech hereunder.

     2.7 Costs Borne by Each Party . Except as expressly set forth herein, including without limitation Sections 7.1 , 7.2 and 7.4 and Schedule 7.4 , all costs and expenses connected with a Party’s activities or performance under any Pre-Clinical Development Program, Clinical Development Plan or this Strategic Alliance Agreement shall be borne solely by that Party.

     2.8 Certain Restrictions on Athersys’ Activities Outside of Cardiovascular Indications . In its research and development activities in connection with Third Parties related to products for Cell Therapy outside of the Cardiovascular Indications, Athersys shall make Commercially Reasonable Efforts to position such products in a way that reduces the potential for such products to be used off label in any of the Cardiovascular Indications.

ARTICLE III.
JOINT STEERING COMMITTEE

     3.1 Joint Steering Committee . Promptly following the Effective Date, the Parties shall establish a Joint Steering Committee (“ JSC ”) to oversee and coordinate the Parties’ responsibilities and activities in accordance with and in furtherance of the Pre-Clinical Development Plan(s), Clinical Development Plan(s) and this Strategic Alliance Agreement. The JSC shall be composed of up to four (4) senior, qualified representatives from each Party (or from a Party’s Affiliate). The total number of JSC members will initially be up to eight (8), but the number may be increased or decreased from time-to-time by mutual written agreement of the Parties; provided that the number of representatives from Angiotech shall always be equal to the number of representatives from Athersys. Each of Angiotech and Athersys may replace any of its representatives on the JSC at will by giving written notice thereof to the other Party.

     3.2 Subcommittees . The JSC shall be empowered to create one or more subcommittees, project teams or working groups, as it may deem appropriate or necessary. Each such subcommittee, project team and working group shall report to the JSC, which shall have authority to approve or reject recommendations or actions proposed thereby, subject to the terms of this Strategic Alliance Agreement. In general, the Parties contemplate that all JSC subcommittees shall have an equal number of members appointed by each Party.

     3.3 Chairperson . Each Party shall appoint one of its representatives on the JSC as a co-chair of the JSC (each, a “ Co-Chair ”), and a Party may change its Co-Chair from time to time by written notice to the other Party. Each Party’s Co-Chair shall serve as a co-chair of the JSC meetings, unless the Co-Chairs jointly determine that they shall alternate responsibility for chairing JSC meetings (whether on a meeting-by-meeting, calendar quarter-by-calendar quarter or calendar year-by-calendar year basis).

     3.4 JSC Meetings .

          (a) The JSC shall meet at least once every calendar quarter during the Term, either in person, by video conference or by telephone conference, as appropriate, as reasonably arranged by the Co-Chairs; provided that at least one (1) JSC meeting per calendar year shall be held in person. Meetings of the JSC shall be effective only if at least one (1) JSC representative of each Party participates in the meeting (in person or by telephone or videoconference). The Co-Chairs (or the responsible JSC chairperson, if applicable) shall be responsible for scheduling meetings of the JSC, preparing agendas for JSC meetings, sending to all JSC members notices of all regular JSC meetings (at least thirty (30) days before such meetings) and agendas for such meetings (at least ten (10) days before such meetings).

          (b) In addition, either Co-Chair may from time to time request a special JSC meeting by contacting the other Co-Chair and providing a proposed agenda for such meeting. The Co-Chairs shall arrange a mutually acceptable time for such special JSC meeting as promptly thereafter as reasonably possible, and shall prepare and circulate an agenda for such special JSC meeting as far in advance of such meeting as reasonably possible.

          (c) The Co-Chairs (or the responsible JSC chairperson, if applicable) shall be responsible for having minutes of each JSC meeting prepared and circulated among the JSC members. The JSC meeting minutes will be documented in writing and shall provide a description in reasonable detail of the discussions held at the JSC meeting, and a list of any actions, decisions or determinations taken or approved by the JSC. In addition, the JSC meeting minutes shall include, with respect to the Parties’ responsibilities, activities and tasks hereunder, (i) the Parties’ progress to date, (ii) difficulties encountered by the Parties to date, (iii) schedules for performing and completing the Parties’ tasks and activities, (iv) each Party’s action plans, and (v) any JSC recommendation that the Parties approve a Proposed Clinical Plan or end an existing Clinical Development Plan. The responsible Co-Chair shall distribute the minutes of the JSC meeting to the Parties and the JSC members within ten (10) days after the conclusion of each JSC meeting. The JSC meeting minutes shall be deemed to be approved by the JSC members if no written objections to the meeting minutes are submitted to the JSC within ten (10) days after being distributed to the JSC members. Each Party shall be responsible for expenses incurred by its JSC representatives in attending or otherwise participating in JSC meetings.

     3.5 Responsibilities of the Joint Steering Committee .

          (a) Clinical Development Plans and Clinical Development Candidates . In addition to its general responsibility to oversee and coordinate the activities of the Parties in connection with the Pre-Clinical Development Plans, Clinical Development Plans and this Strategic Alliance Agreement, the JSC shall in particular:

          (i) monitor the progress made by Athersys in connection with the Pre-Clinical Development Programs in a manner consistent with the corresponding Pre-Clinical Development Plans and this Strategic Alliance Agreement;

          (ii) monitor the Existing Third Party Agreements and any other agreements with a Third Party related to the Pre-Clinical Development Plans, Clinical Development Plans and/or Cell Therapy in the Therapeutic Field, including without limitation monitoring compliance with such agreements and activities thereunder, reviewing reports prepared by or for a Party, evaluating Intellectual Property resulting from such agreements and ensuring that the appropriate Party obtains rights to any such Intellectual Property when advisable;

          (iii) designate Cell(s) as Clinical Development Candidate(s) in accordance with criteria determined by the JSC;

          (iv) monitor the progress made, and direct the activities to be undertaken, by the Parties in connection with the Clinical Development Programs in a manner consistent with the corresponding Clinical Development Plans and this Strategic Alliance Agreement;

          (v) review, modify as it deems appropriate, and recommend, as necessary from time-to-time, the Clinical Development Plan(s);

          (vi) oversee and, whenever practicable, expedite the implementation of each Pre-Clinical Development Plan and each Clinical Development Plan;

          (vii) create and update a risk analysis plan;

          (viii) clarify or adjust the tasks of the respective Parties under the Pre-Clinical Development Plans and Clinical Development Plans, in a manner consistent with this Strategic Alliance Agreement;

          (ix) ensure adequate resources are assigned by each Party for research planning, project management and personnel and other resource management related to the Clinical Development Plans;

          (x) create, review, modify as it deems appropriate, and recommend an annual budget corresponding to each Clinical Development Plan, in a manner consistent with this Strategic Alliance Agreement;

          (xi) reasonably determine or adjust milestones and progress related to the Clinical Development Plans; and

          (xii) recommend whether or not, and to what extent, research or development studies, beyond those identified in an existing Pre-Clinical Development Plan or Clinical Development Plan, should be conducted.

          (b) Existing Third Party Agreements . Within thirty (30) days after the Effective Date, Athersys shall provide to the JSC a report describing the status of, purpose of, scope of activities encompassed by, recent activities conducted under, and Intellectual Property developed under each Existing Third Party Agreement related to the

Pre-Clinical Development Plans, Clinical Development Plans and/or Cell Therapy in the Therapeutic Field, together with complete, unredacted copies of each such agreement and any reports delivered by or provided to Athersys thereunder, subject to confidentiality obligations to the counterparty to each such Agreement; provided that where such obligations of confidentiality preclude or limit any such disclosures hereunder, Athersys shall use Commercially Reasonable Efforts to obtain consent from such counterparty to permit such disclosures to Angiotech.

          (c) Proposed Clinical Plans . The Parties, either separately or jointly, may submit written proposals for Clinical Development Plans for any Clinical Development Candidate (“ Proposed Clinical Plans ”) to the JSC for review (which review shall take place at the first JSC meeting following submission of a Proposed Clinical Plan to the JSC) and recommendation to the Parties; provided that each Party may submit no more than one Proposed Clinical Plan per calendar quarter during the Term. Each Proposed Clinical Plan shall include, as appropriate, (i) an objective, key milestones and a timetable for the Proposed Clinical Plan; (ii) a summary of resources expected to be required to conduct the Proposed Clinical Plan to completion; (iii) a summary of expected Third Party arrangements that may be necessary or useful, including, without limitation, license agreements and/or supply arrangements; and (iv) a proposed budget and term for the Proposed Clinical Plan. Any Proposed Clinical Plan that is recommended by the JSC and approved in writing by the Parties will be deemed a Clinical Development Plan, and each such approved Clinical Development Plan shall be a part of, and subject to all of the provisions of, this Strategic Alliance Agreement and the other Transaction Agreements, as applicable.

          (d) New Pre-Clinical Development Programs . The JSC shall oversee and coordinate the Parties’ responsibilities and activities, and shall recommend to the Parties appropriate cost-sharing by the Parties, in connection with each New Pre-Clinical Development Program.

          (e) Advancement or Termination of Clinical Development Plans . Upon the completion of each Clinical Development Plan, the JSC will have sixty (60) days thereafter to provide written recommendations to the Parties as to whether the Clinical Development Plan should either (i) be advanced to the next phase of development or commercialization, as applicable, or (ii) be terminated by the Parties. With the prior written approval of both Parties, the JSC will also have the authority to terminate a Clinical Development Plan at any time.

          (f) Other Responsibilities . The JSC shall have such other responsibilities as are expressly set forth elsewhere in this Strategic Alliance Agreement, the Transaction Agreements or as are assigned to it as mutually agreed upon by the Parties.

          (g) Angiotech Proposals . During the term of this Strategic Alliance Agreement, Angiotech may, but is not obligated to, present to the JSC for consideration medical devices, biomaterials, compositions and methods that may enhance the development of Cells, Clinical Development Candidates and/or Cell Therapy Products in the Cardiovascular Field. The JSC shall consider the value of any such enhancements

(including where appropriate, for example, an evaluation of market analysis, financial projections, costs, resources, responsibilities of Athersys and Angiotech, and timelines). After due consideration, the Steering Committee shall accept or reject each such proposed enhancement. If the JSC accepts a proposed enhancement, then the JSC shall (i) recommend appropriate compensation to Angiotech with respect to such enhancement and the applicable Pre-Clinical Development Plan or Clinical Development Plan shall be modified to include such enhancement; and (ii) determine ownership of any Intellectual Property related to the accepted enhancement that may be made, created, identified, conceived, reduced to practice or derived by or on behalf of the Parties (either alone or jointly) during the course of performance of a Party’s obligations under the applicable Pre-Clinical Development Plan or Clinical Development Plan; provided that Angiotech shall own all Intellectual Property related to any proposed or accepted enhancement that is made, created, identified, conceived, reduced to practice or derived by or on behalf of Angiotech or its Affiliates at or prior to the time the enhancement is presented to the JSC for consideration.

     3.6 Voting; Decision-Making . Regardless of the number of JSC representatives from any Party, Angiotech shall present one consolidated view and have one vote on any issue before the JSC, to be cast by Angiotech’s Co-Chair or his/her designee, and Athersys shall present one consolidated view and have one vote on any issue before the JSC, to be cast by Athersys’ Co-Chair or his/her designee. Except as otherwise expressly set forth herein, the JSC may only act by unanimous written agreement. Except as otherwise expressly set forth herein, the JSC shall have final decision-making authority (which decision-making authority may be delegated to a subcommittee by the JSC, in its discretion) regarding all issues relating to the Pre-Clinical Development Plans and Clinical Development Plans; provided that the JSC may not modify or renegotiate any terms or conditions of this Strategic Alliance Agreement. In making decisions on the JSC, each Party shall duly consider in good faith any suggestions, opinions and proposals made by the other Party, and shall use good faith efforts to reach consensus with the other Party. If the JSC fails to reach unanimous agreement on any matter within the scope of its responsibilities, as described in this Strategic Alliance Agreement or as expressly delegated to the JSC by written agreement of the Parties, the dispute shall be resolved as set forth in Section 3.7 .

     3.7 JSC Disputes .

          (a) If, before adjourning any JSC meeting, the JSC fails to reach unanimous agreement on any matter or issue upon which the JSC has voted at such JSC meeting, and upon which the JSC has authority to vote, in accordance with this ARTICLE III (each such matter or issue, a “ JSC Dispute ”), such JSC Dispute shall automatically be added as an agenda item for the next regular meeting of the JSC. Between the meeting in which the JSC Dispute arose and such next regularly scheduled JSC meeting, the JSC and/or the Parties may negotiate in good faith to attempt to resolve the JSC Dispute. At any time during such interim time period, the JSC may call a special meeting to attempt to resolve the JSC Dispute.

          (b) If the JSC members are unable to resolve such JSC Dispute before or at the next regularly scheduled JSC meeting, such JSC Dispute shall be referred for resolution to the Chief Scientific Officer (or person fulfilling the equivalent function) of each Party (each, a “ Head of Research ”). Resolution of such JSC Dispute by the Heads of Research shall occur within thirty (30) days after the date of referral to the Heads of Research. If the Heads of Research are unable to reach consensus and resolve such JSC Dispute within such 30-day period after good faith attempts to reach such consensus and resolution, then the JSC Dispute shall be referred for final resolution to Athersys’ President (or other designated executive level officer of Athersys), if the JSC Dispute relates to a Phase I Study completion or earlier matter or issue, and to Angiotech’s CFO (or other designated executive level officer of Angiotech), if the JSC Dispute relates to a post-Phase I Study (or later) or commercialization matter or issue; provided that, when exercising such final, decision-making authority, neither Party’s President, CFO (or other designated executive level officer) shall be empowered to alter the Parties’ respective rights or obligations under this Strategic Alliance Agreement; and provided further that neither Party’s President, CFO (or other designated executive level officer) shall have final decision-making authority with respect to approval or modification of (i) designation of any Cell as a Clinical Development Candidate; (ii) any Pre-Clinical Development Plan or Clinical Development Plan (but expressly excluding any immaterial modifications to such Pre-Clinical Development Plan or Clinical Development Plan); (iii) any Clinical Development Plan budget (but expressly excluding any immaterial modifications to such Clinical Development Plan budget), (iv) any IND filing pertaining to a Clinical Development Candidate, (v) any NDA/BLA filing pertaining to a Clinical Development Candidate; (vi) clinical trial design; or (vii) termination, or advancement to the next stage, of development of a Clinical Development Candidate; instead, such designations, plans, budgets filings, designs, termination and advancements set forth in (i-vii) shall be approved or modified only by consensus of the Parties and shall not be subject to the dispute resolution process described in ARTICLE XVII .

ARTICLE IV.
PRE-CLINICAL DEVELOPMENT

     4.1 Existing Pre–Clinical Development Programs . Athersys shall conduct, and shall be responsible for, the Pre-Clinical Development Programs in existence as of the Effective Date within the Cardiovascular Indications. With respect to each such existing Pre-Clinical Development Program, Athersys may modify its activities and undertake new activities in connection with such Pre-Clinical Development Program, but only after consultation with and approval of the JSC; provided that Athersys shall: (a) use its Commercially Reasonable Efforts to make available the resources specified in the Pre-Clinical Development Plan (or otherwise by mutual agreement of the Parties), (b) use its Commercially Reasonable Efforts to undertake its obligations and responsibilities in the Pre-Clinical Development Plan (or otherwise by mutual agreement of the Parties), (c) perform its activities and discharge the responsibilities that will facilitate the ability of the Parties to obtain Regulatory Approval to manufacture Cells to be used in Clinical Development Candidates and in Cell Therapy Products in the United States and other countries of the Territory, as determined by the JSC, and (d) manufacture the Cells in conformance with the quantity and quality reasonably required for the conduct of the Pre-

Clinical Development Programs. With respect to each such existing Pre-Clinical Development Program, and subject to the foregoing sentence, Athersys shall consider in good faith any recommendations and requests made by Angiotech and its representatives on the JSC concerning the existing Pre-Clinical Development Program. Athersys may subcontract any of its obligations under this Section 4.1 , provided that it furnishes the JSC and Angiotech with advance written notice thereof specifying the work to be subcontracted, and with an opportunity to object to such subcontract for sound business reasons. Any dispute regarding Athersys’ use of a subcontractor pursuant to the foregoing sentence shall be referred to the JSC, and any corresponding JSC Dispute shall be resolved in accordance with Section 3.7 . As of the Effective Date, Athersys has executed agreements related to the existing Pre-Clinical Development Programs with the Third Parties listed on Schedule 4.1 of this Strategic Alliance Agreement (each such agreement, an “ Existing Third Party Agreement ”).

     4.2 Costs for Existing Pre-Clinical Development Programs . Athersys shall be fully and solely responsible for all costs and expenses relating to the activities conducted by or for Athersys in connection with the existing Pre-Clinical Development Programs.

     4.3 New Pre-Clinical Development Programs . During the Term, the Parties expect to undertake additional Pre-Clinical Development Programs (“ New Pre-Clinical Development Programs ”), and the Parties acknowledge that Angiotech may assume certain responsibilities, and may conduct certain activities, in connection with such New Pre-Clinical Development Programs. Irrespective of Angiotech’s responsibilities or activities in connection with any New Pre-Clinical Development Program, the JSC shall assume oversight and coordination of the Parties’ responsibilities and activities (if any), and shall recommend appropriate compensation to Angiotech with respect to its activities under each New Pre-Clinical Development Program and any Intellectual Property and materials (including without limitation biomaterials and medical devices) contributed by Angiotech to such New Pre-Clinical Development Program.

ARTICLE V.
CLINICAL DEVELOPMENT

     5.1 Proposed Clinical Plans; Clinical Development Plans . Angiotech and/or Athersys may prepare and submit a Proposed Clinical Plan to the JSC in accordance with Section 3.5(c) for any Clinical Development Candidate. Each Proposed Clinical Plan shall address the specific roles and responsibilities of each Party consistent with this Strategic Alliance Agreement, shall address and/or incorporate any JSC recommendations, and shall propose appropriate Clinical Development Programs for each stage of development set out in such Proposed Clinical Plan. The responsibilities of the Parties set forth in this ARTICLE V will apply only to those Clinical Development Plans approved by the Parties in accordance with Section 3.5 and 3.7 .

     5.2 Athersys Responsibilities . During each Clinical Development Program, Athersys, after consulting with the JSC, shall direct all Clinical Development Program activities through the completion of Phase I Studies. In this regard, Athersys’ President shall have ultimate, final decision-making authority for JSC Disputes pertaining to Phase

I Study completion or earlier matters and issues, as described in Section 3.7(b) . During the Term, Athersys shall: (a) use its Commercially Reasonable Efforts to make available the resources specified as the responsibility of Athersys in the Clinical Development Plan (or otherwise by mutual agreement of the Parties), (b) use its Commercially Reasonable Efforts to undertake the obligations and responsibilities assigned to Athersys in the Clinical Development Plan (or otherwise by mutual agreement of the Parties), (c) perform the activities and discharge the responsibilities that are required to obtain Regulatory Approval to manufacture Cells that are used in Clinical Development Candidates and in Cell Therapy Products in the United States and other countries of the Territory, as determined by the JSC, and (d) manufacture the Cells in conformance with the quantity and quality reasonably required for the conduct of the Clinical Development Programs, and supply such Cells to Angiotech (or its designee) or to one or more Third Parties engaged by a Party to perform clinical studies of Clinical Development Candidates and/or Cell Therapy Products in accordance with this Strategic Alliance Agreement.

     5.3 Angiotech Responsibilities . During each Clinical Development Program, Angiotech shall direct all Clinical Development Program activities after the completion of Phase I Studies. In this regard, Angiotech’s CFO shall have ultimate, final decision-making authority for JSC Disputes pertaining to post-Phase I Study (or later) matters and issues, as described in Section 3.7(b) . During the Term, Angiotech shall: (a) use its Commercially Reasonable Efforts to make available the resources specified as the responsibility of Angiotech in the Clinical Development Plan (or otherwise by mutual agreement of the Parties), (b) use its Commercially Reasonable Efforts to undertake the obligations and responsibilities assigned to Angiotech in the Clinical Development Plan (or otherwise by mutual agreement of the Parties), and (c) perform the activities and discharge the responsibilities that are required to obtain Regulatory Approval to market and sell Cell Therapy Products in the United States and the other countries of the Territory, as determined by the JSC (to the extent such Regulatory Approval is not described as an obligation of Athersys pursuant to Section 5.2) .

     5.4 Subcontracting . Either Party may subcontract any of its obligations under a Clinical Development Plan, provided that it furnishes the JSC and the other Party with advance written notice thereof specifying the work to be subcontracted, and with an opportunity to object to such subcontract for sound business reasons. Any dispute regarding a Party’s use of a subcontractor pursuant to the foregoing sentence shall be referred to the JSC, and any corresponding JSC Dispute shall be resolved in accordance with Section 3.7 . In any subcontract agreement with a Third Party, the subcontracting Party shall ensure that (a) such Third Party subcontractor is bound by obligations of confidentiality no less stringent than those imposed on the Parties under this Strategic Alliance Agreement, (b) all inventions, copyrightable subject matter, discoveries or materials created, identified, conceived, reduced to practice or developed by the Third Party subcontractor in the scope of its, his or her engagement with a Party in connection with the subcontract agreement, and in furtherance of a Clinical Development Program or this Strategic Alliance Agreement, are appropriately documented and disclosed to the subcontracting Party, and (c) all such inventions, copyrightable subject matter, discoveries or materials directly related to the Cells (and not related to Angiotech

Intellectual Property) shall be owned solely by Athersys (or jointly with Angiotech in the case of Joint IP), or in the case of subcontractors that are not-for-profit institutions, (i) either owned solely by Athersys (or jointly with Angiotech in the case of Joint IP), (ii) jointly owned by Athersys and the institution (and jointly with Angiotech in the case of Joint IP), or (iii) owned solely by the institution, and in the case of (ii) or (iii), the institution’s right, title and interest in such inventions, copyrightable subject matter, discoveries or materials related to the Cells shall be either exclusively licensed to Athersys (and Angiotech in the case of Joint IP) or the institution shall have granted to Athersys (and Angiotech in the case of Joint IP) the exclusive option to obtain an exclusive license thereto; provided, however, that the foregoing shall not require Athersys to modify the terms or conditions of any of the Existing Third Party Agreements which the Parties recognize may not contain the terms described in this sentence. Any subcontract agreement under this Section 5.4 shall (w) grant to the subcontracting Party a right to inspect the subcontractor’s relevant records and facilities; (x) require the subcontractor to be in good standing with all applicable regulatory authorities; (y) require the subcontractor to comply (as appropriate) with current good laboratory practices, current good manufacturing laboratory practices and applicable laws, regulations, rules and guidelines; and (z) require that the subcontractor have no outstanding violations or citations that would or may impair the services or deliverables to be provided to the subcontracting Party by such subcontractor; provided, however, that the foregoing shall not require Athersys to modify the terms or conditions of any of the Existing Third Party Agreements which the Parties recognize may not contain the terms described in this sentence.

ARTICLE VI.
OPT-OUT RIGHTS

     6.1 Opt-Out Rights . Either Party may elect to discontinue (a “ Discontinuing Party ”) joint research on, development and commercialization of a Clinical Development Candidate or a Cell Therapy Product upon six (6) months prior written notice (“ Opt-Out Notice ”) to the other Party; provided that the effective date of either Party’s election to opt out shall not be prior to the completion of the first Phase I Study conducted by the Parties hereunder, and provided further that neither Party shall be relieved of its obligations to pay for its share of Clinical Development Costs for a clinical study that is ongoing at the effective date of a Party’s election to opt-out with respect to the applicable Clinical Development Candidate. Notwithstanding the foregoing, if a Party is unable to pay any or all of its portion of Clinical Development Costs when due, such Party shall be deemed to have delivered an Opt-Out Notice on the date such payment was due. Upon delivery of the Opt-Out Notice, the subject Clinical Development Candidate or Cell Therapy Product shall be deemed a “ Rejected Product .” The Discontinuing Party shall be required to continue co-funding all of its activities under this Strategic Alliance Agreement during such six (6) month notice period (subject to the first sentence of this Section 6.1 ). Upon receipt of an Opt-Out Notice for a Clinical Development Candidate or Cell Therapy Product, the non-discontinuing Party shall have the option (the “ Sole Development Option ”), exercisable by providing written notice to the Discontinuing Party by the end of such six (6) month period, to continue the development and commercialization of such Rejected Product in the Therapeutic Field (and in such event,

such Rejected Product shall thereafter be referred to as a “ Sole Development Product ”), at its own expense. Upon the exercise of such option, the non-discontinuing Party shall be deemed the “ Developing Party ,” and the Developing Party shall be released from its exclusivity obligations set forth in Section 2.5 above with respect only to such Sole Development Product. The Parties shall have the following rights and obligations upon exercise of the Sole Development Option:

          (a) if Angiotech is the Developing Party, such Sole Development Product shall continue to be considered a Clinical Development Candidate or Cell Therapy Product (as applicable) for purposes of the Transaction Agreements; provided, however that (i) the provisions of Section 2.4 and ARTICLES III, V, VII (other than Sections 7.5-7.10 ) and IX (other than Sections 9.7 and 9.8 ) shall no longer apply to such Sole Development Product; (ii) a Supply Disruption shall be deemed to have occurred pursuant to Section 9.7 (and Section 9.7 shall apply in its entirety with respect to such Supply Disruption), and Angiotech shall have the right to engage a back-up supplier pursuant to Section 9.8 (and Section 9.8 shall apply in its entirety with respect to engagement of such back-up supplier); and further provided that if neither a Third-Party manufacturer nor a Third-Party back-up manufacturer of the Cells, Clinical Development Candidates and/or Cell Therapy Products is reasonably available at the effective date of Athersys’ opt-out, Athersys shall manufacture and supply Cells, Clinical Development Candidates and/or Cell Therapy Products to Angiotech (as the supply chain for each exists at such time) for the Territory for a period of up to twenty-four (24) months after the effective date of such opt-out (during which Section 9.6 shall apply in its entirety), wherein such Cells, Clinical Development Candidates and/or Cell Therapy Products supply shall be provided by Athersys on commercially reasonable terms and conditions to be discussed and agreed upon by Angiotech and Athersys at such time (which terms shall include a reasonable price, and shall set forth any subsequent period (after such 24-month period) during which Athersys is willing (in its sole discretion) to supply Cells, Clinical Development Candidates and/or Cell Therapy Products to Angiotech); and (iii) Angiotech shall be responsible for all activities described in ARTICLE X with respect to such Sole Development Product;

          (b) if Athersys is the Developing Party, such Sole Development Product shall no longer be considered a Clinical Development Candidate or Cell Therapy Product for purposes of the License Agreement and Sublicense Agreement, but shall continue to be considered a Clinical Development Candidate or Cell Therapy Product for purposes of this Strategic Alliance Agreement; provided, however, that (i) the provisions of ARTICLES II, III, V, VII (other than Sections 7.5-7.10 ), VIII and IX shall no longer apply to such Sole Development Product, and (ii) Athersys shall be responsible for all activities described in ARTICLE X with respect to such Sole Development Product;

          (c) any Regulatory Approvals filed, and clinical data owned or licensed, and any product trademarks owned or licensed by the Discontinuing Party or its Affiliates relating to the applicable Sole Development Product shall be (i) assigned or (ii) exclusively licensed to the Developing Party or any Third Party or Affiliate designated by such Party, until such time as the Developing Party or its designee is qualified to hold such Regulatory Approvals or product trademarks under applicable laws and regulations,

and then shall be transferred or assigned to the Developing Party or its designee, as appropriate, as soon as practicable thereafter; provided, however, that in any country where such transfer or assignment is not possible, the Discontinuing Party shall use Commercially Reasonable Efforts to ensure that the Developing Party has the benefit of such Regulatory Approvals and product trademarks, and to this end consents to any regulatory authority cross-referencing to the data and information on file with any regulatory authority as may be necessary; and

          (d) the Developing Party shall pay a royalty on Sole Development Products to the Discontinuing Party and shall share Sole Development Income with the Discontinuing Party in accordance with Sections 7.5 through 7.10 below.

     6.2 Development Updates . At least every six (6) months during the Term, the Developing Party shall provide the Discontinuing Party with a written update regarding the status of the Developing Party’s efforts to develop and commercialize Sole Development Products. All information provided by the Developing Party to the Discontinuing Party pursuant to this Section 6.2 shall be considered Confidential Information (as defined in Section 13.1 ) of the Developing Party.

     6.3 Failure to Exercise Sole Development Option . In the event the non-discontinuing Party does not exercise the Sole Development Option within the six (6) month time period set forth in Section 6.1 above, and if agreed upon in writing by the Parties, the JSC may seek, or designate one of the Parties to seek, qualified Third Party(ies) to develop the applicable Clinical Development Candidate or Cell Therapy Product. Both Parties shall have the right to approve any such qualified Third Party(ies). The Parties shall share equally all (a) income received from such Third Party(ies) and (b) Clinical Development Costs, Commercialization Costs and Manufacturing Costs (as applicable) associated with the wind-down of activities related to the applicable Clinical Development Candidate or Cell Therapy Product.

     6.4 Diligence Requirement . The Developing Party’s right to exclusively develop and commercialize a Sole Development Product is expressly conditioned on such Party’s continuing effort to use Commercially Reasonable Efforts to develop such Sole Development Product (the “ Diligence Requirement ”). The Diligence Requirement shall be conditioned upon the continuing absence of any adverse condition or event that warrants a delay in the development, clinical testing or commercialization of a particular Sole Development Product; provided that a delay shall only be warranted for as long as the condition or event preventing the performance continues and, upon cessation of such condition or event, the Developing Party shall promptly resume performance hereunder. Such conditions and events shall include, without limitation, the inability to produce preclinical or clinical supplies, events that would cause delays in clinical studies (e.g., negative toxicological or pharmacological test results or an adverse clinical event), challenges within the regulatory process, or intellectual property impediments to developing a Sole Development Product that the Developing Party could not reasonably have foreseen. If the Discontinuing Party reasonably believes that the Developing Party has failed to satisfy the Diligence Requirement with respect to a Sole Development Product, it shall so notify the Developing Party in writing and the Developing Party shall

then have ninety (90) days to demonstrate to the Discontinuing Party’s reasonable satisfaction that the Diligence Requirement for such Sole Development Product has been satisfied. Any dispute regarding the satisfaction of the Diligence Requirement shall be resolved by the Parties under the terms of ARTICLE XVII below. If it is determined that the Diligence Requirement has not been satisfied with respect to a Sole Development Product, then the Parties shall meet and discuss in good faith a mutually agreeable process for development and commercialization of the Sole Development Product.

ARTICLE VII.
COSTS, PAYMENTS AND FINANCIAL RECORD KEEPING

     7.1 Clinical Development Costs . All Clinical Development Costs incurred in accordance with the corresponding Clinical Development Plan budget shall be borne by Athersys and Angiotech in the following proportions:

          (a) Clinical Development Costs associated with the execution of any Phase I Study or Phase II Study pursuant to any Clinical Development Plan shall be shared [*] percent ([*]%) by Athersys and [*] percent ([*]%) by Angiotech;

          (b) Clinical Development Costs associated with the execution of the first Phase III Study conducted pursuant to this Strategic Alliance Agreement shall be shared [*] percent ([*]%) by Athersys and [*] percent ([*]%) by Angiotech; and

          (c) Clinical Development Costs associated with the execution of any Phase III Study that is subsequent to the first Phase III Study trial described in clause (b) above shall be shared [*] percent ([*]%) by Athersys and [*] percent ([*]%) by Angiotech.

     7.2 Development Costs Quarterly Reconciliation .

          (a) Within thirty (30) days following the end of each calendar quarter during the Term, Athersys shall submit to Angiotech a written report setting forth in reasonable detail, and separately with respect to each Clinical Development Plan and each of the categories of Clinical Development Costs set forth in Section 7.1(a-c) , all associated Clinical Development Costs incurred by Athersys in the immediately preceding calendar quarter.

          (b) Within thirty (30) days following the end of each calendar quarter during the Term, Angiotech shall submit to Athersys a written report setting forth in reasonable detail, and separately with respect to each Clinical Development Plan and each of the categories of Clinical Development Costs set forth in Section 7.1(a-c) , all associated Clinical Development Costs incurred by Angiotech in the immediately preceding calendar quarter.

          (c) Within forty-five (45) days following the end of each calendar quarter, Angiotech shall submit to Athersys a written report (i) reconciling the Clinical Development Costs set forth in the reports required under Section 7.2(a) and Section 7.2(b) , and (ii) setting forth the calculation of any net amount owed by Athersys to Angiotech, or by Angiotech to Athersys (as the case may be) in order to ensure the sharing of such Clinical Development Costs in accordance with Section 7.1 . The net amount payable in accordance with clause (ii) shall be paid by Angiotech or Athersys, as the case may be, within ten (10) business days after Athersys’ receipt of such written report, without regard to any dispute as to the amounts incurred by a Party or owed to a Party under this Section 7.2(c) in accordance with the applicable budget. In the event of such dispute under this Section 7.2(c) , the disputing Party shall provide written notice to the other Party within such ten (10)-business day period after receipt of the written report in question, specifying in detail such dispute. The Chief Financial Officers (“ CFOs ”) of the Parties shall promptly thereafter meet and shall negotiate in good faith a final resolution to such dispute.

     7.3 Milestone Payments . Angiotech shall provide written notice to Athersys within thirty (30) days of achievement of any milestone set forth on Schedule 7.3 ; provided that such notice with respect to items 4 and 5 on Schedule 7.3 shall be given within thirty (30) days following the calendar quarter in which such milestone occurred. Angiotech shall pay to Athersys the corresponding amount set forth on Schedule 7.3 within ten (10) business days following receipt of such written notice by Athersys. An additional milestone payment is described in Section 2.4 .

     7.4 Profit Sharing . Angiotech and Athersys shall share Profits from the sale of Cell Therapy Products in accordance with Schedule 7.4 .

     7.5 Royalties on Sole Development Products .

          (a) Royalty Amounts . During the Royalty Term for each Sole Development Product commercialized by the Developing Party under ARTICLE VI , the Developing Party will pay the Discontinuing Party a royalty on Net Sales of such Sole Development Product (except to the extent otherwise provided under Section 7.5(b) ) at the following rates:

          (i) if, as of the date the Opt-Out Notice is delivered, the first patient has not yet been enrolled in a Phase II Study of such Sole Development Product, such royalty shall be [*] percent ([*%]) with respect to Net Sales of Sole Development Products for which Angiotech is the Developing Party, and no royalty with respect to Net Sales of Sole Development Products for which Athersys is the Developing Party;

          (ii) if, as of the date the Opt-Out Notice is delivered, the first patient has been enrolled in a Phase II Study of such Sole Development Product

but the first patient has not yet been enrolled in a Phase III Study of such Sole Development Product, such royalty shall be [*] percent ([*%]) with respect to Net Sales of Sole Development Products for which Angiotech is the Developing Party, and [*] percent ([*%]) with respect to Net Sales of Sole Development Products for which Athersys is the Developing Party; and

          (iii) if, as of the date the Opt-Out Notice is delivered, the first patient has been enrolled in a Phase III Study for such Sole Development Product and thereafter, such royalty shall be [*] percent ([*%]) with respect to Net Sales of Sole Development Products regardless of which Party is the Developing Party;

provided, however, that if it is unclear whether a clinical trial is in a particular phase, the actual phase of such clinical trial shall be determined by reference to the next following clinical trial for such Sole Development Product (e.g. , a Phase I/II clinical trial would be considered a Phase II Study if, following completion of such trial, the Developing Party commences a Phase III Study of such Sole Development Product). If (xi) Angiotech is the Discontinuing Party and has elected to decline payment of the Phase I Milestone Fee pursuant to Section 2.4(b) , and (xii) Athersys has elected to receive a greater share of Profits pursuant to Section 2.4(b)(ii) , then the royalty rate payable to Angiotech pursuant to clause (ii) above shall be [*] percent [*%] and the royalty rate payable to Angiotech pursuant to clause (iii) above shall be [*] percent [*%]. The royalties payable pursuant to this Section 7.5(a) shall not be creditable against any other payment by the Developing Party under this ARTICLE VII .

          (b) Licensee and Sublicensee Royalties on Sole Development Products . Any sales of Sole Development Products by a licensee or sublicensee of a Developing Party or its Affiliate shall be subject to royalties under Section 7.5(a) to the same extent as if the sale had been made by the Developing Party; provided that the royalty payable to the Discontinuing Party pursuant to (i) Section 7.5(a)(i) shall not exceed twenty-five percent (25%) of the royalty revenue received by the Developing Party from such licensee or sublicensee; (ii) Section 7.5(a)(ii) shall not exceed thirty percent (30%) of the royalty revenue received by the Developing Party from such licensee or sublicensee; and (iii) Section 7.5(a)(iii) shall not exceed thirty-five percent (35%) of the royalty revenue received by the Developing Party from such licensee or sublicensee. The royalties payable pursuant to this Section 7.3(b) shall not be creditable against any other payment by the Developing Party under this ARTICLE VII .

          (c) Third Party Payments on Sole Development Products . The Developing Party shall pay all Third Party Payments due as a result of any Sole Development Product sold by the Developing Party. For the avoidance of doubt, such Third Party Payments shall be in addition to any royalties that may be due pursuant to Sections 7.5(a) and 7.5(b) .

          (d) Reduction due to Royalty Stacking . In the event the Developing Party obtains or possesses a license to one or more Patent Rights of a Third Party in order to make, have made, use, lease, offer to sell, sell, export or import a Sole Development Product and is required to pay Third Party Payments with respect to the Sole Development Product in connection with such license(s), then the Developing Party may deduct, from royalties due the other Party pursuant to this Section 7.5(d) , fifty percent (50%) of the Third Party Payments that are actually paid and are attributable to such Sole Development Product, but in no event may the royalties due to the other Party pursuant to this Section 7.5(d) be reduced by more than fifty percent (50%) as a result of this provision. Any amounts for which the Developing Party is entitled to receive credit, which are not deducted as a result of the fifty percent (50%) cap, shall be carried forward and credited against future royalties due to such Party.

     7.6 Calculation and Payment of Royalties .

          (a) Timing of Royalty Payments . A Party paying a royalty required under Section 7.5 (the “ Paying Party ”) shall pay all such royalties to the other Party (the “ Royalty Recipient ”) within forty-five (45) days after the last day of the calendar quarter in which such royalties accrue; provided that the Paying Party shall be entitled to offset any such royalty payment against amounts owed to the Paying Party by the Royalty Recipient; and provided further that if: (i) Angiotech is the Royalty Recipient and has elected to decline payment of the Phase I Milestone Fee pursuant to Section 2.4(b) ; (ii) Athersys has elected to receive the Replacement Fee pursuant to Section 2.4(b)(i) ; and (iii) the Replacement Fee has not yet been paid, then before paying any royalties to Angiotech under Section 7.5 or Sole Development Income to Angiotech under Section 7.7 , Athersys shall be entitled to withhold from such royalties and Sole Development Income the Replacement Fee (plus interest) on the unpaid amount of the Replacement Fee, at the rate set forth in Section 7.10 , from the date of Successful Completion of the first Phase III Study for a Clinical Development Candidate in the U.S. in any Cardiovascular Indication(s), until the unpaid amounts of the Replacement Fee (plus interest) are recovered by Athersys.

          (b) Payment Method . The Paying Party shall pay royalties hereunder in U.S. dollars by wire transfer in immediately available funds to an account designated by the Royalty Recipient.

          (c) Accrual of Royalties . Sales between a Party and its Affiliates or their respective direct or indirect licensees, sublicensees or subcontractors , or between such parties, shall not be subject to royalties, but in such cases royalties shall be calculated upon the quarterly Net Sales of Sole Development Products by such parties to an independent Third Party. Only one (1) royalty payment shall accrue with respect to the same unit of a Sole Development Product. No royalties shall accrue on disposition of reasonable quantities of Sole Development Products for no charge as samples, pursuant to an indigent patient assistance program, or donations to Third Parties. Royalties shall accrue on Sole Development Products distributed for free other than as described in the preceding sentence based on average Net Sales for such Sole Development Product during the corresponding period, excluding such free Sole Development Product.

          (d) Taxes . Any withholding of taxes levied by tax authorities on the payments hereunder shall be deducted by the Paying Party from the sums otherwise payable by the Paying Party hereunder for payment to the proper tax authorities on behalf of the Royalty Recipient and shall be paid by the Paying Party to such proper tax authorities. The Parties agree to cooperate with each other in the event the Royalty Recipient claims exemption from such withholding or seeks deductions under any double taxation or other similar treaty or agreement from time to time in force, such cooperation to consist of providing receipts of payment of such withheld tax or other documents reasonably available to the Parties.

          (e) Royalty Reports . Within forty-five (45) days after the last day of each calendar quarter in which royalties are due, the Paying Party shall deliver to the Royalty Recipient a report setting forth in reasonable detail the calculation of Net Sales and of royalties payable to the Royalty Recipient for such calendar quarter identifying, by country, the Sole Development Products sold by the Paying Party and its Affiliates, licensees, sublicensees and distributors. Such reports shall be considered Confidential Information of the Paying Party subject to the terms of ARTICLE XII hereof.

     7.7 Sharing of Sole Development Income . The Developing Party shall pay to the Discontinuing Party the following percentage share of all Sole Development Income received by the Developing Party that is attributable to the rights owned by or granted to the Developing Party hereunder: (i) if the royalty rate specified in Section 7.5(a)(i) would be payable on Net Sales of such Sole Development Product, [*] percent ([*%]) of all such Sole Development Income; (ii) if the royalty rate specified in Section 7.5(a)(ii) would be payable on Net Sales of such Sole Development Product, [*] percent ([*%]) of all such Sole Development Income; or (iii) if the royalty rate specified in Section 7.5(a)(iii) would be payable on Net Sales of such Sole Development Product, [*] percent ([*%]) of all such Sole Development Income. All such amounts owed by the Developing Party in accordance with this Section 7.7 shall be due and payable to the Discontinuing Party within thirty (30) days after receipt of such Sole Development Income by the Developing Party, subject to any right of offset pursuant to Section 7.6(a) . In the case of receipt by the Developing Party of any non-cash consideration from a licensee or sublicensee in consideration for the granting of a license or sublicense to a Sole Development Product that is attributable to the rights owned by or granted to the Developing Party hereunder (but excluding, for the avoidance of doubt, consideration received by the Developing Party that is attributable to the items excluded from the definition of Sole Development Income, and further excluding standard contractual benefits, such as indemnities, warranties, diligence and confidentiality obligations and the like), Sole Development Income shall be calculated based on the value of such non-cash consideration received by the Developing Party (and shall be combined with the value of any cash consideration received for purposes of determining the applicable percentage share above).

     7.8 Financial Record Keeping . During the Term and for seven (7) years thereafter, each Party shall keep complete and accurate records of its Clinical Development Costs, Manufacturing Costs, Commercialization Costs, Net Sales and other business and financial data and information underlying the reconciliations, cost reports, calculation of costs and Profits, and payments that are the subject of the Transaction Agreements.

     7.9 Audits . Upon at least forty-five (45) days prior written notice to the other Party, a Party will have the right, once annually at its own expense, to have an independent, certified public accounting firm, selected by such Party and reasonably acceptable to the other Party, inspect relevant books and records of the other Party in the location(s) where such books and records are maintained by the other Party. The written notice from the auditing Party shall name the accounting firm and shall describe the scope of the audit to be conducted and the records and statements sought to be verified. Such audit shall be conducted during regular business hours and under obligations of strict confidence, and shall be conducted for the sole purpose of verifying the basis and accuracy of any report(s) submitted by the audited Party and the payment of costs and Profit-sharing amounts hereunder, as applicable, all to ascertain that all costs charged and payments made hereunder are correct in accordance with the Transaction Agreements, in each case with respect to relevant books and records corresponding to the prior twenty-four (24) month period. If such audit of such books and records concludes that the audited Party has failed to accurately report any cost, Profit or payment information, then in the event of any underpayment, the audited Party shall pay to the auditing Party any undisputed additional amounts due within thirty (30) days after the date the audited Party receives such accounting firm’s written report so concluding, together with interest calculated using the prime rate (as published in The Wall Street Journal on the date when payment was due) plus three percent (3%) for the time from which the amounts should have been paid until the time of actual payment. If such undisputed underpayment exceeds seven and one-half percent (7.5%) of the payments that were to be paid to the auditing Party during the period audited, the audited Party also shall reimburse the auditing Party for the amounts (reasonable fees and expenses) paid to the accounting firm in conducting the audit. If such accounting firm concludes that the audited Party overpaid the auditing Party, the auditing Party shall refund such undisputed overpayments to the audited Party within thirty (30) days after the date the auditing Party receives such accounting firm’s report so concluding. If the audited Party disputes the results of the audit, such dispute shall be resolved by the Parties’ CFOs, and any purported underpayment shall be withheld until such dispute is finally resolved.

     7.10 Late Payments . Interest will be assessed on any overdue payments at a rate equal to the prime rate (as published in The Wall Street Journal on the date when payment was due) plus three percent (3%) for the time from which the amounts should have been paid until the time of actual payment, or at such lower maximum rate permitted by law. The payment of such interest will not prevent the Party to which such payment is due from exercising any other rights it may have as a consequence of the lateness of any payment.

ARTICLE VIII.
COMMERCIALIZATION

     8.1 Commercialization of Cell Therapy Products . During the Term, Angiotech shall have the sole authority and the exclusive right to commercialize Cell Therapy Products (itself or through one or more Third Parties selected by Angiotech), and shall have sole authority and responsibility in all matters relating to the commercialization of Cell Therapy Products including, without limitation, the following activities (and other associated activities) with respect to Cell Therapy Products: (a) executing product promotion, marketing and sales activities; (b) booking sales; (c) handling all aspects of order intake and processing, invoicing and collection, distribution, warehousing, inventory and receivables, and collection of data of sales to hospitals and other end users (i.e. , market research data); (d) handling all privacy and reimbursement-related activities; (e) handling the logistics of all recalls; (f) handling all returns; (g) handling all other customer service related functions; and (h) filing Cell Therapy Product promotional materials with the relevant regulatory authority as permitted or required under applicable law. Angiotech shall use Commercially Reasonable Efforts to commercialize at least one Cell Therapy Product (at its discretion) for a myocardial infarction indication and a peripheral vascular disease indication in countries of the Territory where Regulatory Approval has been obtained for such Cell Therapy Product(s); provided that Angiotech shall consider in good faith any recommendations and requests by Athersys’ representatives on the JSC regarding commercialization of Cell Therapy Products.

ARTICLE IX.
MANUFACTURE AND SUPPLY OF CLINICAL DEVELOPMENT CANDIDATES AND CELL THERAPY PRODUCTS

     9.1 Athersys’ Manufacturing Obligation . Athersys shall be responsible for manufacturing and supplying Clinical Development Candidates and Cell Therapy Products for development and commercialization by the Parties in accordance with the Transaction Agreements. In accordance with this ARTICLE IX , Athersys shall supply (or shall engage a Third-Party manufacturer to supply) sufficient quantities of the Clinical Development Candidates and Cell Therapy Products in final packaged form to the extent reasonably required by Athersys and Angiotech to implement the Clinical Development Programs and by Angiotech to commercialize the Cell Therapy Products in the Territory. The specific terms and procedures by and upon which Athersys shall supply the Cell Therapy Products to Angiotech hereunder shall be reasonably mutually determined by the Parties in good faith, and shall be set forth in a separate manufacturing and supply agreement not less than twelve (12) months prior to the anticipated First Commercial Sale of a Cell Therapy Product in the Territory, such terms and procedures to be commercially reasonable and consistent with the provisions of the Transaction Agreements. The Parties also may agree to negotiate in good faith a separate quality agreement that sets forth the Parties’ obligations with respect to current good manufacturing practices, production, release and/or distribution of Clinical Development Candidates and Cell Therapy Products in the Territory, the first draft of which shall be prepared collaboratively by the quality departments of each Party. Unless otherwise provided herein, Athersys shall have the exclusive right and obligation to manufacture

(itself and/or through Third Parties selected by Athersys) and supply Clinical Development Candidates and Cell Therapy Products for development and commercialization hereunder.

     9.2 Manufacturing Costs . Athersys shall keep, and shall require all Third-Party manufacturers of the Clinical Development Candidates and/or Cell Therapy Products to keep, accurate records in sufficient detail concerning the Manufacturing Costs. Angiotech shall be entitled to engage an independent public accounting firm to audit the Manufacturing Costs as provided in, and in accordance with, Section 7.6 . For this purpose, Athersys itself shall keep, and to the extent that Athersys has obtained records or documents from its Third-Party manufacturers shall keep, such account books and related records or documents for a period of at least seven (7) years after the end of the fiscal year to which the Manufacturing Costs relate.

     9.3 Manufacturing Compliance . All Clinical Development Candidates and Cell Therapy Products supplied hereunder shall be manufactured by or on behalf of Athersys in compliance with current good manufacturing practices, other applicable requirements of relevant regulatory authorities, and other applicable laws and regulations, including applicable laws and regulations relating to the transportation, storage, use, handling and disposal of waste materials and hazardous materials used to manufacture Clinical Development Candidates and/or Cell Therapy Products. Athersys, at its expense, shall obtain and maintain, and/or shall require that its Third-Party manufacturers obtain and maintain, for so long as Athersys is supplying Clinical Development Candidates and/or Cell Therapy Products hereunder, all facility licenses and government permits necessary to manufacture and supply the Clinical Development Candidates and Cell Therapy Products.

     9.4 Product Conformity . Angiotech, in consultation with the JSC, shall determine the Clinical Development Product and Cell Therapy Product specifications and testing methods (“ Product Specifications ”) for the Clinical Development Products and Cell Therapy Products to be supplied by Athersys hereunder, and such specifications and testing methods shall be consistent with industry standards and applicable regulatory requirements. When Regulatory Approval is obtained in any country of the Territory, the Product Specifications shall be those specifications and testing methods which have been approved by the regulatory authority in that country. The Product Specifications may be amended from time to time by written mutual agreement of the Parties. Athersys shall, and shall ensure that any Third-Party manufacturer shall, manufacture the Clinical Development Products and Cell Therapy Products in conformance with the Product Specifications and in compliance with the requirements set forth in Section 9.3 .

     9.5 Ordering; Forecasting; Acceptance and Rejection . The terms and procedures set forth in the manufacturing and supply agreement described in Section 9.1 may include provisions related to Cell Therapy Product orders and forecasts, Cell Therapy Product acceptance, and, subject to the provisions of this Section 9.5 , Cell Therapy Product rejection and remedies for defective Cell Therapy Product. Any dispute arising between Athersys and Angiotech concerning a shipment of Cell Therapy Product that the Parties do not resolve within thirty (30) days of Angiotech providing a notice of shipment of

defective Cell Therapy Product shall be submitted to a reputable independent test organization located in the Territory, to be mutually agreed upon by the Parties. Such independent test organization shall determine whether the Cell Therapy Product in a given shipment was defective, and the decision of said independent test organization shall be final and binding on Athersys and Angiotech. If the defective Cell Therapy Product was supplied by a Third-Party manufacturer or by Athersys, then any expenses actually incurred by Athersys in connection with such defective Cell Therapy Product shall be borne solely by Athersys, and shall not be included in Manufacturing Costs hereunder.

     9.6 Inspection . With respect to the manufacture of the Clinical Development Candidates and Cell Therapy Products, Angiotech may, at its expense, upon reasonable notice and during normal business hours, conduct appropriate review and inspection of the Clinical Development Candidates and Cell Therapy Products manufacturing facilities, procedures and related documentation to verify Athersys’ and/or its Third-Party manufacturer’s (as applicable) compliance with current good manufacturing practices, other applicable requirements of relevant regulatory authorities, and other applicable laws and regulations, and conformity of Clinical Development Candidates and Cell Therapy Products with the applicable Product Specifications.

     9.7 Supply Disruption . In the event that Athersys is materially unable, at any time, to fulfill its obligation to supply Clinical Development Candidates or Cell Therapy Products in a timely manner, as required hereunder, for any reason (a “ Supply Disruption ”), Athersys shall promptly notify Angiotech of such Supply Disruption and the estimated extent of such Supply Disruption (including the anticipated delay time and the quantity of Clinical Development Candidate or Cell Therapy Product involved). Athersys shall use its Commercially Reasonable Efforts to cure the Supply Disruption as soon as practicable. In the event that such Supply Disruption is expected to continue for at least three (3) months from the date of such notification, Angiotech shall have the right to have the Clinical Development Candidate or Cell Therapy Product (as applicable) manufactured by itself or by a Third-Party supplier/manufacturer, and Athersys shall cooperate and use its Commercially Reasonable Efforts to transfer to Angiotech (or Angiotech’s designee) all Athersys Intellectual Property (including, without limitation, Athersys Stem Cell Technology and production and manufacturing technology) that is necessary or useful to enable Angiotech to establish (or be) a source for supply of the Clinical Development Candidate or Cell Therapy Product (as applicable). In addition, Athersys shall teach and instruct personnel of Angiotech (or Angiotech’s designee) how to obtain appropriate raw materials and how to reproduce the production and manufacturing processes and techniques used by Athersys for production and manufacturing of the Clinical Development Candidate or Cell Therapy Product (as applicable).

     9.8 Back-Up Supplier . If Angiotech, through exercise of reasonable business judgment, determines that it is reasonable and prudent to obtain a back-up supplier to prevent a Supply Disruption, then Athersys shall use its Commercially Reasonable Efforts to identify, engage and qualify at least one back-up supplier for the Clinical Development Candidate(s) or Cell Therapy Product(s). If a Third-Party is or will be the principal manufacturer of the Clinical Development Candidate(s) or Cell Therapy Product(s), such back-up supplier may be Athersys or its

Affiliate or Angiotech or its Affiliate. In a manner similar to that described in Section 9.7 regarding a Supply Disruption, Athersys shall transfer or license to each such back-up supplier such Athersys Intellectual Property as is necessary or useful to permit such back-up supplier to implement and practice processes related to manufacture and supply of Clinical Development Candidate(s) or Cell Therapy Product(s), and/or to maintain its status as a qualified manufacturing entity under any and all applicable laws and regulations with respect to such processes or Clinical Development Candidate(s) or Cell Therapy Product(s). If Athersys decides to designate and qualify a back-up supplier, Athersys agrees to consult with Angiotech in identifying and selecting an appropriate Third Party as back-up supplier, and the Parties shall work together to establish each selected Third Party back-up supplier as expeditiously as reasonably possible, so as to minimize the period of absence of supply of Clinical Development Candidate(s) and/or Cell Therapy Product(s), as the case may be.

ARTICLE X.

REGULATORY MATTERS

     10.1 Ownership of Regulatory Documentation and Reference Rights; Regulatory Strategy . Athersys (in collaboration with Angiotech) shall prepare and file, in its own name, all IND applications for Clinical Development Candidates throughout the Territory, such filings to be consistent with the JSC’s regulatory strategy and decisions and subject to Angiotech’s prior written approval. Upon Angiotech’s reasonable request and to the extent permitted by applicable law, within thirty (30) days after the completion of each such Phase I Study hereunder, Athersys shall assign and transfer to Angiotech Athersys’ entire right, title and interest in and to any corresponding IND and other regulatory filings and documentation pertaining thereto. Angiotech shall own (a) all regulatory filings and documentation pertaining to all post-Phase I Studies of Clinical Development Candidates, and all Regulatory Approvals and related regulatory documents prepared for and/or submitted to the applicable regulatory authorities in the Territory for all Cell Therapy Products. Upon the reasonable request of Angiotech, and within a time period that is reasonable and appropriate in view of the nature and volume of documents so requested, Athersys shall make available to Angiotech such regulatory filings and related regulatory documents owned by Athersys (including a right to reference the foregoing) if and to the extent necessary to enable Angiotech to fulfill its obligations and to exercise its rights under the Transaction Agreements.

     10.2 Regulatory Communications . Athersys shall have the primary responsibility for communicating with any regulatory authority regarding any IND application or other regulatory filing pertaining to a Clinical Development Candidate that has not yet completed a Phase I Study. Angiotech shall have the primary responsibility for communicating with any regulatory authority regarding any IND application or other regulatory filing pertaining to a Clinical Development Candidate that has completed a Phase I Study, and regarding any Clinical Development Candidate or Cell Therapy Product that has been submitted for, or has obtained, Regulatory Approval. Each Party shall reasonably advise, assist and cooperate with the other Party with respect to regulatory communications within the primary responsibility of the other Party. Each Party shall promptly notify the other Party in writing of any material communications

with a regulatory authority regarding any Clinical Development Candidate or any Cell Therapy Product in the Territory.

     10.3 Other Regulatory Responsibilities . At the time when the first Phase I Study is completed for any Clinical Development Candidate, Angiotech thereafter shall be responsible for (a) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, each regulatory authority with respect to such Clinical Development Candidate and any resulting Cell Therapy Product(s); (b) interfacing, corresponding and meeting with each regulatory authority; (c) maintaining all regulatory filings; (d) responding to any action by a regulatory authority that would prohibit the marketing or the continued marketing of a Cell Therapy Product, or that would result in any shortage or projected shortage of a Cell Therapy Product; and (e) filing all adverse event reports. Using its Commercially Reasonable Efforts, Athersys shall cooperate with Angiotech and assist Angiotech in the performance of all such activities, and shall provide Angiotech with any information in Athersys’ possession or control that Angiotech or Athersys reasonably deems to be relevant to any such activities. To the extent either Party or its Affiliate has or receives any information regarding any new adverse event or any serious adverse event that may be relevant to the use of any Clinical Development Candidate or Cell Therapy Product, such Party shall immediately contact the other Party and provide the other Party with all such information in accordance with the adverse event reporting procedures established by Angiotech from time to time.

     10.4 Cell Therapy Product Complaints and Recalls . Angiotech shall be solely responsible for responding to any Cell Therapy Product complaints. In the event (a) any governmental agency or regulatory authority issues a request, directive or order that a Cell Therapy Product be recalled; (b) a court of competent jurisdiction orders that Cell Therapy Product be recalled; or (c) Angiotech reasonably determines that a Cell Therapy Product should be recalled or withdrawn from the market by Angiotech, or that a “Dear Doctor” letter should be sent relating to use of a Cell Therapy Product (wherein Angiotech shall determine the form and content of each such “Dear Doctor” letter), then Angiotech shall take all appropriate remedial actions with respect thereto. The cost of any recall, field alert, Cell Therapy Product withdrawal, or field corrective action shall be considered a Commercialization Cost, unless such recall, field alert, Cell Therapy Product withdrawal, or field corrective action is caused in material part by a Party’s breach of its obligations under this Strategic Alliance Agreement (including obligations regarding manufacturing, advertising, distribution and storage of the Cell Therapy Products) or applicable laws, or by its willful misconduct; then such cost shall be borne by the breaching Party to the extent such recall, field alert, Cell Therapy Product withdrawal, or field corrective action was due to such causes.

     10.5 Compliance With All Applicable Laws and Regulations; Cooperation . Each Party shall perform its obligations under the Transaction Agreements, and its responsibilities and rights under the Clinical Development Plans and otherwise in connection with the development and commercialization of Clinical Development Candidates and Cell Therapy Products, in accordance with all applicable laws, rules and regulations, including those of all regulatory authorities in the Territory, applicable

reporting obligations, applicable import and export laws and regulations, current good clinical practices. Each Party shall fully cooperate with the other Party in all reasonable respects useful or necessary to enable each to be and remain in compliance with all such applicable laws, rules and regulations.

ARTICLE XI.

INTELLECTUAL PROPERTY

     11.1 Existing Intellectual Property Rights Retained . Angiotech and Athersys shall each retain all of their respective ownership interests in their respective Intellectual Property, as such exists as of the Effective Date. Nothing in this Strategic Alliance Agreement or any Transaction Agreement shall be construed to transfer ownership of any Intellectual Property rights existing as of the Effective Date from one Party to another Party.

     11.2 Ownership Of New Intellectual Property . Ownership and treatment of Intellectual Property resulting from the Parties’ activities under the Transaction Agreements shall be as set forth in the License Agreement.

ARTICLE XII.

CLINICAL PROGRAM RECORD KEEPING

     12.1 Scientific, Patent and Regulatory Records . When performing its responsibilities and activities under each Pre-Clinical Development Program, New Pre-Clinical Development Program and Clinical Development Program or under any Transaction Agreement, each Party shall maintain, and shall cause its employees and contractors to maintain, scientific and regulatory records, in sufficient and reasonable detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of such responsibilities and activities by such Party.

     12.2 Review of Records . On reasonable advance written notice, and at reasonable intervals, during normal business hours each Party shall have the right to inspect and copy records of the other Party maintained in connection with the activities conducted, work performed and results achieved in the performance of its responsibilities and activities under each Pre-Clinical Development Program, New Pre-Clinical Development Program and Clinical Development Program or under any Transaction Agreement, including, without limitation, records reflecting inventions, ideas, information or data developed by a Party in the course of or work done hereunder, to the extent such access is reasonably necessary or useful for a Party to exercise its rights and perform its obligations under this Strategic Alliance Agreement or other Transaction Agreements. Notwithstanding the definition of “Confidential Information” all such records and the information disclosed therein shall constitute Confidential Information of the Party creating such records, and shall be maintained in confidence by the receiving Party in accordance with ARTICLE XIII .

     12.3 Policies For Records . In order to protect each Party’s Patent Rights under United States and foreign law in any inventions conceived or reduced to practice in connection with any activities or work performed by the Parties under this Strategic Alliance Agreement or any Transaction Agreement, each Party shall require its employees to record and maintain data and information developed pursuant to the Transaction Agreements in such a manner as to enable the Parties to use such records to establish inventorship and corroborated and documented dates of conception, diligence to reduction to practice and/or actual reduction to practice. Each Party shall require its employees engaged in activities or work in connection with the Transaction Agreements to assign all Intellectual Property created, conceived or reduced to practice in connection therewith to their respective employer, and each Party shall ensure that each such employee has signed such an agreement before any activities or work in connection with the Transaction Agreements commences.

ARTICLE XIII.

CONFIDENTIAL INFORMATION

     13.1 Confidential Information . “ Confidential Information ” means all proprietary, non-public Intellectual Property and other information, including, but not limited to, proprietary information and materials (whether or not patentable) regarding a Party’s technology, products, business information or objectives, that is communicated in any way or form by such Party (a “Disclosing Party” ) to the other Party (a “Receiving Party” ), and all copies thereof made, in whole or in part, by the Receiving Party in any form. Notwithstanding the foregoing, the term “Confidential Information” shall not include any information of a Disclosing Party that: (a) was already known by the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party and other than through any act or omission of the Receiving Party in breach of this Strategic Alliance Agreement or any Transaction Agreement; (d) was subsequently lawfully disclosed to the Receiving Party by a Third Party on a non-confidential basis; (e) can be shown by written records of the Receiving Party to have been independently developed by the Receiving Party without reference to the Confidential Information of the Disclosing Party, and without breach of any of the provisions of this Strategic Alliance Agreement or any Transaction Agreement; or (f) is information that the Disclosing Party has specifically agreed in writing that the Receiving Party may disclose. The existence and terms of each of the Transaction Agreements, the transactions described thereby and the performance of any Party’s rights or any Party’s obligations under them shall be considered the Confidential Information of both of the Parties for which each of the Parties are deemed to be the Disclosing Party.

     13.2 Confidentiality Obligations . For the Term and for five (5) years thereafter:

          (a) Except as expressly permitted in the Transaction Agreements, the Receiving Party shall keep completely confidential, and shall not publish or otherwise

- 38 -

disclose, and shall not use for any purpose, any Confidential Information of the Disclosing Party; provided, however, that the Receiving Party may disclose any Confidential Information of the Disclosing Party to a Third Party to the extent necessary to allow the Receiving Party to collaborate with such Third Party in performing any of its obligations or exercising any of its rights under any Transaction Agreement or to allow the Disclosing Party to make the regulatory filings with such Third Party as advisable or required to obtain approval to conduct clinical trials or obtain Regulatory Approval for a Clinical Development Candidate or Cell Therapy Product, and in each case then only after (i) first advising such Third Party of the Receiving Party’s obligations under this Strategic Alliance Agreement and the Transaction Agreements, and (ii) securing from such Third Party a written obligation of confidentiality no less stringent than that imposed on the Receiving Party under this Strategic Alliance Agreement and the Transaction Agreements (except when not possible with regard to governmental authorities or agencies).

          (b) Except as expressly permitted in the Transaction Agreements, the Receiving Party shall not disclose the Confidential Information of the Disclosing Party to any person or entity except the Receiving Party, its Affiliates and their respective employees, consultants and agents who have a need to know such Confidential Information of the Disclosing Party to further the purposes of any of the Transaction Agreements, and then only after (i) first advising such employees, consultants and agents of the Receiving Party’s obligations under this Strategic Alliance Agreement and the Transaction Agreements, and (ii) securing from such employees, consultants and agents a written obligation of confidentiality no less stringent than that imposed on the Receiving Party under this Strategic Alliance Agreement and the Transaction Agreements.

          (c) Except with the prior written consent of the other Party, a Party shall not make any public announcement or press release concerning any of the Transaction Agreements, the transactions contemplated by any of them, the rights or obligations of the Parties under any of them, or any of the activities that have occurred or may occur thereunder.

          (d) The Parties agree on the importance of coordinating their public announcements respecting the Transactional Agreements and the subject matter thereof (other than academic, scientific or medical publications that are subject to the publication provision set forth below). Angiotech and Athersys shall, from time to time, and at the request of the other Party, discuss and agree on the general information content relating to the Transactional Agreements which may be publicly disclosed (including, without limitation, by means of any printed publication or oral presentation).

     13.3 Permitted Disclosures . Notwithstanding Section 13.2 :

          (a) The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent the Receiving Party is compelled to disclose such information by a court or other tribunal of competent jurisdiction; provided, however, that in such case the Receiving Party shall immediately give notice to the Disclosing Party, so that the Disclosing Party may seek a protective order or other remedy from said

- 39 -

court or tribunal. In any event, the Receiving Party shall disclose only that portion of the Confidential Information of the Disclosing Party that, in the opinion of its legal counsel, is legally required to be disclosed, and will exercise reasonable efforts to ensure that any such Confidential Information of the Disclosing Party so disclosed will be accorded confidential treatment by said court or tribunal.

          (b) The Receiving Party may disclose the terms and conditions of this Strategic Alliance Agreement or any Transaction Agreement (including providing a copy hereof or thereof, redacted as appropriate) to any bona fide potential permitted assignee or successor to a Party’s interest under this Strategic Alliance Agreement or any Transaction Agreement, or to a bona fide potential lender from which a Party is considering borrowing money, or to a bona fide potential collaborator in connection with the Transaction Agreements, or in the case of Athersys, to any bona fide financial investor from which it may take money; provided, however, in any such case such that the Receiving Party shall first obtain a written obligation of confidentiality no less stringent than that imposed on the Receiving Party under this Strategic Alliance Agreement and the Transaction Agreements from the bona fide potential permitted assignee or successor, bona fide potential lender, bona fide potential collaborator or bona fide financial investor.

          (c) The Receiving Party may disclose the terms and conditions of this Strategic Alliance Agreement and/or the Transaction Agreements (including providing a copy hereof, redacted (as appropriate) with the prior written approval of the other Party, such approval not to be unreasonably withheld or delayed) in connection with filings with the U.S. Securities and Exchange Commission or otherwise pursuant to applicable securities laws and regulations, filings with the Internal Revenue Service and otherwise pursuant to applicable tax laws and regulations, and other filings required by law or regulation; provided, however, that the Receiving Party shall provide to the other Party a copy of any such proposed filing at least two (2) business days in advance of the filing, and shall consider in good faith the other Party’s suggested redactions. In any event, the Receiving Party shall disclose only that portion of the Confidential Information of the Disclosing Party that, in the reasonable opinion of its legal counsel, is legally required to be disclosed by law or regulation. Additionally, so long as Athersys’ securities are not publicly traded, Athersys may disclose (including providing a copy hereof, redacted as appropriate) to any bona fide potential purchaser of Athersys’ securities the foregoing information; provided, however, that Athersys first obtains a written obligation of confidentiality from the recipient that is no less stringent than Athersys’ obligations under this Strategic Alliance Agreement and the Transaction Agreements.

          (d) The Third Party collaborators set forth on Schedule 4.1 with which Athersys has executed an agreement as of the Effective Date, and which might be considered a subcontractor of Athersys’ obligations under this Strategic Alliance Agreement and the Transaction Agreements may have limited rights to publish their results obtained pursuant to such agreements. Any publication by a Third Party collaborator in accordance with the terms and conditions of its executed Existing Third Party Agreement with Athersys shall not be considered a breach of Athersys’ obligations hereunder.

          (e) The Parties agree that the public announcement of the execution of this Strategic Alliance Agreement shall be in the form of a press release to be mutually agreed upon within five (5) business days after the Effective Date; provided that such press release shall not be publicly disseminated by either Party prior to May 15, 2006. A Party may republish, reuse or disclose the same content of any prior publication, press release or disclosure, if such republication, reuse or disclosure is presented in substantially the same form in which it was previously published, used or disclosed, without modification of the content that was previously published, used or disclosed.

     13.4 Publication . Except as provided in Section 13.3(e) , during the Term each Party will submit to the other Party for review and approval all proposed academic, scientific and medical publications and public presentations relating to the Pre-Clinical Development Programs, New Pre-Clinical Development Programs, Clinical Development Programs, or the Transactional Agreements, for review in connection with preservation of Patent Rights and/or to determine whether any of such other Party’s Confidential Information should be modified or deleted. Written copies of such proposed publications and presentations shall be submitted to the non-publishing Party no later than thirty (30) days before submission for publication or presentation, and the non-publishing Party shall provide its comments with respect to such publications and presentations within fifteen (15) business days of its receipt of such written copy. The review period may be extended for an additional thirty (30) days in the event the non-publishing Party can demonstrate reasonable need for such extension, including, but not limited to, the preparation and filing of patent applications. By mutual agreement, this period may be further extended. Athersys and Angiotech will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publications pursuant to this Section 13.4 . With regard to proposed publications and presentations by a Third Party pursuant to an Existing Third Party Agreement, the time periods set forth above shall be complied with by the Parties to the extent possible, taking into account the applicable provisions of the subject Existing Third Party Agreement.

ARTICLE XIV.

REPRESENTATIONS AND WARRANTIES

     14.1 Authority . Each Party represents and warrants that, as of the Effective Date, it has the full right, power and authority to enter into this Strategic Alliance Agreement and the other Transaction Agreements, and that this Strategic Alliance Agreement and the other Transaction Agreements have been duly executed by such Party and constitute the legal, valid and binding obligations of such Party, enforceable in accordance with their terms, subject to (a) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights and remedies generally, and (b) the effect of general equitable principles, regardless of whether asserted in a proceeding in equity or at law.

     14.2 No Conflicts . Each Party represents and warrants that the execution, delivery and performance of this Strategic Alliance Agreement and the other Transaction Agreements do not conflict with, or constitute a breach or default under, any of its charter

or organizational documents, any law, order, judgment or governmental rule or regulation applicable to it, or any material agreement, contract, commitment or instrument to which it is a party.

     14.3 Additional Representations and Warranties of Athersys . In addition to the representations and warranties made by Athersys in Sections 14.1 and 14.2 , Athersys, subject to Section 14.6 , hereby represents and warrants that as of the Effective Date:

          (a) it has not granted to any Third Party any right or license which would conflict with the rights granted by it to Angiotech under any of the Transaction Agreements;

          (b) except as disclosed in Schedule 14.3(b) attached hereto, Athersys is the sole and exclusive owner of the Athersys Patent Rights set forth in Schedule 1.33 , and Athersys has not placed, or suffered to be placed, any liens, charges or encumbrances on or against such Athersys Patent Rights;

          (c) Schedule 1.33 is a true and complete list of Athersys’ Patent Rights that pertain to the subject matter of the Transaction Agreements.;

          (d) Athersys has submitted to the United States Patent and Trademark Office all information related to the Cells, pre-clinical development candidates, Clinical Development Candidates and Cell Therapy Products that is required to be submitted in accordance with 37 C.F.R. 1.56, 1.97 and 1.98;

          (e) the Athersys Intellectual Property that is the subject of the rights and licenses granted to Angiotech under the Transaction Agreements constitutes all intellectual property owned or controlled by Athersys that is necessary or useful to manufacture, research, develop, use or commercialize the Cells, pre-clinical development candidates, Clinical Development Candidates and Cell Therapy Products for the Cardiovascular Indications, and to the knowledge of Athersys there is no other Intellectual Property necessary for such purposes that is owned or controlled by Athersys;

          (f) the Athersys Patent Rights set forth in Schedule 1.33 are existing and inventorship of the Athersys Patent Rights not licensed by Athersys from the University of Minnesota has been properly determined and to Athersys’ knowledge inventorship of the Athersys Patent Rights licensed from the University of Minnesota has been properly determined, and to Athersys’ knowledge, no issued or granted patents within the Athersys Patent Rights licensed or sublicensed to Angiotech under the Transaction Agreements are invalid or unenforceable;

          (g) except as set forth in Schedule 14.3(g) attached hereto, no Athersys Patent Rights listed in Schedule 1.33 are subject to any funding agreement with any government or government agency;

          (h) Athersys has received no written notice alleging infringement of a Third Party Patent Right in connection with its research and development of Cells, pre-clinical development candidates, Clinical Development Candidates and/or Cell Therapy

- 42 -

Products, and Athersys has disclosed to Angiotech all material information of which Athersys is aware as to whether the research, development, manufacture, use, sale, offer for sale or importation of Clinical Development Candidates or Cell Therapy Products infringes or would infringe issued or granted patents owned by a Third Party as of the Effective Date;

          (i) the Athersys Patent Rights licensed or sublicensed to Angiotech under the Transaction Agreements are not subject to any litigation, judgments or settlements against or owed by Athersys, nor has Athersys received written notice of any threats of such litigation;

          (j) the Athersys Patent Rights licensed or sublicensed to Angiotech under the Transaction Agreements are not the subject of any interference, opposition, reissue or reexamination proceeding in the United States or, to the knowledge of Athersys, any opposition proceeding outside of the United States;

          (k) Athersys has not knowingly used any Intellectual Property misappropriated from a Third Party in connection with the subject matter of the Transactional Agreements, and Athersys is not aware of any claim by a Third Party that Intellectual Property misappropriated from such Third Party has been used by Athersys in its research and development of Cells, pre-clinical development candidates, Clinical Development Candidates and/or Cell Therapy Products;

          (l) except as set forth in Schedule 14.3(l) attached hereto, to Athersys’ knowledge, there is no unauthorized use, infringement or misappropriation of any of the Intellectual Property that is the subject of the rights and licenses granted to Angiotech under the Transaction Agreements by any Third Party, including any current or former employee or consultant of Athersys and its Affiliates;

          (m) with respect to activities conducted by Athersys, and to Athersys’ knowledge with respect to activities conducted by Third Parties on behalf of Athersys, there has not been any scientific fraud regarding Cells, Clinical Development Candidates or Cell Therapy Products or Intellectual Property of Athersys licensed to Angiotech under the Transaction Agreements;

          (n) to Athersys’ knowledge, no employee or agent of Athersys or any of its Affiliates has made an untrue statement of a material fact to any governmental authority with respect to the Cells, pre-clinical development candidates, Clinical Development Candidates and/or Cell Therapy Products (whether in any submission to such governmental authority or otherwise), or failed to disclose a material fact required to be disclosed to any governmental authority with respect to the Cells, pre-clinical development candidates, Clinical Development Candidates and/or Cell Therapy Products;

          (o) none of it, its officers, directors, employees, or Affiliates is debarred under the Generic Drug Enforcement Act or convicted of a crime which could lead to debarment, and it has not knowingly utilized, and has not knowingly utilized, the services of any individual or entity in conducting its manufacturing activities hereunder that has

- 43 -

been debarred under the Generic Drug Enforcement Act or convicted of a crime that could lead to debarment;

          (p) that its employees have complied materially with all safety and environmental procedures, protocols, systems, laws, rules and regulations applicable to or associated with its Cell isolation, purification and production activities hereunder;

          (q) Athersys and its Affiliates have complied materially with all applicable laws, rules, regulations, permits, governmental licenses, registrations, approvals, concessions, franchises, authorizations, orders, injunctions and decrees, including the Federal Food, Drug and Cosmetic Act, in the research, development, manufacture and use of the Cells, pre-clinical development candidates, Clinical Development Candidates and/or Cell Therapy Products, and neither Athersys nor any of its Affiliates has received any written notice from any regulatory authority claiming that any such activities as conducted by them are not in such compliance; and

          (r) that the Cells are not derived from embryonic sources (i.e., the Cells are not embryonic stem cells).

     14.4 Additional Covenants of Athersys . In addition to the representations and warranties made by Athersys in Sections 14.1 , 14.2 , and 14.3 Athersys, subject to Section 14.6 , hereby covenants to Angiotech that during the Term:

          (a) it will not grant to any Third Party any right or license which would conflict with the rights granted by it to Angiotech under any of the Transaction Agreements;

          (b) Athersys will not place, or suffer to be placed, any liens, charges or encumbrances on or against any Athersys Patent Rights that may have an adverse effect on Angiotech’s rights or licenses with respect to Athersys Patent Rights licensed to Angiotech under the Transaction Agreements;

          (c) Athersys will submit to the United States Patent and Trademark Office all information related to the Cells, pre-clinical development candidates, Clinical Development Candidates and Cell Therapy Products that is required to be submitted in accordance with 37 C.F.R. 1.56, 1.97 and 1.98;

          (d) the Athersys Intellectual Property that is the subject of the rights and licenses granted to Angiotech under the Transaction Agreements constitutes all intellectual property owned or controlled by Athersys that is necessary or useful to manufacture, research, develop, use or commercialize the Cells, pre-clinical development candidates, Clinical Development Candidates and Cell Therapy Products for the Cardiovascular Indications, and to the knowledge of Athersys there is no other Intellectual Property necessary for such purposes that is owned or controlled by Athersys;

          (e) Athersys will take all steps necessary to ensure that the Athersys Patent Rights set forth in Schedule 1.33 are existing and that inventorship of the Athersys Patent Rights is properly determined, and Athersys’ will promptly inform Angiotech in

- 44 -

- 45 -

- 46 -

- 47 -

- 48 -

discretion to settle any such claim or suit if they have first waived their rights to indemnification hereunder.

     15.3 Insurance . During the Term and for a period of two (2) years thereafter, each Party shall obtain and maintain commercial general liability insurance, including products liability insurance, with reputable and financially secure insurance carriers with respect to its obligations, responsibilities and activities under the Transaction Agreements. Such insurance shall be in such amounts and subject to such deductibles as the Parties may agree based upon standards prevailing in the industry at the time, but in each case with limits of not less than Five Million Dollars ($5,000,000.00) per occurrence and in the aggregate.

ARTICLE XVI.

TERM AND TERMINATION

     16.1 Term . This Strategic Alliance Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to Section 16.2 , shall continue in full force and effect until the earlier to occur of: (a) five (5) years after the Effective Date, if the JSC has not approved any Clinical Development Program on or before such fifth year anniversary; (b) if at least one Cell Therapy Product has obtained Regulatory Approval in the Territory and the Parties have shared Profits with respect to at least one Cell Therapy Product, on the date that there has been no sales for twelve (12) months of any Cell Therapy Product that has been the subject of Profit-sharing, unless a Clinical Development Candidate is in Phase III Studies or later; or (c) the later of (i) the expiration date of the last-to-expire patent licensed to Angiotech under the Transaction Agreements, or (ii) fifteen (15) years after the Effective Date. The period of time from the Effective Date until expiration or early termination is the “ Term .”

     16.2 Termination .

          (a) Uncured Breach of Athersys . The failure by Athersys to substantially comply with any of the material obligations contained in this Strategic Alliance Agreement or any Transaction Agreement shall entitle Angiotech to give written notice to have the default cured. If such default is not cured within sixty (60) days after the receipt of such written notice, or if by its nature such default is not capable of cure within such sixty (60)-day period, then Angiotech shall be entitled, without prejudice to any of its other rights conferred on it by this Strategic Alliance Agreement or any Transaction Agreement, and in addition to any other remedies that may be available to it, to terminate this Strategic Alliance Agreement; provided, however , that such right to terminate shall be stayed in the event that, during such sixty (60)-day period, Athersys shall have: (i) initiated dispute resolution in accordance with ARTICLE XVII below with respect to the alleged default, and (ii) diligently and in good faith cooperated in the prompt resolution of such dispute resolution process.

          (b) Uncured Breach of Angiotech . The failure by Angiotech to substantially comply with any of the material obligations contained in this Strategic Alliance Agreement or any Transaction Agreement shall entitle Athersys to give written

- 49 -

notice to have the default cured. If such default is not cured within sixty (60) days after the receipt of such written notice, or if by its nature such default is not capable of cure within such sixty (60)-day period, then Athersys shall be entitled, without prejudice to any of its other rights conferred on it by this Strategic Alliance Agreement or any Transaction Agreement, and in addition to any other remedies that may be available to it, to terminate this Strategic Alliance Agreement; provided, however, that such right to terminate shall be stayed in the event that, during such sixty (60)-day period, Angiotech shall have: (i) initiated dispute resolution in accordance with ARTICLE XVII below with respect to the alleged default, and (ii) diligently and in good faith cooperated in the prompt resolution of such dispute resolution process.

          (c) Insolvency of Athersys . In the event that Athersys has filed or instituted bankruptcy, reorganization, liquidation or receivership proceedings, or has assigned a substantial portion of its assets for the benefit of creditors during the Term, Angiotech may immediately terminate the Transaction Agreements in their entirety upon written notice of termination to Athersys; provided, however, that in the event of any involuntary bankruptcy or receivership proceeding, such right of Angiotech to terminate the Transaction Agreements shall only become effective if Athersys consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof; and further provided that, if the Transaction Agreements are terminated by Angiotech due to the rejection of this Strategic Alliance Agreement or any Transaction Agreement by or on behalf of Athersys under Section 365 of the United States Bankruptcy Code (the “ Code ”), all licenses and rights to licenses granted under or pursuant to the Transaction Agreements by Athersys to Angiotech are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Code, licenses of rights to “intellectual property” as defined under Section 1010(35A) of the Code. The Parties agree that Angiotech, as a licensee of such rights under the Transaction Agreements, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against Athersys under the Code, Angiotech shall be entitled to a complete duplicate of, or complete access to (as Angiotech deems appropriate), any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be promptly delivered to Angiotech (a) upon any such commencement of a bankruptcy proceeding and upon written request therefor by Angiotech, unless Athersys elects to continue, and does continue, to perform all of its obligations under the Transaction Agreements, or (b) if not delivered under (a) above, upon the rejection of this Strategic Alliance Agreement or any Transaction Agreement by or on behalf of Athersys and upon written request therefor by Angiotech. Athersys agrees not to interfere with Angiotech’s exercise under the Code of rights and licenses to intellectual property licensed hereunder and embodiments thereof in accordance with this Section 16.2(c) and agrees to use Commercially Reasonable Efforts to assist Angiotech to obtain such intellectual property and embodiments thereof in the possession or control of Third Parties as are reasonably necessary or useful for Angiotech to exercise such rights and licenses in accordance with the Transaction Agreements. The foregoing provisions are without prejudice to any rights Angiotech may have arising under the Code or other applicable law.

          (d) Termination for Cause . Angiotech shall have a right to terminate the Transaction Agreements for cause (as set forth in (i) or (ii) below), which termination right may be exercised at any time during the Term. Such termination shall require at least one hundred twenty (120) days prior written notice by Angiotech that terminates for cause, and during such 120-day period the Parties shall continue to share costs that are incurred and Profit that is obtained in connection with activities under the Transaction Agreements that have been commenced but not yet completed.

     (i) Grounds that Constitute “For Cause” . If Angiotech, using its reasonable and sound business judgment, determines that (A) a primary endpoint(s) in a clinical study within a Clinical Development Plan has not been fulfilled or met; (B) at least one (1) IND has not been filed by the Parties within three (3) years after the Effective Date; (C) clinical efficacy and/or safety with respect to Cells, a Clinical Development Candidate or a Cell Therapy Product have not been demonstrated; (D) applicable regulatory requirements for Cells, a Clinical Development Candidate or a Cell Therapy Product in one or more Major Markets in the Territory shall have a material adverse impact on the ability to obtain Regulatory Approval for a Cell Therapy Product in such countries; (E) Athersys data regarding Cells, a Clinical Development Candidate or a Cell Therapy Product were obtained, in whole or in part, through scientific fraud; and/or (F) a Cell Therapy Product is not (or is not expected to be) commercially viable or profitable for a Party in at least one of the Major Market in the Territory, then any of the conditions (A-F) above shall constitute a grounds for termination of the Transaction Agreements “ for cause .”

     (ii) Decision to Terminate For Cause . If Angiotech decides to terminate the Transaction Agreements for cause, then Angiotech shall provide written notice to Athersys of such decision (and this written notice shall also serve as a notice of termination as specified in such written notice); provided that with respect to each instance of an event giving rise to the applicable grounds for termination, in order to be effective such written notice shall be provided to Athersys within one hundred eighty (180) days after Angiotech, using its reasonable and sound business judgment, makes a determination that such event has occurred.

          (e) Change of Control of Athersys . For purposes of this clause (e), “ Change of Control ” means the consummation of a transaction during the Term in which a Third Party acquires, merges or consolidates with Athersys; or possesses (directly or indirectly) the power to direct or cause the direction of management or policies of Athersys through ownership of a majority of securities, partnership, or other ownership rights or agreements; or in which Athersys transfers or sells all or substantially all of its assets or business to which the Transaction Agreements relate; provided, however, that none of the following shall be considered a Change in Control: (i) a merger effected exclusively for the purpose of changing the domicile of Athersys; (ii) an equity financing in which Athersys is the surviving corporation; or (iii) a transaction in which the stockholders of Athersys immediately prior to the transaction own fifty percent (50%) or more of the voting power of the surviving corporation following the transaction. In the

mediation under the Commercial Mediation Rules of the American Arbitration Association.

          (c) If efforts at mediation are unsuccessful within sixty (60) days after the date that one Party notifies the other Party that it desires to resolve a dispute, controversy or claim through mediation, any unresolved dispute, controversy or claim between the Parties shall be resolved at the mutual agreement of the Parties by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association, except as modified herein. Failing mutual agreement to submit such unresolved dispute, controversy or claim to arbitration, either Party may resort to other legal remedies.

          (d) If the Parties mutually agree to submit an unresolved dispute, controversy or claim to arbitration, each Party shall select one arbitrator and the two (2) arbitrators so selected shall choose a third arbitrator to resolve the dispute. Prior to the commencement of arbitration, each Party shall certify that its chosen arbitrator is competent to decide such dispute and the two (2) arbitrators so certified shall jointly certify that their chosen third arbitrator is likewise competent to decide such dispute. Such competence may include the ability to understand disputes which are primarily scientific in nature or which require expertise and knowledge of processes related to the commercial development of a pharmaceutical/medical device product which is peculiar to persons in the biotechnology/pharmaceutical industry. A reasoned arbitration decision shall be rendered in writing within six (6) months of the conclusion of mediation and shall be binding and not be appealable to any court in any jurisdiction. The prevailing Party may enter such decision in any court having competent jurisdiction. The mediation and arbitration proceedings shall be conducted in the English language and shall be held in New York, New York, U.S.A. The Parties agree that they shall share equally the cost of the mediation and arbitration filing and hearing fees, and the cost of the mediator/arbitrator. Each Party must bear its own attorneys’ fees and associated costs and expenses with respect to any such mediation and arbitration proceedings.

     17.2 Injunctive Relief . Each Party acknowledges that (a) the covenants and the restrictions of the other Party that are contained in this Strategic Alliance Agreement and the other Transaction Agreements are an inducement to enter into this Strategic Alliance Agreement and the other Transaction Agreements, and are necessary and required for the protection of the Parties, (b) such covenants and restrictions may relate to matters that are of a special, unique and extraordinary character that may give each of such covenants a special, unique and extraordinary value, and (c) a material breach of any of such covenants and restrictions may result in irreparable harm and damages to a Party in an amount that may be difficult to ascertain, and which may not be adequately compensated by a monetary award. Accordingly, in addition to any of the relief to which a Party may be entitled under this Strategic Alliance Agreement or any other Transaction Agreement, at law or in equity, such Party shall be entitled to seek temporary and permanent injunctive relief from any such breach or threatened breach of such covenants or restrictions without proof of actual damages that have been or may be caused to such Party by such breach or threatened breach. In the event an action for injunctive relief is

brought by a Party, the other Party waives any right to require the Party bringing such action to post any bond or other security with the court in connection therewith.

ARTICLE XVIII.

MISCELLANEOUS PROVISIONS

     18.1 Governing Law . The Transaction Agreements shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the principles of conflict of laws.

     18.2 Assignment . Neither Party shall be permitted to assign or otherwise transfer any of its rights or obligations under the Transaction Agreements without the prior written consent of the other Party; provided, however, that, subject to Section 16.2(e) , a Party may assign or otherwise transfer all of its rights and obligations under the Transaction Agreements without the prior written consent of the other Party (a) in connection with a sale of all or substantially all of its business or assets, whether by merger, sale of stock, sale of assets or otherwise or (b) to an Affiliate of such Party. Notwithstanding the foregoing, in the event of any such permitted assignment or other transfer, all rights and obligations under the Transaction Agreements must be assigned or otherwise transferred together in their entirety to such assignee or successor.

     18.3 Compliance With Laws . Each Party shall comply with all applicable laws, rules and regulations in connection with its performance of its obligations and exercise of its rights under the Transaction Agreements. Each Party shall furnish to the other Party any information reasonably requested or required by the requesting Party during the Term to enable the requesting Party to comply with the requirements of any United States or foreign federal, state, and/or government agency.

     18.4 Further Assurances . At any time, or from time to time, following the date of the Transaction Agreements, each Party shall, at the request of the other Party (a) deliver or cause to be delivered to the requesting Party any records, data or other documents consistent with the provisions of the Transaction Agreements, (b) duly execute and deliver, or cause to be duly executed or delivered, all such consents, assignments, documents or further instruments of transfer or license as required by the Transaction Agreements, and (c) take or cause to be taken all such actions, in each case as the requesting Party may reasonably deem necessary in order for the requesting Party to obtain the full benefits of the Transaction Agreements and the transactions contemplated hereby.

     18.5 Severability . In the event that any provision of the Transaction Agreements is determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Transaction Agreements shall remain in full force and effect without said provision. In such event, the Parties shall in good faith attempt to negotiate a substitute clause for any provision declared invalid or unenforceable, which substitute clause shall most nearly approximate the intent of the Parties in agreeing to such invalid provision, without itself being invalid.

     18.6 Waivers And Amendments; Preservation Of Remedies . The Transaction Agreements may be amended, modified, superseded, canceled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by the Parties or, in the case of a waiver, the Party waiving compliance. No delay on the part of any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any Party of any right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege hereunder, preclude any other or other exercise thereof hereunder. The rights and remedies herein provided are cumulative and are not exclusive of any rights or remedies which any Party may otherwise have at law or in equity.

     18.7 Headings . The captions to the several Articles and Sections hereof are not a part of the Transaction Agreements, but are included merely for convenience of reference only and shall not affect its meaning or interpretation.

     18.8 Counterparts . The Transaction Agreements may be executed by original or facsimile signature in any number of counterparts, and each such counterpart shall be deemed to be an original instrument, and all of which counterparts together shall constitute one instrument.

     18.9 Successors . This Strategic Alliance Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.

     18.10 Notices . All notices, requests, demands, claims and other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered personally, by fax, sent by nationally recognized overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid, to the Parties at the addresses set forth below (or at such other address for such party as shall be specified by like notice). All such notices and other communications shall be deemed to have been given and received (a) in the case of personal delivery, on the date of such delivery, (b) in the case of delivery by facsimile transmission, on the date of such delivery, (c) in the case of delivery by nationally recognized express courier, on the date of such delivery, and (d) in the case of mailing within the United States, on the fifth (5 ^th ) business day following such mailing.

If to Angiotech :

Angiotech Pharmaceuticals, Inc.
1618 Station Street
Vancouver, BC Canada V6A 1B6
Fax: 604-221-2330
Attn: Vice President Business Development

with a required copy to:

Angiotech Pharmaceuticals, Inc.
1618 Station Street

Vancouver, BC Canada V6A 1B6
Fax: 604-221-2330
Attn: General Counsel

If to Athersys :

Athersys, Inc.
3201 Carnegie Avenue
Cleveland, OH 44115-2634
Fax: (216) 361-9495
Attn: Chief Executive Officer

with a copy (which shall not constitute notice) to:

Jones Day
North Point
901 Lakeside Avenue
Cleveland, OH 44114
Fax: (216) 579-0212
Attn: Thomas A. Briggs, Esq.

     18.11 No Consequential Damages . EXCEPT IN CONNECTION WITH A PARTY’S OBLIGATIONS UNDER ARTICLE XV , IN NO EVENT SHALL A PARTY BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS OR REVENUE.

     18.12 Independent Contractor . Neither Party shall be construed to be a partner, joint venturer, franchisee, employee, principal, agent, representative or participant of or with the other Party for any purpose whatsoever by virtue of the Transaction Agreements. No Party has any right or authority to assume or to create any obligation or responsibility, express or implied, on behalf of or in the name of the other Party in any manner by virtue of the Transaction Agreements.

     18.13 Complete Agreement . This Strategic Alliance Agreement, together with its Schedules and Exhibits, and any Pre-Clinical Development Plans and Clinical Development Plans approved by the Parties, the Note and Purchase Agreement, and the Mutual Confidential Disclosure Agreement between the Parties dated July 20, 2005, along with any other letters or agreements signed by both Parties and of even date herewith, constitute the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, expressed or implied, are merged and canceled, and are null and void and of no effect.

[Signature page follows]

     IN WITNESS WHEREOF, the Parties have caused this Strategic Alliance Agreement to be executed by their duly authorized officers, effective as of the Effective Date.

		ATHERSYS, INC.
		By:
		Name:
		Title:
		ANGIOTECH PHARMACEUTICALS, INC.
		By:
		Name:
		Title:

[Signature page to Strategic Alliance Agreement]

Schedule 1.13
Cost Definitions

1.

“ Clinical Development Costs ” means, with respect to each Clinical Development Plan, all of the external and internal costs and expenses (including applicable overhead costs and expenses, including applicable general and administrative expenses, but excluding any Commercialization Costs and Commercial Manufacturing Costs) incurred or paid by a Party and its Affiliates in connection with the clinical development of Clinical Development Candidates or Cell Therapy Products, including, without limitation, the following costs to the extent such costs are actually incurred by a Party, accounted for in accordance with U.S. GAAP as consistently applied by such Party and attributable to the activities assigned to it under the Clinical Development Plan (except to the extent such costs constitute Commercialization Costs or Commercial Manufacturing Costs):

	(a)		All direct costs of preparing and conducting clinical trials that is/are subject of the Clinical Development Plan, including all direct costs related to site recruitment, enrollment, project management, site management and monitoring, biostatistics, clinical event classification, medical communication, data management, outcome studies, regulatory submissions and compliance, safety surveillance, clinical monitoring and all Clinical Manufacturing Costs; and
	(b)		A reasonable allocation of indirect costs associated with the foregoing.

2.

“ Commercialization Costs ” means, with respect to each Cell Therapy Product, all of the external and internal costs and expenses (including applicable overhead costs and expenses, including applicable general and administrative expenses, but excluding any Clinical Development Costs and Commercial Manufacturing Costs) incurred or paid by Angiotech and its Affiliates in connection with the commercialization of Cell Therapy Products, including, without limitation, the following costs to the extent such costs are actually incurred by a Party, accounted for in accordance with U.S. GAAP as consistently applied by such Party and attributable to the promotion, marketing, advertising, sale, or distribution of the Cell Therapy Product and preparing and conducting Phase IV Studies:

	(a)		All direct costs of promoting, marketing, advertising and selling the Cell Therapy Product, including sales commissions, product labels, marketing brochures, graphic and media design, website modification and license fees (if any);
	(b)		All Third Party Payments; and
	(c)		A reasonable allocation of indirect costs associated with the foregoing;
			provided that any costs described above incurred or paid by Angiotech and its Affiliates in connection with the preparation for commercialization of a Clinical Development Candidate that Angiotech reasonably believes will obtain Regulatory Approval for at least one Cardiovascular Indication (and thereby become a “Cell Therapy Product” hereunder) shall also be deemed to be “Commercialization Costs”.

3.

“ Manufacturing Costs ” means, with respect to each Clinical Development Candidate (the “ Clinical Manufacturing Costs ”) and Cell Therapy Product (the “ Commercial Manufacturing Costs ”), all of the external and internal costs and expenses (including applicable overhead costs and expenses, including applicable general and administrative expenses, but excluding any Clinical Development Costs) incurred or paid by Athersys and its Affiliates (or Angiotech and its Affiliates if Angiotech has acquired manufacturing rights hereunder) in connection with the manufacturing of Clinical Development Candidates or Cell Therapy Products (as applicable), including, without limitation, the following costs to the extent such costs are actually incurred by the manufacturing Party, accounted for in accordance with U.S. GAAP as consistently applied by the manufacturing Party and attributable to the manufacture and supply of the Clinical Development Candidate or Cell Therapy Product (as applicable) to Angiotech or any Third Party:

	(a)		All direct costs of manufacturing and supply the Clinical Development Candidate or Cell Therapy Product (as applicable), including all direct costs of raw materials, labor, license fees (if any), maintenance and repair of equipment used to manufacture the Clinical Development Candidate or Cell Therapy Product (as applicable), storage and packaging and shipping costs; and
	(b)		A reasonable allocation of indirect costs associated with the foregoing, including depreciation associated with the cost of capital for equipment used to manufacture the Clinical Development Candidate or Cell Therapy Product (as applicable).

Schedule 1.14
Clinical Development Plans

[Each Clinical Development Plan to be developed by the Parties in accordance with the
Strategic Alliance Agreement and attached hereto]

Schedule 1.33
Patent Rights Related To MAPCs

APPLICATION

U.S. FILING DATE /

NO./

NATIONAL PHASE

PUBLICATION

PATENT

PRIORITY

DATE /

NO.

NO.

COUNTRY

INFORMATION

TITLE

PATENT ISSUE DATE

60/147,324

U.S.

N/A

Totipotent Adult Stem Cells and Methods for Isolation

5 August 1999

60/164,650

U.S.

N/A

Multipotent Adult Stem Cells and Methods for Isolation

10 November 1999

PCT/US00/21387 Pub. No.: WO 01/11011

PCT

60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

4 August 2000 15 Feb. 2001

784163

Australia

PCT/US00/21387 60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

12/20/05

2,381,292

Canada

PCT/US00/21387 60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

4 February 2002

EP 00953840.6

Europe

PCT/US00/21387 60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

5 March 2002

02109304.0

Hong Kong

PCT/US00/21387 60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

23 December 2002

147990

Israel

PCT/US00/21387 60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

4 February 2002

IN/PCT/2002/00311/CHE

India

PCT/US00/21387 60/147,324 60/164,650

Multipotent Adult Stem Cells and Methods for Isolation

28 February 2002